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Stellingen behorende bij het proefschrift
1. Bij patiënten met congenitale bijnierhyperplasie kunnen op de kinderleeftijd al 
ongunstige veranderingen in het cardiovasculaire risicoprofiel worden gezien.
(Dit proefschrift)
2. Een verhoogde body mass index, toegenomen percentage lichaamsvet, 
verhoogde bloeddruk en insulineresistentie kunnen worden veroorzaakt door 
zowel de medicamenteuze behandeling als ook het hyperandrogenisme bij 
patiënten met congenitale bijnierhyperplasie. (Dit proefschrift)
3. Een verhoogde body mass index speelt een cruciale rol in het ontwikkelen van 
een ongunstig cardiovasculair risicoprofiel bij (pediatrische) patiënten met 
congenitale bijnierhyperplasie door 21-hydroxylase deficiëntie. (Dit 
proefschrift)
4. Reguliere evaluatie van minimaal bloeddruk en body mass index vanaf de 
kinderleeftijd zal leiden tot vroegtijdige detectie van ongunstige veranderingen 
in het cardiovasculaire risicoprofiel van patiënten met congenitale 
bijnierhyperplasie. (Dit proefschrift)
5. Vanwege verhoogde concentraties van steroidprecursors met glucocorticoïde 
activiteit voor het enzymatische blok, met name 21-deoxycortisol, is bij 
patiënten met milde 21-hydroxylase deficiëntie wellicht geen behandeling met 
glucocorticoïden noodzakelijk. (Dit proefschrift)
6. Reductie van cardiovasculaire morbiditeit bij patiënten met congenitale 
bijnierhyperplasie, door vroegtijdig signaleren en behandelen van
ongunstige veranderingen in het cardiovasculaire risicoprofiel, zal resulteren in 
een verbetering van levenskwaliteit en verlaging van de zorgkosten.
(gebaseerd op Hummel S et al. Clin Endocrinol 2016; 85:361-368)
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GENERAL INTRODUCTION
CHAPTER 1

Congenital adrenal hyperplasia – etiology and clinical aspects
Text	is	partially	based	on	sections	from	“Disorders	of	Adrenal	Steroidogenesis:	Impact	
on	Gonadal	Function	and	Sex	Development.	Mooij	CF,	van	Herwaarden	AE,	Claahsen-	
van der Grinten HL. Pediatric Endocrinology Reviews. 2016. 14(2):109-128”
CHAPTER 1.1
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General introduction
1
Congenital adrenal hyperplasia (CAH) is a group of rare diseases affecting adrenal 
steroidogenesis (see chapter 1.3; figure 1) due to a defect in one of the enzymes involved 
in steroid synthesis. Disorders in adrenal steroidogenesis may affect glucocorticoid 
synthesis, mineralocorticoid synthesis and androgen synthesis leading to either lack 
of adrenal (and gonadal) androgen production or excess of androgen production 
(causing 46,XX Disorder of Sexual Differentiation (DSD)). In more than 90% of the 
cases CAH is caused by 21-hydroxylase (also termed CYP21A2 or P450c21) deficiency 
(21OHD). Deficiencies of e.g. 11-beta-hydroxylase, 3-beta-hydroxysteroid dehydrogenase, 
17-alpha-hydroxylase can also cause disorders of adrenal steroid ogenesis. In this thesis 
we discuss CAH due to 21OHD unless stated otherwise.
 CAH is one of the most common inherited autosomal recessive disorders. 
Compound heterozygous or homozygous mutations in the genes encoding the enzymes 
involved in adrenal steroidogenesis are causative for the disorders. The clinical 
phenotype in these disorders depends on the mutation with the highest percentage 
of residual enzymatic activity with a more severe phenotype in patients with lower 
residual enzymatic activity. In all cases of CAH, the basic defect leads to a lack of 
cortisol synthesis resulting in stimulation and hyperplasia of the adrenals by ACTH 
and accumulation of the precursors before the enzymatic block due to the lack of 
negative feedback. Some of these precursors are diverted to the synthesis of androgens, 
causing ambiguous genitalia in newborn females and rapid postnatal growth in both 
sexes. 
 As an introduction we will briefly discuss the genetic background, the clinical 
phenotype, the diagnostic workup and current treatment of 21OHD.
21-hydroxylase deficiency
The defect in steroidogenesis
The CYP21A2 gene is located on chromosome 6p21.3 consisting of 10 exons. 
Mutations in the CYP21A2 gene lead to insufficient synthesis of the enzyme 21-
hydroxylase. 21-hydroxylase converts progesterone to 11-deoxycorticosterone (DOC) 
in the zona glomerulosa and 17-OH progesterone (17OHP) to 11-deoxycortisol in the 
zona fasciulata of the adrenal. In case of complete absence of 21-hydroxylase these 
conversions are not facilitated leading to cortisol and aldosterone deficiency. Low 
(fetal) cortisol levels stimulate ACTH secretion in utero leading to adrenal hyperplasia 
and increased androgen production as the enzymes necessary for synthesis of adrenal 
androgens in the zona reticularis are not affected. Postnatally increased ACTH levels 
result in elevated levels of steroids before the enzymatic block: 17OHP and andro-
stenedione. Figure 1 shows the effect of 21OHD on steroidogenesis schematically.
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General introduction
1
The clinical phenotype of 21OHD is a continuum depending on the residual enzymatic 
activity. Traditionally, the clinical presentation of 21OHD is classified as classic 
salt-wasting (SW) CAH, classic simple virilizing (SV) CAH and non-classic (NC) CAH. 
Patients with the classic SW form have no residual enzymatic activity leading to 
severe salt losing typically after the first week of life and prenatal virilization of the 
female external genitalia (46,XX DSD). Patients with the classic SV form of CAH have a 
residual enzymatic activity of 1-2 % and usually have sufficient aldosterone production 
to prevent severe salt loss. The SV form leads to prenatal virilization of the female 
external genitalia and postnatal androgen excess in both sexes.1,2  Classic 21OHD is 
detected in approximately 1 in 10.000 to 20.000 births in most populations, with an 
estimated carrier frequency of 1:55 based on newborn screening data.3,4 
 NC CAH is the mildest form of CAH and has a prevalence of about 0.1% in the 
general population.5 In general NC CAH patients have a residual enzymatic activity of 
20-50%. Clinical characteristics of NC CAH depend on the percentage of residual 
enzyme activity including premature pubarche and menstrual disturbances or mimic 
those found in polycystic ovary syndrome, but most male NC CAH patients are free of 
symptoms.1,2,6
The diagnostic workup of 21OHD patients
In several countries, such as The Netherlands, newborn screening, measuring 17OHP 
levels by immunoassay, has been introduced to screen for 21OHD to prevent severe 
salt wasting crisis in the neonatal period. In newly diagnosed CAH patients elevated 
ACTH and renin concentration are found as well as elevated concentrations of 
precursors 17OHP and androstenedione. Basal 17OHP values usually exceed 300 
nmol/l in affected infants with the classic form of CAH, whereas the levels in 
unaffected newborns are below 3 nmol/l.7 A cosyntropin stimulation test may be 
used to measure 17OHP and other elevated steroid precursors if basal 17OHP values 
do not prove or exclude the diagnosis of 21OHD. 21-deoxycortisol, a 11-hydroxylated 
product of 17OHP, has been described as a potential more sensitive marker for the 
diagnosis of 21OHD in premature neonates, NC patients and carriers.8,9 Prenatal 
diagnosis of 21OHD is possible, and may be desirable if prenatal treatment with 
dexamethasone is considered in classic forms of 21OHD with virilization of the 
external genitalia. 10
The treatment of 21OHD patients
Current treatment of CAH, caused by 21OHD, consists of lifelong replacement of 
gluco corticoids and, in cases with insufficient aldosterone production, also mineralo-
corticoids.7 By treatment with glucocorticoids also suppression of adrenal androgen 
production can be achieved. However, in most patients supraphysiological doses of 
glucocorticoids are necessary to normalize androgen levels. Further treatment is 
18
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multidisciplinary, including surgical correction of ambiguous genitalia in affected 
female patients when desired.7 Frequent follow-up of CAH patients is important to 
monitor mineralocorticoid and glucocorticoid replacement therapy. The follow up of 
CAH patients should also focus on long-term health problems that may be caused 
by androgen excess in CAH or by over-treatment or under-treatment (e.g. exogenous 
glucocorticoid excess). Therefore, evaluation of growth, reproductive health, cardio-
vascular and metabolic health and bone health should be incorporated in the follow 
up of CAH patients.11 In Chapter 1.2b we will give more insights in long-term health 
consequences in young CAH patients.
19
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Cardiovascular and metabolic risk in congenital  
adrenal hyperplasia
Chapter 1.2a
Unfavorable trends in cardiovascular and metabolic risk in pediatric  
and adult patients with congenital adrenal hyperplasia?
Mooij CF, Kroese JM, Claahsen-van der Grinten HL, Tack CJ, Hermus AR. 
Clinical Endocrinology. 2010; 73(2): 137-146
CHAPTER 1.2
22
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Summary
Context: As a result of the introduction of treatment with glucocorticoids and mine-
ralocorticoids, now 60 years ago, congenital adrenal hyperplasia has become a 
lifelong chronic disease. Whether long-term treatment of the disease leads to 
long-term side effects remains unknown. In this respect, especially cardiovascular 
risk seems to be important.
Evidence synthesis: We reviewed the reported prevalence of conventional cardio- 
vascular risk factors, i.e. obesity, insulin resistance, high blood pressure and 
dyslipidemia in patients with congenital adrenal hyperplasia. Overall, the studies 
suggest a tendency towards an increased body mass index and fat mass, the presence 
of insulin resistance and hypertension, although data are relatively scarce and 
obtained in heterogeneous populations.
Conclusions: Our findings suggest that adult CAH patients tend to have a cluster of 
metabolic risk factors, which are consistent with the metabolic syndrome. This notion 
may have consequences for the care for this group of patients.
23
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Introduction
Congenital adrenal hyperplasia (CAH) is a disorder of adrenal steroidogenesis. 
Treatment with glucocorticoids and, if necessary, mineralocorticoids prevents adrenal 
crises and suppresses abnormal secretion of adrenal androgens. As a result of the 
introduction of treatment with glucocorticoids and mineralocorticoids, now 60 years 
ago, nearly all CAH patients currently reach adulthood. This renders it possible to 
unfold the clinical spectrum of CAH as a lifelong chronic disease, with the oldest 
salt-wasting patients now being in their 60s, and long-term consequences of therapy 
becoming increasingly important. Patients with CAH are at risk of developing signs and 
symptoms of iatrogenic Cushing’s syndrome1,2 as the therapeutic range of treatment 
with glucocorticoids is narrow and supraphysiological doses of glucocorticoids are 
used to suppress hyperandrogenism. As hypercortisolism is associated with cardio-
vascular morbidity,3 it is suggested that patients with CAH may show an adverse 
cardiovascular risk profile.4 Furthermore, other factors such as obesity and alterations 
in the leptin axis may contribute to the development of an unfavorable cardiovascular 
risk profile in CAH patients. In this review, we discuss cardiovascular risk factors in 
pediatric and adult CAH patients. Data reviewed in this paper are from patients 
suffering from CAH because of 21-hydroxylase deficiency unless stated otherwise.
Overview of CAH
In 95% of cases, CAH is caused by 21-hydroxylase deficiency.2 Deficiency of 21-hydro-
xylase results in impaired adrenal synthesis of cortisol and often also of aldosterone, 
causing increased secretion of ACTH by the pituitary gland, adrenal hyperplasia and 
excessive production of adrenal androgens.
 The symptoms of CAH depend on the degree of enzyme deficiency. Patients with 
the classic salt wasting (SW) type of CAH have no residual enzyme activity resulting in 
disturbed cortisol and aldosterone production typically leading to an Addisonian 
crisis 7–14 days after birth and prenatal virilization of the external genitalia in females. 
Patients with the classic simple virilizing (SV) type of CAH have a residual enzyme 
activity of 1–2% and are considered to have sufficient aldosterone production to 
prevent severe salt wasting. The simple virilizing form results in prenatal virilization in 
females and postnatal androgen excess in both sexes, when left untreated, leading to 
precocious pseudopuberty at a young age. The two classic forms of CAH have an 
incidence of approximately 1 in 15 000 live births worldwide.5 The nonclassic or late 
onset form of CAH with a residual enzyme activity of 30–50% has a prevalence of 
0.1% in the general white population,6 a higher frequency being reported in Eastern 
European Jews (3–4%), and in Hispanics and Yugoslavs (1–2%).6 Female patients may 
24
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be asymptomatic or are characterized by signs and symptoms of hyperandrogenism 
such as abnormalities of the menstrual cycle, acne, hirsutism and subfertility. 
Therefore, signs and symptoms in women with the late onset form of congenital 
adrenal hyperplasia are comparable with those seen in women with polycystic ovary 
syndrome.2,7 Male patients are usually asymptomatic but occasionally, they present 
with subfertility caused by hypogonadotrophic hypogonadism because of suppression 
of gonadotrophins by elevated adrenal androgens.
Risk factors for atherosclerotic vascular disease
Atherosclerotic vascular disease is caused by a complex process, to which several risk 
factors contribute.8 Traditional risk factors include age, male gender, familial 
predisposition, obesity, diabetes mellitus, dyslipidemia, hypertension, smoking and a 
sedentary lifestyle. In addition, several new nontraditional risk factors have been 
identified.8 In the following part, some of these risk factors in CAH patients will be 
discussed in more detail.
Obesity
An increased fat mass and the presence of abdominal obesity are important factors 
in the development of cardiovascular disease. Many studies have investigated body 
mass index (BMI) in CAH patients and most,9–18 but not all,19,20 of them report an 
elevated BMI. Studies regarding body composition in patients with CAH are 
summarized in Table 1. Most studies used dual X-ray absorptiometry (DXA) scans to 
evaluate body composition, and one study used skinfold measurements.
 In a cross-sectional study, Stikkelbroeck et al.9 found an elevated BMI in young 
male and female adult CAH patients (n = 30, aged 17–25 years) compared with healthy 
controls. Increase in BMI was caused by an increase in fat mass. Fat mass adjusted for 
height and relative fat mass (i.e. fat mass divided by total body mass) was significantly 
higher in both males and females. Body fat distribution (measured by DXA) did not 
differ between patients and controls. Falhammar et al.10 found a higher BMI in female 
CAH patients aged 30 years or older (n = 34) compared with controls. The elevated 
BMI in female CAH patients was not accompanied by elevation of total fat mass as 
found by Stikkelbroeck et al.9 Falhammar et al.10 did not find differences either in BMI 
or in body composition in female CAH patients younger than 30 years of age (n = 27) 
compared with controls. Bachelot et al.11 reported a high BMI in adult male and 
female CAH patients (n = 45), but BMI in CAH patients was not compared with control 
subjects. BMI did not differ between the various clinical forms of CAH. BMI also 
showed no correlation with duration of treatment, dosage of hydrocortisone and 
17alpha-hydroxyprogesterone (17-OHP) levels.
25
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In a study by Hagenfeldt et al.12 a significantly higher weight, BMI and absolute 
amount of body fat were found, but the fat/lean body mass ratio was not different 
between adult female CAH patients and age-matched healthy reference subjects. 
Cameron et al.19 and Christiansen et al.21 described an increased fat mass in male but 
not in female CAH patients. However, because different parameters were used in the 
different studies, i.e. relative fat mass and fat mass adjusted for height by Stikkelbroeck 
et al.,9 fat/lean ratio by Cameron et al.19 and fat mass percentage by Christiansen et 
al.,21 it is difficult to compare these results.
 Two studies have described BMI and body composition in children with CAH. 
Cornean et al.13  reported an increased BMI in 21-hydroxylase-deficient children in a 
retrospective study. ‘Adiposity rebound’, defined as the age at which the decrease in 
BMI reverses, was assessed in a subset of 13 patients (nine boys, four girls) in which 
longitudinal data were available from birth. ‘Adiposity rebound’ took place at a mean 
age of 1.74 years in the patients compared with 5.5 years for controls from the normal 
UK population. Early ‘adiposity rebound’ is of importance as it increases the risk for 
the development of obesity in adolescence.22 The increment in BMI was attributed to 
an increase in fat mass, skinfold thickness increasing significantly between 2.5 and 5.5 
years. A limitation of this study is that data were collected retrospectively and that 
skinfold measurements to determine body composition were used. Völkl et al.14 
evaluated BMI in children in a retrospective cross-sectional study of 89 CAH patients 
(aged 0.2–17.9 years). BMI SDS of the whole group was significantly elevated. In 
addition, a significantly higher frequency of obesity, defined as BMI SDS >2.0, was 
observed. Glucocorticoid dosage was positively correlated with BMI SDS, although 
there was no significant difference in glucocorticoid and mineralocorticoid dosage 
between patients with a BMI SDS of >2.0 and <2.0.
 In summary, CAH is associated with an increase in BMI and an increase in body 
fat in both adult and pediatric patients.9,10,12,13,19,21 Further investigations are 
needed to define the time of onset of obesity especially in children with CAH. The 
cause of the excessive increase in body weight remains unclear, but several factors 
may contribute. It is suspected that obesity in CAH patients is related to glucocorticoid 
treatment. Obesity is reported in patients treated with both ‘physiological’ and 
 supraphysiological doses of glucocorticoids. Furthermore, adrenomedullary dysfunction 
with decreased secretion of adrenaline may play a role in the development of 
obesity.23 Catecholamines, such as adrenaline, contribute to lipolysis and inhibit 
insulin secretion, thereby preventing an increase in fat mass.24 The decreased secretion of 
adrenaline in CAH is the result of prenatal adrenomedullary maldevelopment,23 
caused by low intra-adrenal levels of glucocorticoids.25 Hypogonadism in men and 
 hyperandrogenism in women are also associated with the development of obesity in 
CAH patients.26 Another possible explanation for the presence of obesity in CAH 
patients is an altered leptin axis.17
26
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Leptin is known to play a role in the regulation of body weight, with an increased 
leptin level suppressing appetite. The fact that most obese persons exhibit high leptin 
concentrations is often explained by the hypothesis that obesity is a state of leptin 
‘resistance’.27 Changes in the leptin axis, for example a decrease in leptin receptor 
levels, may play a role in the development of obesity.28–31 Both glucocorticoids and 
insulin increase leptin concentrations.32,33 In contrast, androgens are known to 
decrease leptin concentrations.34,35 Therefore, in CAH patients, an altered leptin axis 
may play a role in the development of obesity.
 A decrease in soluble leptin receptor (sOB-R) serum levels has been described in 
CAH patients (aged 5.6–19.6 years, n = 51).17 This observation suggests that also 
membrane leptin receptors are decreased leading to a state of ‘leptin resistance’. 
In this study, sOB-R:leptin ratios and serum leptin levels were significantly correlated 
with insulin levels and insulin sensitivity. Serum leptin levels were not different in 
CAH patients compared with matched controls. In other studies, serum leptin levels 
have been described to be elevated36 or normal37 in CAH patients. Leptin levels are 
known to be correlated with fat mass. Two studies showed a positive correlation 
between BMI and serum leptin levels.17,37 A positive correlation between the 
percentage of body fat and leptin levels was noted by Saygili et al.37
Dyslipidemia
Only five studies have reported on lipid profiles in CAH patients.10,11,38–40 Bayraktar 
et al.38 studied untreated adult female nonclassic CAH patients (n = 50, aged 22 ± 2.91 
years) and found that lipid profiles were not different from controls (i.e. total 
cholesterol, 4.6 ± 0.83 vs. 4.7 ± 0.77 mmol/l; HDL-cholesterol, 1.50 ± 0.28 vs. 1.55 ± 
0.26 mmol/l; LDL-cholesterol, 2.56 ± 0.56 vs. 2.58 ± 0.58 mmol/l; and triglycerides, 
1.14 ± 0.13 vs. 1.01 ± 0.12 mmol/l). Sartorato et al.39 found similar results in male and 
female adult patients with the classic form of CAH caused by 21-hydroxylase 
deficiency, all treated with glucocorticoids (n = 19, aged 28 ± 3.5 years). Lipid profiles 
were not significantly different compared with healthy controls (total cholesterol, 
168 ± 49 vs. 189 ± 36 mg/dl; HDL-cholesterol, 65 ± 15 vs. 61 ± 32 mg/dl; and 
triglycerides, 83 ± 37 vs. 84 ± 56 mg/dl). Falhammar et al.10 evaluated serum lipids in 
treated adult females with classic and nonclassic CAH caused by 21-hydroxylase 
deficiency (n = 61). Patients were divided into two groups: patients younger than 30 
years and patients 30 years or older. All patients received treatment with prednisolone 
or hydrocortisone. Most patients (50 of 61) also received fludrocortisone. Total 
cholesterol, HDL-cholesterol, LDL-cholesterol, HDL to LDL ratio and triglycerides did 
not differ between younger patients and controls. Patients of 30 years of age or older 
had higher HDL to LDL ratios (P = 0.03) and a tendency towards higher HDL-cholester-
ol (P = 0.074) compared with healthy controls. This change in lipid profile is considered 
to be protective for cardiovascular disease. Falhammar et al.10 did not show any 
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unfavorable changes in the lipid profile of adult female CAH patients. Bachelot et al.11 
found normal total cholesterol, triglycerides and LDL-cholesterol levels in adult 
patients with classic CAH, both with a BMI < 25 (n = 24) and with a BMI > 25 (n = 21).
Only one study evaluated lipid profiles in children with CAH. Botero et al.40 determined 
serum lipid profiles in 14 prepubertal children with CAH caused by 21-hydroxylase 
deficiency (four boys and 10 girls; aged 13 months–10 years) and in 14 healthy 
prepubertal children (eight boys and six girls; aged 21 months–9 years). All CAH 
patients were on glucocorticoid treatment with prednisone (dosage equivalent to 
10–20 mg/m2/day hydrocortisone). The study provided no information about the 
type of CAH and no matched control group was used. A statistically significant larger 
percentage of patients in the CAH group had serum triglycerides above 1.0 mmol/l 
compared with the control group (64.3%vs. 14.3%). Mean serum levels of triglycerides 
were also significantly elevated compared with the control group (1.32 ± 0.15 vs. 0.75 
± 0.07 mmol/l; P = 0.04). These findings were attributed to the use of glucocorticoids, 
especially prednisone. Furthermore, insulin resistance may also have contributed 
to the elevated levels of triglycerides. Mean serum levels of total cholesterol, LDL- 
cholesterol and HDL-cholesterol were not significantly different compared with controls.
 In summary, studies evaluating the lipid profile in adult CAH patients10,11,38,39 
did not show unfavorable changes. Therefore, an altered lipid profile does not seem 
to be an important cardiovascular risk factor in adult CAH patients. Because obesity 
and insulin resistance (see further), both observed in CAH patients, are known to be 
associated with dyslipidaemia,41 it is surprising that lipid profiles in CAH patients are 
normal. A possible explanation for this finding is that lipid profiles were mainly 
evaluated in younger CAH patients. Evaluation of dyslipidemia in older CAH patients, 
especially those older than 50 years of age, is needed.
Hypertension
Seven studies have evaluated blood pressure in CAH patients10,39,42–46 as summarized 
in Table 2. Two studies10,39 have evaluated blood pressure only in adult CAH patients, 
four studies42–45 in both pediatric and young adult patients and one study46 reports 
on blood pressure in pediatric CAH patients only.
 Falhammar et al.10 found supine and upright blood pressure values mostly within 
the normal range, both in female CAH patients younger than 30 years (n = 27) and 30 
years or older (n = 34). No differences in supine and upright blood pressures were 
observed in female CAH patients and healthy controls. Three CAH patients older than 
30 years received antihypertensive therapy, whereas controls did not receive anti-
hypertensive medication. Defining hypertension as a supine blood pressure >140/90 
mmHg, three CAH patients and four controls older than 30 years showed hypertension. 
Sartorato et al.39 found blood pressure values within the normal range in both male 
and female classic CAH patients receiving glucocorticoid replacement therapy with 
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Table 1  Summary of studies addressing body composition in congenital adrenal 
hyperplasia due to 21-hydroxylase deficiency
Study Study population (n) Gender Age (years),  
mean ± SD
Stikkelbroeck et al.9 Salt-wasting (24)
Simple virilizing (3)
Nonclassic (3)
Controls (30)
12 ; 12 
  3 
  3 
15 ; 15 
: 22 ± 2
: 21 ± 3
: 22 ± 2
: 21 ± 2
Falhammar et al.10 Salt-wasting (27)
Simple virilizing (28)
Non-classic (6)
Age-matched controls (61)
61 
61 
18-63 (range)
18-63 (range)
Hagenfeldt et al.12 Salt-wasting (12)
Simple virilizing (1)
Controls (12)
13 
12 
24 ± 3
22 ± 1
Cameron et al.19 Salt-wasting (18)
Simple virilizing (3)
Age-matched controls (21)
  8 ; 10 
  3 
10 ; 11 
8 – 32 (range)
not mentioned
Christiansen et al.21 Salt-wasting (17)
Simple virilizing or nonclassic (1)
Age-matched controls (120)
 8 ; 10 
 
80 ; 40 
18 – 33 (range)
not mentioned
Cornean et al.13 Salt-wasting (19)
Simple virilizing or nonclassic (3)
Controls: normal UK population
 14 ; 8 12.6
(range 7.1-20.4)
# calculated from table 1 in Cameron et al.19 using anti-inflammatory hydrocortisone equivalents for gluco-
corticoid doses60;  SD, standard deviation; CAH, congenital adrenal hyperplasia; DXA, dual x-ray absorptiometry
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Therapy CAH group Methods Outcome
Cumulative hydrocortisone dose 5 yr
•	Anti-inflammatory (g/m2)
 24 ± 5
 17 ± 5
•	Growth retarding (g/m2)
 26 ± 6
 18 ± 5
DXA 	 ↑Fat mass (adjusted for height)
	 ↑Relative fat mass
All patients: glucocorticoids (±50% 
prednisolone, mean dosage  6.3±0.32 
mg / day, ± 33% hydrocortisone 33.3 ± 
2.1 mg / day, others cortisone acetate, 
dexamethasone or combination. 82% 
fludrocortisone (0.09±0.01 mg/day)
DXA Similar percentage body fat and 
total and regional fat mass in 
patients and controls
Higher total and regional fat mass 
in patients older than 30 years 
compared to younger patients
5: dexamethasone 0.5-0.75 mg/day
5: prednisolone 5.6 –12.5 mg/day
1: cortisone acetate 37.5 mg/day
1: triamcinolone 8 mg/day
1: cortisone acetate 15 mg &
prednisolone 3.75 mg/day
12: fludrocortisone 0.075-0.15 mg/day
DXA 	↑ Body fat
Mean hydrocortisone dose: 32.7 mg/day #
Mean fludrocortisone dose: 0.17 mg/day #
DXA 	 ↑Fat/lean ratio in 
All patients: glucocorticoids  
17: mineralocorticoids 
Dose unknown
DXA 	 ↑Fat mass percentage in 
Mean hydrocortisone dose: 18.9 mg/m2/day
Mean fludrocortisone dose: 0.13 mg/m2/day
Skinfold 
measurement
	 ↑Fat mass
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Table 2  Summary of studies addressing blood pressure in congenital  
adrenal hyperplasia
Study Study population (n) Gender Age (years), 
mean ± SD
Falhammar et al.10 Salt-wasting (27)
Simple virilizing (28)
Non-classic (6)
Age-matched controls (61)
61 
61 
18-63 (range)
18-63 (range)
Sartorato et al.39 Classic 21-OH deficiency (19)
•	Salt-wasting (12)
•	Simple virilizing (7)
Controls (19)
10 ; 9 
10 ; 9 
28 ± 3.5
De Silva et al.42 Classic 21-OH deficiency (9)
•	Salt-wasting (5)
11β-hydroxylase deficiency (1)
Lipoid adrenal hyperplasia (1)
  7 ; 4 14.5, range: 
8.5-27.2
Roche et al.43 Classic 21-OH deficiency (38)
•	Salt-wasting (38)
23 ;15 11.2, range: 
6.1-18.2
Völkl et al.44 Classic 21-OH-deficiency (55)
•	Salt-wasting (45)
•		Simple virilizing (10)
32 ;23 5.3-19.0 (range)
Hoepffner et al.45 Classic 21-OH deficiency (34)
•	Salt-wasting (28)
•	Simple virilizing (6)
21 ;13 6-17 years 
(n=23)
18-26 years 
(n=11)
Nebesio et al.46 Classic 21-OH deficiency (91) 49 ;42 Unknown
SD, standard deviation; OH, hydroxylase; BP, blood pressure; SBP, systolic blood pressure; DBP: diastolic 
blood pressure; ABPM: ambulatory blood pressure monitoring
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Therapy CAH group Methods Blood pressure (mmHg) (± SD)
All patients: glucocorticoids (±50% 
prednisolone, ± 33% hydrocortisone, 
others cortisone acetate, 
dexamethasone or combination. 82% 
fludrocortisone 
BP was registered 
supine and standing
<30 years: 110/71 (supine)  
<30 years: 120/75 (upright) 
>30 years: 110/75 (supine)  
>30 years: 115/79 (upright) 
All patients: glucocorticoid 
replacement with hydrocortisone 
or dexamethasone. 12 patients 
mineralocorticoid therapy.
Average of three BP 
measurements with a 
sphygmomanometer 
on separate occasions
:  SBP 123.3 ± 13.2
:  DBP 83.3 ± 8.7
:  SBP 126.5 ± 7.5
:  DBP 83.9 ± 4.9
All patients were on glucocorticoid 
replacement at supraphysiological 
doses
24 hour ABPM SBP: 115.1 ± 10.3
DBP: 68.3 ± 7.2
All patients received replacement 
therapy in the form of oral
hydrocortisone and fludrocortisone
24-hour ABPM Mean 24-hour BP: 
SBP: 124.9 ± 11.7
DBP: 76.2 ± 14.9
All patients received replacement 
therapy with glucocorticoids: 
hydrocortisone (40), prednisone (12) 
or dexamethasone (3). 53 patients 
received fludrocortisone.
24-hour ABPM 24-hour BP in SDS for age:
:  SBP 0.23
:  DBP -0.65
:  SBP 0.47
:  DBP -0.65
All patients received glucocorticoid 
treatment with hydrocortisone
In outpatient clinic: 
oscillometric device 
(n=34), under 
hospitalisation: 
24-hour BP 
measurement with 
portable oscillometric 
device (n=34) and 24-
hour ABPM (n=11)
BP values in 11 children and adolescents 
who participated in all  
3 measurements:
Day-mean SBP in hospital:125.9 ± 9.6
Day-mean DBP in hospital:78.5 ± 7.0
SBP in outpatient clinic:117.1 ± 11.8
DBP in outpatient clinic:72.6 ± 6.3
Day-mean SBP of ABPM:114.8 ± 5.7
Day-mean DBP of ABPM:68.7 ± 4.6
All patients with hypertension were 
treated with both hydrocortisone and 
fludrocortisone (n=5)
Retrospective chart 
review, methods of 
BP measurement 
unknown
Peak recorded SBP for each patient with 
hypertension (n=4): 115 / 146 / 300 / 146
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hydrocortisone or dexamethasone. In both male (n = 9) and female (n = 10) CAH 
patients, systolic and diastolic blood pressures did not differ from healthy controls.
 De Silva et al.42 performed 24-h ambulatory blood pressure monitoring in 11 
treated CAH patients (M:F = 4:7) with a mean age of 14.5 years. Nine patients were 
21-hydroxylase deficient (five salt losers), one patient had 11β-hydroxylase deficiency 
and one had lipoid adrenal hyperplasia. None of the patients had hypertension 
defined as a mean systolic and diastolic blood pressure >95th percentile. However, 
five patients had a high mean blood pressure (90th percentile) with elevated mean 
systolic and diastolic pressures during the awake period. Limitations of this study are 
the small sample size of the study population and the heterogeneity of patients, with 
inclusion of both children and adults, two of them not being 21-hydroxylase deficient. 
In addition, two different blood pressure references were used: 24-h ambulatory 
blood pressure specific references and office blood pressure references. When using 
specific ambulatory reference data, one patient showed both daytime and nocturnal 
hypertension, six patients (54%) had nocturnal hypertension and eight patients (73%) 
had nocturnal blood pressures above the 90th percentile.
 Roche et al.43 performed 24-h ambulatory blood pressure monitoring in 38 salt- 
wasting 21-hydroxylase-deficient patients (15 males, 23 females) with a mean age of 
11.2 years. Using task force references for office blood pressure measurements47 
instead of 24-h ambulatory specific references, which would have been more 
appropriate, they found that 58% of the patients had systolic hypertension and 24% 
had diastolic hypertension. Mean daytime systolic blood pressure was significantly 
higher than in the reference population and 84% had no physiological nocturnal 
systolic dip. Mean systolic and diastolic blood pressures were not significantly 
different between males and females. In CAH patients, there was a positive relationship 
between systolic blood pressure and BMI, which was most marked in females.
 Völkl et al.44 performed 24-h ambulatory blood pressure monitoring in 55 treated 
patients with proven 21-hydroxylase deficiency (32 females, 23 males) aged between 
5 and 19 years. Measured blood pressure values were transformed into SDS matched 
for age, height, sex and the same oscillometric method respectively. Their data showed 
a significantly elevated systolic blood pressure during both day- and night-time 
(daytime 0.67 SDS, nighttime 0.63 SDS). Surprisingly, diastolic blood pressure was 
significantly decreased during the day with normal values during the night. A normal 
nocturnal drop of systolic blood pressure was found. Blood pressure parameters 
positively correlated with BMI and skinfold thickness.
 Hoepffner et al.45 focused on differences in blood pressure measured in the 
outpatient clinic and in the ward in 23 children and adolescents and 11 adult CAH 
patients. All patients received glucocorticoid treatment with hydrocortisone. Blood 
pressure measured during hospital admission was significantly elevated in children 
and adolescents compared with that measured in the outpatient clinic. All blood 
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pressures measured were within the normal range. Measurement of 24-h ambulatory 
blood pressure showed blood pressure values in the normal range in all patients. 
No correlations were found between blood pressure on one hand, and sex, BMI or 
dosage of mineralocorticoids on the other hand.
 Nebesio et al.46 performed a retrospective chart review of children with 
21-hydroxylase deficiency to evaluate the prevalence of hypertension, defined as 
blood pressure >95th percentile for age and gender, using published reference values. 
Six of 91 patients showed hypertension (6.6%). Patients were aged 58 days – 12.6 
years at the time of hypertension diagnosis. No relation between blood pressure and 
BMI or dosage of hydrocortisone was found. Nebesio et al.46 concluded that children 
with 21-hydroxylase deficiency have a higher prevalence of hypertension compared 
with historical reports on hypertension in a pediatric population.
 In conclusion, in most studies performed in young CAH patients, there is a 
tendency towards an increased prevalence of hypertension. Further studies are required 
to investigate this relation in older CAH patients. It is well known that  mineralocorticoid 
excess, like in primary aldosteronism or in forms of CAH with elevated levels of 
adrenal steroids with mineralocorticoid effect such as 11-hydroxylase deficiency, 
results in high blood pressure.48 Therefore, treatment with too high doses of 
mineralo corticoids or unjustified treatment with mineralocorticoids in patients with 
the SV type of CAH with suppressed renin levels may cause high blood pressure. 
However, in the reviewed papers, no correlations between renin levels and blood 
pressure values were observed in CAH patients.42–46 Glucocorticoid excess, as in 
Cushing’s syndrome, is also known to result in high blood pressure.49 Therefore, 
treatment with relatively high doses of glucocorticoids may also play a role in the 
development of high blood pressure in CAH patients.50
Insulin resistance
Nine studies have investigated insulin sensitivity in CAH patients, as summarized in 
Table 3.11,17,27,36–39,51–53 Most studies have used the homeostasis model assessment 
method (HOMA-IR) or the oral glucose tolerance test (OGTT) to assess insulin 
sensitivity. Only the study of Paula et al.51 has applied the forearm model combined 
with local indirect calorimetry, and showed that insulin sensitivity was decreased in 
adult females with CAH, compared with female controls. Thirty minutes after glucose 
ingestion, the serum insulin levels in their group of patients were significantly higher 
than in healthy controls. In a study by Speiser et al.,52 using OGTT, insulin sensitivity 
was significantly lower than expected for BMI in patients compared with controls 
(4.1 ± 0.6 vs. 9.7 ± 1.2 [min/μU/ml]; P < 0.05). Saygili et al.37 measured insulin sensitivity 
by HOMA-IR in untreated nonclassic 21-hydroxylase-deficient adult women, and 
found insulin resistance and hyperinsulinaemia. HOMA-IR was 3.2 ± 0.8 in patients 
and 1.8 ± 0.6 in controls. Serum fasting and nonfasting insulin levels in patients were 
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Table 3  Summary of studies addressing insulin resistance in congenital adrenal 
hyperplasia
Study (ref) Study population (n) Gender Age (years),  
mean ± SD
Paula et al.51 Classic 21-OH deficiency (4)
Nonclassic 21-OH deficiency (3)
Controls (9)
  7 
  9 
28 ± 3
27 ± 2
Speiser et al.52 Nonclassic 21-OH deficiency (6)
Controls (12)
  6 
12 
27
27 
Saygili et al.37 Nonclassic 21-OH deficiency (18)
Controls (26)
18 
26 
26 ± 9
29 ± 5
Sartorato et al.39 Classic 21-OH deficiency (19)
• Salt-wasting (12)
• Simple virilizing (7)
Controls (19)
10 ; 9 
10 ; 9 
28 ± 3.5
Bachelot et al.11 Classic 21-OH-deficiency (45)
• Salt-wasting (23)
• Simple virilizing (12)
• Non-classical form (10)
36 ; 9 18-47 (range)
Bayraktar et al.38 Nonclassic 21-OH deficiency (50)
Controls (25)
50 
25 
22 ± 3
22 ± 3
Buffington et al.53 Nonclassic 21-OH deficiency (3)
3β-HSD deficiency (5)
Controls (14)
• Lean (6)
• Obese (8)
  8 
14 
not mentioned
not mentioned
Charmandari et al.36 - Classic 21-OH deficiency (16)
• Salt-wasting (12)
• Simple virilizing (4)
- 11β-OH deficiency (2)
Controls (28)
  6 ; 12 
12 ; 16  
7 ± 3
9 ± 2 
Völkl 2009 et al.17 Classic 21-OH-deficiency (51)
• Salt wasting (42)
• Simple virilizing (9)
30 ; 21 5-19 (range)
SD, standard deviation; OH, hydroxylase; 3β-HSD, 3β-hydroxysteroidde hydrogenase; GnRH, gonadotropin- 
releasing hormone; iv GTT, intravenous glucose tolerance test; HOMA, homeostasis model assessment; 
OGTT, oral glucose tolerance test; ITT, intravenous insulin tolerance test; Si, insulin sensitivity
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Therapy CAH group Methods Insulin resistant?
(CAH patients vs controls)
Discontinuation of dexamethasone in 
classic 21-OH deficiency for 2-3 weeks 
prior to the study
Forearm model 
& local indirect 
calorimetry
Yes: 
Forearm glucose uptake (100.9 ± 10.0 
vs 132.5 ± 21.2 mg/100 ml forearm), 
insulin response (98.6 ± 19.4 vs 59 
± 6.5 mU.ml-1/mg.100ml forearm) 
(P<0.05)
None iv GTT Yes: 
Si: 4.1 ± 0.6 vs 9.7 ± 1.2 (P<0.05)
None HOMA Yes:
HOMA: 3.2 ± 0.8 vs 1.8 ± 0.6 (P<0.05)
All patients: glucocorticoid 
replacement with hydrocortisone 
or dexamethasone. 12 patients 
mineralocorticoid therapy.
OGTT
HOMA
Yes:
HOMA: 2.46 ± 1.92 vs 1.12 ± 0.58 
(P=0.00)
All patients: long term glucocorticoids OGTT
HOMA
Yes:
BMI < 25: HOMA 1.31 ± 0.23
BMI > 25: HOMA 2.05 ± 0.49
None HOMA No
None OGTT
ITT
No
All patients: Hydrocortisone & 
Fludrocortisone; 6 GnRH agonists
Hydrocortisone
HOMA Yes:
HOMA: 2.2 ± 0.3 vs 0.7 ± 0.04 
(P<0.001)
All patients: glucocorticoid 
substitution with hydrocortisone or 
dexamethasone
HOMA Yes:
HOMA: 2.7
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significantly higher than in controls (14.6 ± 10.3 vs. 4.2 ± 0.5 IU/l, P < 0.001 and 85.4 ± 
20.5 vs. 30.2 ± 3.5 IU/l, P < 0.001, respectively). Insulin resistance and hyperinsulin-
emia were associated with hyperandrogenism. Serum leptin levels did not differ 
between patients and controls.
 Sartorato et al.39 studied insulin sensitivity in 19 adult patients with CAH caused 
by 21-hydroxylase deficiency, using OGTT and HOMA-IR. Significantly elevated fasting 
plasma insulin levels (11.6 ± 3.20 μU/ml vs. 5.18 ± 2.4 μU/ml, P < 0.0001) and HOMA-IR 
(2.46 ± 1.9 vs. 1.12 ± 0.58, P = 0.0033) were found in CAH patients compared with 
controls.
 An OGTT was also performed in adult CAH patients by Bachelot et al.11 HOMA-IR 
was used to calculate insulin sensitivity. No control subjects were used in this study. 
During OGTT, two of 45 CAH-patients were identified with glucose intolerance. 
HOMA-IR was calculated in 40 patients: 1.58 ± 0.26 in salt wasting patients, 2.01 ± 
0.91 in simple virilizing patients and 1.39 ± 0.19 in patients with the nonclassical form 
of CAH. HOMA-IR was significantly correlated with BMI and 17-OHP levels. Bachelot 
et al.11 concluded, based on HOMA-IR, that insulin sensitivity tends to decrease when 
BMI and androgen levels increase.
 In contrast to the studies discussed earlier, Bayraktar et al.,38 using HOMA-IR, did 
not find a decrease in insulin sensitivity in CAH patients. HOMA-IR was 2.18 ± 0.11 for 
CAH patients and 2.16 ± 0.09 in controls. In addition, Buffington et al.53 found no 
insulin resistance in CAH patients. Fasting and glucose-challenged insulin levels, 
glucose disappearance rates after insulin injection and in vitro insulin binding were 
similar to lean controls. However, the inclusion of both nonclassic 21-hydroxylase-de-
ficient patients and 3β-hydroxysteroid dehydrogenase-deficient patients results in 
difficulty to arrive at solid conclusions. Furthermore, no data were provided about 
the age of the participating patients and controls.
 Two studies have evaluated insulin sensitivity in pediatric CAH patients.17,36 
Charmandari et al.36 found that HOMA-IR was significantly elevated in children with 
classic CAH, compared to healthy children (2.2 ± 0.3 vs. 0.7 ± 0.04, P < 0.001). CAH 
patients had significantly higher fasting serum insulin concentrations and significantly 
lower serum adrenaline and metanephrine levels. Völkl et al.17 measured HOMA-IR 
in 51 patients, aged 5.1–19.6 years, with CAH caused by 21-hydroxylase deficiency. 
No control subjects were investigated. A HOMA-IR of 2.7 was found and the authors 
concluded that CAH patients were characterized by insulin resistance.
 In summary, nine studies have explored insulin sensitivity either in adult or in 
pediatric CAH patients. Different methods were used to assess insulin sensitivity. 
Most studies suggest that CAH patients tend to develop insulin resistance, but studies 
using the gold standard technique to measure insulin sensitivity (euglycemic hyper-
insulinemic clamp method) are lacking. In female CAH patients, hyperandrogenism may 
induce insulin resistance. In males, hypogonadism is associated with insulin resistance. 
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Most studies assessing insulin sensitivity in CAH patients contained only female 
patients.37,38,51–53 Studies evaluating insulin sensitivity in a selected population with 
male CAH patients are lacking and a possible association between hypogonadism and 
insulin sensitivity has not been studied. No differences in insulin sensitivity between 
males and females were discussed in the studies containing both male and female 
CAH patients.11,17,36,39 Unfortunately, glucocorticoids used to treat hyperandro-
genism also induce insulin resistance.3 Therefore, both treated and untreated CAH 
patients seem to be at risk to develop insulin resistance. In children, reference data 
are lacking for most parameters used to diagnose insulin resistance. Therefore, it is 
difficult to diagnose insulin resistance in children and predict future disease risk.54
Intima-media thickness
An increased intima-media thickness (IMT) has been described as a surrogate marker 
of atherosclerosis and consequently a higher cardiovascular risk.55,56 Sartorato et 
al.39 used the echo-Doppler method for evaluation of IMT of the abdominal aorta, 
right and left common carotid arteries, carotid bulbs and common femoral arteries in 
adult CAH patients, all treated with glucocorticoids (aged 28 ± 3.5 years, n = 19). 
Significantly increased values for IMT in all arteries were found compared with 
healthy controls. No correlation was found between IMT on the one hand and fasting 
glucose, insulin levels, cumulative doses of glucocorticoids, 17-OHP or androstenedi-
one levels on the other hand. As increased IMT is an independent predictor of vascular 
events, Sartorato et al.39 concluded that CAH patients might be at risk of developing 
coronary, cerebrovascular and peripheral vascular disease.
Conclusion
We have reviewed the current evidence regarding the presence of conventional 
cardiovascular risk factors, more specifically obesity, insulin resistance, high blood 
pressure and elevated lipid concentrations in CAH patients. Overall, these studies 
demonstrate the existence of an increased fat mass, insulin resistance and an elevated 
blood pressure but a normal lipid profile in CAH patients. Taken together, these 
findings suggest that adult CAH patients seem to have a high risk to cluster a number 
of risk factors, fitting within the metabolic syndrome. The finding of an increased IMT 
in these patients suggests that these risk factors may indeed translate to cardiovascular 
disease.
 It has been suggested that CAH patients develop an unfavorable cardiovascular 
risk profile either because the existence of hyperandrogenism in untreated or under- 
treated patients or because of the (supra)physiological doses of glucocorticoids used to 
suppress androgen levels to normal values (graphically shown in Fig. 1). Many other 
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metabolic abnormalities, such as an altered leptin axis, may contribute to the 
development of cardiovascular disease. Further studies providing comprehensive 
information regarding cardiovascular risk profile are warranted, especially in older 
patients. Whether these risks are of a magnitude that justifies pharmacological 
intervention and at what age this should be started are further issues that need to 
be solved.
Figure 1  Hypothetical curves, showing the relation between androgen levels and glucocorticoid 
dosages in CAH patients. Untreated CAH patients have high androgen levels. Supraphysiological 
doses of glucocorticoids are needed to normalize androgen levels. Interindividual differences 
in glucocorticoid sensitivity (shown by the different curves), caused by different mechanisms,57–59 
may explain differences in glucocorticoid dosage between individual patients. Patients with impaired 
glucocorticoid sensitivity need higher glucocorticoid dosage to suppress androgen levels and these 
patients might have a higher chance to develop an unfavourable cardiovascular risk.
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Cardiovascular and metabolic risk in congenital  
adrenal hyperplasia
Chapter 1.2b
Cardiovascular health, growth and gonadal function in children  
and adolescents with congenital adrenal hyperplasia
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Abstract
After the introduction of replacement therapy with glucocorticoids and mineralo-
corticoids in the 1950s, congenital adrenal hyperplasia (CAH) is no longer a life-limiting 
condition. However, due to the successful introduction of medical steroid hormone 
replacement, CAH has become a chronic condition, with associated comorbidities 
and long-term health implications. The aim of treatment is the replacement of 
mineralo corticoids and glucocorticoids and the normalisation of elevated androgen 
concentrations. Long-term consequences of the condition and current treatment 
regimens include unfavorable changes in the cardiovascular risk profile, impaired 
growth, testicular adrenal rest tumors (TART) in male and subfertility in both male 
and female patients with CAH. Optimizing replacement therapy in patients with CAH 
remains challenging. On one hand, treatment with supraphysiological doses of gluco-
corticoids might be required to normalise androgen concentrations and decrease size 
or presence of TARTs. On the other hand, treatment with supraphysiological doses of 
glucocorticoids is associated with an increased prevalence of unfavorable cardio- 
vascular and metabolic risk profiles as well as impaired longitudinal growth and 
gonadal function. Therefore, treatment of children and adults with CAH requires an 
individualized approach. Careful monitoring for early signs of complications is already 
warranted during pediatric healthcare provision to prevent and reduce the impact 
of comorbidities in later life.
43
General introduction
1
Introduction
Congenital adrenal hyperplasia (CAH) is one of the most common inherited autosomal 
recessive disorders of metabolism. In 95% of cases, it is caused by 21-hydroxylase 
deficiency (21OHD).1 Steroid 21OHD results in impaired adrenocortical synthesis of 
cortisol. Due to reduced negative feedback to the hypothalamus and pituitary gland, 
cortisol deficiency results in increased secretion of adrenocorticotropic hormone 
(ACTH) from the pituitary. This in turn leads to the accumulation of steroid hormone 
precursors and androgens. Depending on the severity of the enzymatic deficiency, 
21OHD manifest as a continuum. Prenatal virilization in females depends on the 
degree of residual enzyme activity resulting in increased production of adrenal 
androgens, with a possible additional role for the production of androgens via the 
‘backdoor pathway’.2
 The CYP21A2 gene, encoding for 21-hydroxylase, is located on chromosome 6p21.3 
within the human leucocyte antigen major histocompatibility complex.3 Besides this 
active gene, humans also have a 98% homologous pseudogene (CYP21A1P), situated 
within 30 kb encoding a truncated, inactive enzyme.3 Most of the mutations causing 
21OHD derived from intergenic recombinations due to gene conversions between 
the two CYP21A genes. In most cases, the phenotype correlates with the milder 
affected allele, and consequently the residual 21-hydroxylase activity. For example, 
two severely affected alleles resulting in complete loss of 21-hydroxylase activity 
(such as complete deletions, chimeric genes and nonsense or frameshift mutations), 
typically result in the salt wasting (SW) form of 21OHD. In the case of a severely 
affected allele and a mildly affected allele, the mildly affected allele is responsible for 
the phenotype. In such cases, milder mutations have an in vitro residual 21-hydroxylase 
activity of approximately 20%–50%, which is sufficient for adequate production of 
cortisol and aldosterone. However, ACTH overstimulation leads to adrenal androgen 
excess and these variants are associated with non-classic 21OHD. The intron 2 splice 
site mutation is associated with both the SW and the simple virilizing (SV) form. 
The I172N mutation causes a variable phenotype, and is in most cases associated with 
a milder SV form. A strong genotype-phenotype correlation of 80%–90% have been 
described for 21OHD, but several studies showed discordance in individual cases.4–9
 Historically, two clinical forms of 21OHD are distinguished: a classic form 
(commonly subdivided in a SW and SV form) and a non-classic form. The classic form 
has an incidence of between 1 in 10 000 and 1 in 15 000 live births in most Caucasian 
populations.3 Patients with the classic SW form of CAH have no residual activity or 
hardly any residual activity when both alleles have the intron 2 splice site mutation. 
Females present most commonly at birth with virilization of the female external 
genitalia due to elevated adrenal androgen exposure in utero. Males present later in 
the neonatal period with SW. Patients with SV CAH have mutations with an in vitro 
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residual enzyme activity of 1%–2%. This enzyme activity is sufficient to produce 
aldosterone preventing clinically relevant SW; however, most patients will require 
cortisol replacement.1,10 The non-classic form is the mildest form of CAH and has a 
prevalence of about 0.1% in the general white Caucasian population.11 Patients with 
non-classic CAH have mutations causing an in vitro residual 21-hydroxylase activity 
of 20%–50%.11 They frequently have elevated androgen concentrations resulting in 
a variable phenotype of premature pubarche, menstrual disturbances and polycystic 
ovary syndrome (PCOS).1,10 Importantly, clinical phenotypic expression of CAH 
follows a continuum rather than a strict division in different forms. Thus, patient care 
needs to be individualized rather than following strict categorization in historic 
disease severities.
 Treatment of classic CAH consists of lifelong glucocorticoid treatment and in 
patients with evident salt-loss mineralocorticoid replacement. In contrast to individuals 
with primary adrenal insufficiency, cortisol treatment also aims to reduce ACTH-driven 
adrenal androgen excess by reducing pituitary ACTH secretion. Unfortunately, with 
current cortisol replacement regimens, normalization of androgen concentrations 
frequently requires supraphysiological doses of glucocorticoids.
 As a result of the treatment with glucocorticoids and mineralocorticoids, introduced 
in the 1950s, nearly all patients with CAH in Western countries currently reach 
adulthood.12 Therefore, increased awareness of long-term complications and 
comorbidities in patients with CAH is becoming significantly more important to reduce 
long-term risks. Herein, we review unfavorable effects on the cardiovascular risk 
profile and gonadal function in children and young persons with 21OHD.
Cardiovascular and metabolic risk profile in children  
and young adults with CAH
The evidence for increased cardiovascular and metabolic risk in  
patients with CAH
There is clear evidence to show that adults with CAH have an increased cardiovascular 
and metabolic risk. Adults with CAH have been shown to may have an increased 
prevalence of insulin insensitivity, hypertension and obesity, with most body composition 
studies identifying an increase in overall and abdominal fat mass.13–19 Increased 
cardiovascular and metabolic morbidity in patients with CAH has been described in 
a Swedish population-based cohort study with higher frequencies of hypertension, 
hyperlipidemia, atrial fibrillation, venous thromboembolism, obesity and type 2 
diabetes.20
 Data on cardiovascular and metabolic risk factors in children and young adults 
with CAH remain scarce with most studies including only small numbers of patients. 
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However, children and adolescents with CAH also show early signs of cardiovascular 
abnormalities. Increased intima-media thickness, a surrogate marker of atherosclerosis, 
has been described in adolescents and young adults with CAH.21,22 Blood pressure 
within the first year of life has only been systematically assessed in two studies and 
was reported to be either normal or elevated.23,24 Bonfig and Schwarz23 described 
a correlation between hypertension and fludrocortisone as well as an inverse 
relationship with plasma renin activity (PRA), suggesting a role of over -treatment 
with fludrocortisone in the etiology of hypertension in infancy. Close monitoring of 
individual mineralocorticoid replacement is essential to reduce the potential negative 
side effects of fludrocortisone overexposure.25 Furthermore, during childhood, a trend 
towards high blood pressure including absent nocturnal dipping and elevated body 
mass index (BMI) has been described,13,15,19,26 which emphasizes the requirement 
of blood pressure monitoring in patients with CAH of all ages.
 Glucocorticoid dose, advanced maturation of the bone age and parental obesity 
contribute to increased BMI-SD score (SDS) in children and adolescents with CAH.27,28 
An early ‘adiposity rebound’, defined as the age at which the physiological decrease 
in BMI reverses, has also been described in children with CAH.29 The early ‘adiposity 
rebound’ increases the risk of developing obesity in adolescence.30 Children and 
young adults with CAH do already show signs of impaired insulin sensitivity, which 
seems to be associated with glucocorticoid treatment.15,26,31 There is no strong 
evidence for dyslipidemia in children, adolescents and adults with CAH.15
 In summary, it is highly likely that overexposure to glucocorticoids, mineralo-
corticoids, and androgens contribute to the development of an unfavorable cardio-
vascular risk profile in patients with CAH. Since treatment with glucocorticoids and 
mineralocorticoids is ideally initiated within the first weeks of life, careful monitoring 
at close intervals of serum androgen precursors and renin concentrations is necessary 
to prevent overexposure to glucocorticoids and mineralocorticoids. Regular assessment 
of blood pressure is warranted in children and young adults with CAH to prevent 
iatrogenic hypertension due to mineralocorticoid overexposure.
Cardiovascular and metabolic risk profile—possible mechanisms
Glucocorticoid excess
The daily dose of glucocorticoids in the treatment of children with CAH has reduced 
over the last decades, with a current recommended daily hydrocortisone dose of 
10–15 mg/m2/day.32 In most of the patients, supraphysiological glucocorticoid 
concentrations are needed to achieve sufficient normalization of adrenal androgens.1,33 
Hypercortisolism is associated with hypertension, obesity with abdominal fat 
accumulation and diabetes mellitus.34 A Swedish population study described an 
increased risk ratio for all-cause mortality in adult patients with Addison’s disease 
mainly due to cardiovascular death. This increase in cardiovascular morbidity and 
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mortality was hypothesized to be secondary to excess glucocorticoid exposure.35 
Similarly in patients with CAH the increased risk for cardiovascular mortality might 
well be caused by the exposure to supraphysiological doses of glucocorticoids from 
an early age.36 Close individual tailoring of glucocorticoid treatment from an early 
age to limit overtreatment may reduce these adverse effects. Especially during 
puberty, steroid precursors increase significantly with the need of adaption of 
glucocorticoid medication. However, clear data on different glucocorticoid treatment 
regimens and their effects on the cardiovascular health in children are lacking. A small 
study in children with CAH showed that a hydrocortisone treatment regimen with 
the highest dose in the evening led to increased 24 hour blood pressure levels and did 
not improve biochemical control.37 Population studies in adults do not show a clear 
superiority of a specific treatment regimen that warrants current clinical use.38,39 
Furthermore, the need of supraphysiological doses of glucocorticoids leads to loss of 
the cortisol circadian rhythm, which is associated with an increased incidence of 
obesity, diabetes mellitus and an increase in biomarkers of cardiovascular disease.40 
In adults with adrenal insufficiency, there is some evidence that mimicking the 
circadian rhythm of cortisol excretion with glucocorticoid replacement is associated 
with lower total daily doses of hydrocortisone and potentially reduces the prevalence 
of associated metabolic and cardiovascular complications.41,42 Recently, novel 
approaches have been published to implement more physiological glucocorticoid 
replacement including continuous hydrocortisone infusion, once-daily modified- 
release hydrocortisone and delayed and sustained absorption hydrocortisone 
formulations.40
Hyperandrogenism
Many patients with CAH have persistently or intermittently elevated adrenal androgens 
despite treatment with supraphysiological glucocorticoid doses. Strong evidence 
suggests hyperandrogenism induces impaired insulin sensitivity;43 thus contributing 
to an increased risk for cardiovascular disease in patients with CAH. An increased 
cardiovascular disease risk has also been described in PCOS, with hyperandrogenism 
being associated with visceral obesity and consequently impaired insulin sensitivity, 
hypertension, decreased leptin and increased adiponectin concentrations.44 
Therefore, elevated androgen concentrations are likely to increase the risk of early 
cardiovascular morbidity in patients with CAH with manifestations of its forerunners 
already in childhood.
Mineralocorticoid excess
High blood pressure is a characteristic and well-established feature in patients with 
mineralocorticoid excess syndromes such as primary aldosteronism and rare forms 
of CAH such as 11β-hydroxylase deficiency. Therefore, it has be suggested that 
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 mineralocorticoid excess may also play an important role in the development of 
hypertension in CAH.45 Mineralocorticoid treatment needs to be carefully monitored 
by evaluating renin concentrations every 3–6 months, and even more frequently 
during the first years of life. Regular evaluation of blood pressure is warranted to 
diagnose hypertension due to mineralocorticoid overexposure at an early stage. 
To prevent overtreatment with mineralocorticoids, especially together with salt 
 supplementation in the first year of life, suppressed renin levels should be avoided. 
We, therefore, aim for renin concentrations in the upper normal or slightly elevated 
range in our clinical practice. Close monitoring is required in infants with CAH as min-
eralocorticoid sensitivity rapidly increases in the first few months and years of life. 
At birth there is a low expression of the mineralocorticoid receptor in the kidneys 
causing partial aldosterone resistance in newborns. The relative expression of 
the mineralocorticoid receptor increases within the first year of life causing an 
increased mineralocorticoid sensitivity.46,47 Elevated 17-hydroxyprogesterone (17-OHP) 
concentrations, exhibiting anti-mineralocorticoid effects, can also influence the 
 mineralocorticoid requirement due to antagonistic effects of 17-OHP on the mineralo-
corticoid receptor.48 The Endocrine Society guidelines on CAH recommend treatment 
with mineralocorticoid in all patients with classic CAH during the newborn period and 
early infancy to avoid potential salt loss.32 A recent report finding significant rates of 
hypertension despite adhering to the recommended fludrocortisone doses emphasizes 
the importance to closely monitor and titrate mineralocorticoid replacement to 
individual requirements to avoid iatrogenic mineralocorticoid excess.23
Bone health and linear growth in CAH
Chronic glucocorticoid excess leads to osteopenia and osteoporosis.49 In patients with 
CAH aged over 40 years decreased bone mineral density has been described.16,19,50,51 
Similar abnormalities have not been identified in young adults with CAH.19,52,53
 It is well established that glucocorticoid excess leads to impaired linear growth 
and consequently reduced final height. Continuous treatment with supraphysiological 
doses of glucocorticoids impairs growth by several mechanisms, including direct 
effects on the growth plate, resulting in disruption of the growth plate architecture 
and interference with the growth hormone—insulin-like growth factor-1 axis with 
long-term daily glucocorticoid treatment resulting in impaired growth hormone 
secretion and action.54,55 On the other hand, hyperandrogenism results in advanced 
skeletal maturation and early epiphyseal fusion and has also a negative impact on 
final height. Several studies demonstrated a dose-dependent negative relationship 
between glucocorticoid dose and linear growth in patients with CAH during infancy, 
puberty and adolescence.56–59 In contrast, a recent meta-analysis and a natural 
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history study showed that the cumulative glucocorticoid dose did not significantly 
influence the final height.19,60,61 The meta-analysis showed a final height of −1.38 SDS 
in adult patients with CAH. All patients were treated with high doses of glucocorti-
coids in early life,60 emphasizing the need to find the lowest glucocorticoid dose from 
early life onwards. It will be of great interest to evaluate the effect on linear growth 
of lower glucocorticoid doses used for treating patients with CAH after treatment 
regimens changed in the early 2000s.
 Infancy is by far the most sensitive period of growth as the growth velocity is 
fastest. Higher glucocorticoid doses during infancy impair final height, and impaired 
linear growth during this time will not be recovered later in life.56,57,60 Moreover, 
during the first 12–18 months of life androgen excess does not lead to a significant 
acceleration of growth and bone age maturation. Therefore, glucocorticoid doses are 
advised to be limited to a replacement dose during infancy, as growth in the first year 
of life is not impaired by hyperandrogenism. Overtreatment with glucocorticoids 
during puberty also negatively influences final height by suppressing growth hormone 
synthesis and consequently resulting in an impaired pubertal growth spurt. The hydro - 
cortisone dose should not exceed 17 mg/m2/day to improve final height to avoid 
suppression of pubertal growth.62 Careful titration of the hydrocortisone dose 
reduces the risk of overtreatment and is likely to result in improved height outcomes 
in patients with CAH.
Male gonadal function in CAH
Fertility is decreased in males with classic CAH and lower child rate, abnormal semen 
analysis, decreased inhibin B and abnormal gonadotropin concentrations have been 
described. The most frequently reported causes of gonadal dysfunction and infertility 
in patients with CAH are the presence of testicular adrenal rest tumors (TART) and 
gonadotropin deficiency due to central hypogonadism.63
 TART are benign lesions, typically localized within the rete testis and have 
adrenocortical features including the expression of adrenal-specific enzymes, adrenal 
steroid production, ACTH, luteinizing hormone (LH) and angiotensin II receptor type 2. 
Due to the common localization in the testes, TART often lead to compression of 
the seminiferous tubules consequently resulting in obstructive azoospermia and 
irreversible damage of the surrounding testicular tissue resulting ultimately in 
infertility.64 The reported prevalence of TART in adults with CAH varies between 0% 
and 94%, depending on the selection of patients and the method of tumor detection.64 
Recent studies have shown that TART can already be found in childhood and infancy 
with a reported overall prevalence in children up to 39% and an increase in prevalence 
during puberty,65 suggesting a role of LH in TART growth during puberty.19,66–70 
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Importantly, in most cases tumors were not detectable by palpation suggesting an 
important role for testicular ultrasound for diagnosing TART.68 Tumors <2 cm are 
generally not palpable because of their central location. Therefore, without additional 
imaging such as ultrasound these tumors will be missed.19,64,71,72 The situation 
regarding gonadal dysfunction during childhood and adolescence remains unclear.68 
A Dutch study investigating 34 patients aged 2–18 years showed normal testicular 
function,68 whereas a study from Chile reported lower values for inhibin B, 
anti-Müllerian hormone-stimulated testosterone in 19 patients with CAH aged 
2–10 years.69
 The exact etiology of TART remains unclear. Since TART have been identified in 
young infants with severe 21OHD, it has been hypothesized that TART may have their 
origin in utero.64 Interestingly, TART seems to be a characteristic feature in CAH as 
these cells are not found in unaffected newborn males.73 Recent studies showed that 
TART express both adrenal and Leydig cell features, suggesting a more totipotent 
embryologic origin.74 Therapeutic options remain limited. The first choice of 
treatment is optimizing glucocorticoid therapy to suppress ACTH as a probable 
growth factor for TART. However, due to the uncertain prognosis and the risk of 
irreversible damage of the testicular tissue, semen cryopreservation should be 
offered as soon as possible. Furthermore, regular ultrasound evaluation of TART 
might be beneficial from puberty to detect small non-palpable lesions to adjust 
treatment individually and subsequently prevent TART progression and ultimately 
improve male fertility.
 Untreated or not well-controlled patients with CAH are exposed to elevated 
concentrations to androgens which are in part aromatized to estrogens. Exposure to 
long-term high concentrations of sex steroids leads to suppression of the hypotha-
lamic-pituitary-gonadal (HPG) axis manifesting clinically as hypogonadotropic 
hypogonadism, but with normal production of testosterone from adrenal origin.75–78 
Therefore, inhibin B is superior marker for Sertoli cell function over follicle-stimulating 
hormone in adult males with CAH.68,79 In addition, secondary hypogonadism in males 
with CAH can also be caused by suppression of the HPG axis due to glucocorticoid 
overtreatment, which is associated with reduced fecundity in males with CAH.79
Female gonadal function in CAH
Menstrual cycle
Disturbances of the menstrual cycle are regularly seen in females with CAH. 
Oligomenorrhea or amenorrhoea in patients with CAH is often associated with poor 
therapeutic control. In patients with non-classic CAH menstrual irregularity frequently 
is one of the presenting signs.80 Even in the absence of adrenal androgen excess, 
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elevated progesterone concentrations of adrenal origin may cause menstrual cycle 
irregularity.81 Therefore, it can be used as an important clinical parameter to monitor 
the degree of adrenal hormonal control in adolescent females with CAH.
Fertility
Reduced fertility, but normal fecundity, has been described in adult females with 
CAH.57,82–87 Females with CAH appear to be less sexually active and are less likely to 
have children compared with the general population. The more severely girls are 
affected the more pronounced is the reduced interest having children.19,88 Impaired 
fertility in patients with CAH has several causes including adrenal overproduction 
of androgens and progestins, ovarian hyperandrogenism, polycystic ovaries, neuro-
endocrine factors (eg, suppression of the HPG axis due to glucocorticoid over-
treatment), genital surgery and psychosocial factors such as delayed psychosexual 
development, reduced (hetero-)sexual activity and low maternal feelings.80,89,90 
Insufficient treatment with glucocorticoids, and consequently elevated adrenal 
androgen and progesterone concentrations, are therefore the most important 
medical cause of impaired fertility in females with CAH. The severity of 21OHD 
correlates with the severity of subfertility.82 Treatment with increased doses of 
 glucocorticoids is effective in improving fertility in almost all female patients.91 
On the other hand, overtreatment with glucocorticoids can cause hypogonadotropic 
hypogonadism via suppression of the HPG axis and consequently reduced fertility.
 Besides hormonal causes, psychological causes seem to play an important role in 
the reduced female fertility in CAH. Impaired psychosexual development and sexual 
motivation may be caused by the stress due to genital surgery and following vaginal 
dilatation and repetitive genital examinations. Furthermore, early vaginoplasty may 
cause strictures leading to dyspareunia. The anatomical outcome of genital surgery is 
an important determinant of the sexual motivation in women with CAH.80
Conclusion
Unfavorable changes in the cardiovascular and metabolic risk profile and gonadal 
function can be commonly identified in children with CAH. Treatment with high doses 
of glucocorticoids might be necessary to suppress androgen concentrations and to 
decrease the prevalence and size of TARTs. However, supraphysiological doses of 
 glucocorticoids increase the risk of patients with CAH developing an unfavorable 
cardiovascular risk profile and secondary hypogonadism (figure 1). In contrast, 
androgen excess may also affect cardiovascular health, growth and fertility in 
undertreated patients with CAH (figure 1). Therefore, treatment of children and 
adolescents with CAH needs to be personalized to the individual requirements 
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Figure 1  Balancing between the effects of hyperandrogenism and the effects of treatment 
with supraphysiological doses of glucocorticoids in congenital adrenal hyperplasia (CAH). 
Both under treatment and overtreatment have effects on cardiovascular and metabolic health; 
bone health and gonadal function in patients with CAH. TART, testicular adrenal rest tumor.
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balancing the use of supraphysiological glucocorticoid doses and hyperandrogenism. 
Optimization of care should focus on long-term aims of preserving fertility and 
preventing increased cardiovascular morbidity in adult life.
 The current development of novel therapies mimicking a more physiological 
glucocorticoid replacement such as sustained-release hydrocortisone preparations 
and novel strategies towards anti-androgenic therapy may help in the long term to 
reduce the risk of overtreatment with glucocorticoids and may improve the balance 
between androgen levels and treatment with (supraphysiological of doses) gluco-
corticoids. Further improvements in the medical care and control of patients with 
CAH should lead to improved long-term health.
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The role of adrenal steroid precursors in the pathophysiology 
of congenital adrenal hyperplasia
Text	is	partially	based	on	sections	from	“Disorders	of	Adrenal	Steroidogenesis:	Impact	
on	Gonadal	Function	and	Sex	Development.	Mooij	CF,	van	Herwaarden	AE,	Claahsen-	
van der Grinten HL. Pediatric Endocrinology Reviews. 2016. 14(2):109-128”
CHAPTER 1.3
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Adrenal steroidogenesis in CAH is altered compared to healthy people due to its 
enzymatic defect. CAH due to 21-hydroxylase deficiency (21OHD) leads to cortisol 
deficiency and (in most cases) aldosterone deficiency. The compensatory increase in 
ACTH secretion by the pituitary gland results in stimulation of the adrenal cortex and 
consequently in accumulation of steroid hormone precursors before the enzymatic 
defect. In contrast to other types of adrenal insufficiency, the presence of increased 
concentrations of steroid precursors is a hallmark feature in patients with CAH and 
this can be used as a diagnostic marker.1 
Adrenal steroidogenesis
The adrenal cortex consists of three different functional zones (zona glomerulosa, 
fasciculata and reticularis) which produce different steroid hormones. The zones differ 
in terms of presence of enzymes involved in specific steroid production. Mineralo-
corticoids (with its final product aldosterone) are mainly produced within the zona 
glomerulosa, glucocorticoids (with its final product cortisol) within the zona fasciculata 
and androgen precursors in the zona reticularis.
 Cholesterol is the substrate for the synthesis of all steroid hormones within the 
gonad and adrenal cortex.2 Most cholesterol used in steroidogenesis comes from 
plasma low density lipoproteins which contain dietary cholesterol.3 Some cholesterol 
is synthesized within the adrenal cells by the endoplasmatic reticulum from acetate. 
The steroidogenic acute regulatory protein (StAR) facilitates the first step in the 
 steroidogenesis by transporting cholesterol from the outer mitochondrial membrane 
to the inner mitochondrial membrane.4,5 Once cholesterol is transported to the inner 
mitochondrial membrane it can be converted into pregnenolone by mitochondrial 
cytochrome P450 side-chain cleavage enzyme (p450scc; CYP11A1).2 Further steps in 
steroidogenesis are facilitated by several steroidogenic enzymes within the mito - 
chondria and the endoplasmatic reticulum. Most of these steroidogenic enzymes 
are cytochrome P450 enzymes (CYPs) or hydroxysteroid dehydrogenases (HSDs).2 
The first steps in both adrenal and gonadal steroid synthesis are driven by the same 
enzymatic steps (common pathway). The enzymes involved in the common pathway 
are StAR, CYP11A1, CYP17 and 3BHSD2. A defect in one of these enzymes can lead to 
both impairment of gonadal and adrenal steroid synthesis. The last steps in the 
steroid synthesis are driven by characteristic enzymes within the specific zonas of 
the adrenal or within the gonads.
 The quantitative regulation of steroidogenesis occurs at the first step, the 
conversion of cholesterol to pregnenolone by CYP11A1. ACTH stimulates a rapid 
increase in adrenal steroidogenesis, by stimulating cholesterol delivery to the 
mitochondria where CYP11A1 is located, and a longer-term chronic cyclic AMP/
protein kinase A based response that affects both gene transcription and translation 
of a variety of steroidogenic enzymes. However, the qualitative regulation of adrenal 
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 steroidogenesis, determining the class of steroid produced, is principally determined 
by CYP17A1. The presence or absence of 17alpha-hydroxylase and 17,20 lyase activity 
determines which class of steroids will be produced. The discrimination between 
17alpha- hydroxylase and 17,20 lyase activities is regulated by two posttranslational 
events, the serine phosphorylation of CYP17 and the allosteric action of cytochrome 
b5, both of which act to optimize the interaction of CYP17 with its obligatory electron 
donor, P450 oxidoreductase.6 Adrenal steroidogenesis, the involved enzymes and 
produced (precursor) steroids are schematically shown in figure 1. 
 In healthy individuals adrenal steroidogenesis leads to the stepwise conversion 
of cholesterol into aldosterone, cortisol or adrenal androgens. Levels of precursor 
steroids are generally low. However, in patients with impaired enzymatic activity of 
one of the enzymes involved in adrenal steroidogenesis, elevated levels of steroid 
precursors before the enzymatic block are found. For example in 21OHD patients, 
levels of progesterone, 17OHP, androstenedione and 21-deoxycortisol are increased. 
In 21OHD CYP11B1 facilitates the conversion of 17OHP into 21-deoxycortisol 
(as indicated in figure 1).
Steroid hormone receptors
Adrenal steroid hormones exhibit their action via binding to a steroid receptor. 
Steroid hormone receptors are intracellular transcription factors that can be 
activated, by the specific and high affinity binding of ligand (steroid hormone) to 
exert positive or negative effects on the expression of target genes. The steroid 
hormone receptor family consists of nuclear receptors sharing a common structure.7 
The glucocorticoid receptor (GR; NR3C1), mineralocorticoid receptor (MR; NR3C2), 
progesterone receptor (PR; NR3C3) and androgen receptor (AR; NR3C4) are members 
of the nuclear receptor family, together composing subfamily C3. The GR, MR, PR and 
AR share structural similarities. All four receptors contain three functional domains: 
the N-terminal transactivation domain followed by the DNA-binding domain and the 
C-terminal ligand-binding domain.8 A hinge region links both binding domains. 
Compared with the GR, the sequence identities of the N-terminal domains of the MR, 
PR and AR are 38, 24, and 16%, of the DNA binding domains 94, 91 and 79%, and of 
the ligand binding domains 57, 54 and 51%, respectively.9,10 One of the common 
features of the ligand-binding domains of the GR, MR, PR and AR is their structural 
composition and organization. However, several structural features ensure ligand 
selectivity. For example, a unique hydrogen bond network between the receptor and 
the bound ligament establishes specific recognition between the ligand and receptor.9 
The shape of the steroid and the topology inside the binding pocket enhance 
selectivity. Furthermore, the relative position of the binding pocket within the 
receptor ligand binding domain plays a role in ligand selectivity.9 
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The endogenous ligand of the GR is the major glucocorticoid cortisol, but also 
exogenous glucocorticoids like dexamethasone, prednisolone and hydrocortisone 
can act as agonists of the GR. In high concentrations also aldosterone may act as a 
ligand for the GR.10 The most important mineralocorticoid is aldosterone exhibiting 
its action by binding to the MR. Besides its affinity for aldosterone the MR has 
an equivalently high affinity for cortisol, corticosterone and progesterone.10,11 
The endogenous ligands for both the GR and MR are C21 steroids, based on a 
21-carbon skeleton. In contrast, the C19 steroids, based on a 19-carbon skeleton, 
 dihydrotestosterone, testosterone and androstenedione are the physiological 
ligands of the AR. Not all ligands exhibit agonistic effects. Some ligands have 
antagonistic properties, like progesterone on the MR. The exact mechanism how 
ligands fulfill their antagonistic action is not fully elucidated, one may hypothesize 
that it may cause inhibition of all steps involved in binding, translocalization and 
transactivation of the steroid receptors. As steroid precursors show structural 
similarity to aldosterone or cortisol, they may also act as a ligand for the steroid 
hormone receptors. Especially in patients with elevated levels of steroid hormone 
precursors, like in CAH, the effects of these steroid hormones as potential ligand of 
the GR, MR and AR are of great interest. The structural similarity of these steroid 
hormone precursors is illustrated in figure 2.
Figure 2  The chemical structures of cortisol, 17OHP, 21-deoxycortisol, progesterone and 
aldosterone illustrating their structural similarity.
17-hydroxy progesterone 
Progesterone 
21-   
Aldosterone 
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At equilibrium the GR and MR are localized both in the cytoplasm and the nucleus, 
the AR is predominantly localized in the cytoplasm without the presence of a ligand.12 
Hormone induced nuclear translocation is described for both the GR, MR and AR.12-15 
Within the nucleus the ligand-activated receptors regulate transcription via three 
major pathways. Transactivation requires receptor dimerization and binding to cis- 
activating palindromic response elements located in the promotor region of target 
genes.16,17 A second way of gene regulation is the binding to negative response 
elements causing transrepression.18 The third mechanism of action is transrepression 
via protein-protein interactions by inactivation of transcription factors such as 
activator protein-1, nuclear factor-kappa B and NF-AT (e.g. playing a role in the anti- 
inflammatory action of glucocorticoids).19-21 Furthermore, extragenomic effects have 
been described for both glucocorticoids and mineralocorticoids.22-24 The presence 
of glucocorticoid receptor agonists is known to result in down-regulation of the 
glucocorticoid receptor,25 suggesting that the presence of elevated concentrations of 
steroids and its precursors may also lead to steroid hormone resistance. A schematic 
and simplified overview of steroid hormone action is shown in figure 3.
Figure 3  A schematic overview of steroid hormone action including binding to the steroid 
hormone receptor, translocation of the receptor/steroid hormone complex to the nucleus leading 
to gene transcription. Image	credit	to	Alila	Medical	Media	(www.alilamedicalmedia.com).
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Clinical observations in CAH suggesting a role of adrenal steroid precursors 
in steroid metabolism
The structural similarity between the steroid hormone receptors as well as the 
steroid hormones and their precursors suggest that elevated levels of steroid hormone 
precursors may also lead to binding to steroid hormone receptors, and consequently 
activation or inhibition of glucocorticoid, mineralocorticoid and androgen receptor 
mediated action. Furthermore, several clinical observations suggest that adrenal steroid 
precursors in CAH patients may have some compensatory mineralocorticoid feature 
and play a role in glucocorticoid and/or mineralocorticoid metabolism: 
• Untreated newborn patients with the SW CAH phenotype usually present with salt 
wasting crisis after the first week of life. However, most of them do not present 
with typical symptoms of infantile glucocorticoid deficiency such as hypoglycaemia 
or conjugated hyperbilirubinemia.26,27  
• In countries where no neonatal screening for CAH is implemented males with the 
SV CAH phenotype often present with signs of androgen excess in childhood, 
without a history of Addisonian crises during illness or surgery prior to diagnosis.28 
• Adult CAH patients who are lost to follow up and are not adherent to glucocorticoid 
therapy often do not develop adrenal crises.29
• Reduced fludrocortisone requirement after lowering precursor concentrations can 
be clinically observed even in the absence of an increased hydrocortisone dose. 
Therefore, this effect is very likely due to direct competition of steroid hormone 
precursors with fludrocortisone for binding to the mineralocorticoid receptor.30
All above described observations may be caused by potent effects of high circulating 
amounts of adrenal steroid precursors, in untreated or suboptimally treated patients, 
on the glucocorticoid and/or mineralocorticoid receptor. In untreated and poorly 
controlled CAH patients levels of steroid hormone precursors, including progesterone, 
17OHP, 21-deoxycortisol and androstenedione, are elevated. These precursors are 
known to have structural similarities to cortisol,31 and therefore may exhibit 
glucocorticoid properties. The exact role of the steroid precursors in the steroid 
metabolism in CAH patients still has to be elucidated. Previous studies showed that 
progesterone and 17OHP may contribute to mineralocorticoid deficiency in classic 
CAH patients, due to antagonistic properties on the human mineralocorticoid 
receptor.30 Other studies suggested that at least some of these steroid precursors 
have glucocorticoid or mineralocorticoid activity interfering with the glucocorticoid 
and/or mineralocorticoid receptor.32 In this thesis we will discuss the role of steroid 
precursors in both mineralocorticoid and glucocorticoid metabolism in more detail.
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After a brief introduction on CAH (Chapter 1.1), a review of the literature on the 
cardiovascular and metabolic risk profile in both pediatric and adult CAH patients 
(Chapter 1.2a and 1.2b), and an introduction on the role of steroids and steroid 
precursors in CAH (Chapter 1.3) is given, this thesis continues with describing the 
results of original studies on these subjects. The most important questions we wanted 
to answer in this thesis were: 
1.  Is there an unfavorable cardiovascular and metabolic risk profile in adult and 
pediatric CAH patients?
2.  Which factors contribute to an unfavorable cardiovascular and metabolic risk 
profile in adult and pediatric CAH patients? 
3.  What is the role of steroid precursors on the steroid metabolism in CAH patients 
in vitro?
In the first part of the thesis, we describe the results of a cross-sectional study 
evaluating the cardiovascular risk profile in adult CAH patients (Chapter 2.1) and the 
results of a placebo controlled trial on the use of pioglitazone to improve insulin 
sensitivity in adult CAH patients (Chapter 2.2). 
 In the second part of the thesis we focus on the cardiovascular and metabolic risk 
profile of pediatric CAH patients. Chapter 3.1 describes the results of a retrospective 
study evaluating blood pressure levels during the first year of life in pediatric CAH 
patients. Chapter 3.2 shows cross-sectional data on several cardiovascular and 
metabolic risk factors in pediatric CAH patients aged 8 to 16 years. Furthermore, we 
have evaluated cardiac function in the same group of pediatric CAH patients by elec-
trocardiogram, conventional echocardiography, tissue Doppler imaging and 2D 
myocardial strain (rate) imaging (Chapter 3.3). 
 Data on the role of steroids and steroid precursors in CAH are presented in the 
third part of the thesis. Chapter 4.1 describes the influence of steroids and steroid 
precursors whose concentrations are increased in CAH on the in vitro transactivation 
and translocation of the human mineralocorticoid receptor. In Chapter 4.2 we 
present data on the role of steroids and steroid precursors accumulating in CAH on 
the transactivation of the human glucocorticoid receptor. 
 We conclude this thesis by reflecting on the main findings of this thesis, discussing 
the broader perspective of our results in relation to current literature, reflect upon 
the limitations of our studies and discuss the clinical implications of our work and the 
directions for future research in Chapter 5.
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CARDIOVASCULAR AND METABOLIC RISK 
PROFILE IN ADULT PATIENTS WITH 
CONGENITAL ADRENAL HYPERPLASIA
CHAPTER 2

Adult patients with congenital adrenal hyperplasia  
have elevated blood pressure but otherwise a normal 
cardiovascular risk profile
Mooij CF, Kroese JM, Sweep FCGJ, Hermus ARMM, Tack CJ.
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Abstract
Objective: Treatment with glucocorticoids and mineralocorticoids has changed 
congenital adrenal hyperplasia (CAH) from a fatal to a chronic lifelong disease. 
Long-term treatment, in particular the chronic (over-) treatment with glucocorticoids, 
may have an adverse effect on the cardiovascular risk profile in adult CAH patients. 
The objective of this study was to evaluate the cardiovascular risk profile of adult 
CAH patients.
Design: Case-control study.
Patients and Measurements: In this case-control study the cardiovascular risk profile 
of 27 adult CAH patients and 27 controls, matched for age, sex and body mass index 
was evaluated by measuring ambulatory 24-hour blood pressure, insulin sensitivity 
(HOMA-IR), lipid profiles, albuminuria and circulating cardiovascular risk markers 
(PAI-1, tPA, uPA, tPA/PAI-1 complex, hsCRP, adiponectin, IL-6, IL-18 and leptin).
Results: 24-Hour systolic (126.3 mmHg±15.5 vs 124.8 mmHg±15.1 in controls, 
P = 0.019) and diastolic (76.4 mmHg±12.7 vs 73.5 mmHg±12.4 in controls, P<0.001) 
blood pressure was significantly elevated in CAH patients compared to the control 
population. CAH patients had higher HDL cholesterol levels (P<0.01), lower hsCRP 
levels (P = 0.03) and there was a trend toward elevated adiponectin levels compared 
to controls. Other cardiovascular risk factors were similar in both groups.
Conclusion: Adult CAH patients have higher ambulatory blood pressure compared 
to healthy matched controls. Other cardiovascular risk markers did not differ, while 
HDL-cholesterol, hsCRP and adiponectin levels tended to be more favorable. 
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Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder of adrenal 
steroidogenesis. In 95% of cases it is caused by 21-hydroxylase deficiency.1 Deficiency 
of 21-hydroxylase results in impaired adrenal synthesis of cortisol and often also of 
aldosterone leading to increased secretion of ACTH by the pituitary gland, adrenal 
hyperplasia, and excessive production of adrenal androgens. Current treatment of 
CAH consists of administration of glucocorticoids and, if necessary, of mineralo-
corticoids to prevent adrenal crises and to suppress the abnormal secretion of adrenal 
androgens. Patients with CAH are at risk of developing signs and symptoms of Cushing’s 
syndrome, as the therapeutic range of treatment with glucocorticoids is narrow and 
slightly supraphysiological doses of glucocorticoids are needed.1,2 Cushing’s syndrome is 
associated with insulin resistance and cardiovascular morbidity.3 Therefore, patients 
with CAH may develop an adverse cardiovascular risk profile, which is of increasing 
clinical importance as nowadays nearly all CAH patients reach adulthood.
 A recent Swedish population study described an increased risk ratio for all-cause 
mortality of 2.19 (confidence interval 1.91–2.51) for men and 2.86 (confidence 
interval 2.54–3.20) for women treated with glucocorticoids in Addison’s disease.4 
The excess mortality in both males and females was mainly attributable to 
cardiovascular disease (risk ratio (RR) for cardiovascular death in men 1.97 (confidence 
interval 1.61–2.39); RR in women 2.31 (confidence interval 1.94–2.74)). The increased 
cardiovascular mortality in Addison’s patients is most likely caused by excess 
glucocorticoid exposure. CAH patients are commonly treated with significantly higher 
doses of glucocorticoids than Addison’s patients, already starting directly after birth. 
Therefore, evaluating the cardiovascular risk profile in CAH patients is of importance, 
with the oldest CAH patients now being in their sixties.
 So far, few studies have focused on cardiovascular risk in CAH patients. An elevated 
body mass, an increased fat mass and insulin resistance have been described in adult 
and pediatric CAH patients.5 Blood pressure has been studied mainly in pediatric 
and young adult CAH patients and showed a tendency towards high blood pressure 
in some, but not all, studies.5 Lipid profiles in adult CAH patients did not show 
unfavorable changes.5
 We hypothesized that adult CAH patients are at risk to develop an unfavorable 
cardiovascular risk profile due to lifelong treatment with glucocorticoids. As described 
above, results of prior studies concerning the cardiovascular risk profile in CAH 
patients are inconclusive. Furthermore, most studies were performed in small patient 
groups, or mainly in pediatric patients or without a proper control group. As adult 
CAH patients tend to become obese, especially proper matching for body mass is 
warranted. More recent markers for cardiovascular risk, like plasminogen activator 
inhibitor type 1 (PAI-1), tissue-type plasminogen activator (tPA), urokinase-type 
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plasminogen activator (uPA), tPA/PAI-1 complex and high sensitive CRP (hsCRP), have 
not been studied before in CAH patients. Therefore, the aim of this study was to 
evaluate insulin sensitivity, blood pressure, albuminuria, lipid profile, and other 
circulating cardiovascular risk markers in adult CAH patients and to compare to the 
cardiovascular risk profile of carefully matched control subjects.
Materials and Methods
Patients
Adult patients with proven congenital adrenal hyperplasia were included in this study. 
Inclusion criteria for patients were biochemically and genetically proven CAH and 
stable glucocorticoid and mineralocorticoid therapy for 3 months. For each individual 
patient a healthy, age-, sex- and body mass index (BMI)-matched control was recruited 
by advertisements. Inclusion criteria for control subjects were an unremarkable 
medical history and at present no evidence of disease, no medication (except for oral 
contraceptives) and Caucasian race. Exclusion criteria for patients and control 
subjects were age <18 years and inability to give informed consent. All patients were 
fully informed about the aim and design of the study and all the methods involved. 
They consented with the study protocol according to the recommendations of the 
medical ethical committee of the Radboud University Nijmegen Medical Centre.
Methods
Each participant visited the hospital on two consecutive days. On the first day, 
participants visited the hospital in the morning after abstinence of caffeine containing 
substances and an overnight (10-hour) fast. All participants received a physical examination 
including anthropometric measurements. Blood was drawn to assess fasting glucose, 
insulin, HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, and several 
circulating cardiovascular risk markers, like PAI-1, tPA, uPA, tPA/PAI-1 complex, hsCRP, 
adiponectin, IL-6, IL-18 and leptin. Plasma concentrations of total adiponectin, IL-6 
and IL-18, hsCRP and leptin were determined using ELISAs (R&D Systems, Minneapolis, 
MN). ELISAs, developed by our department, were used for assessment of components of 
the plasminogen activation system (uPA, tPA and PAI-1) and its complexes (tPA:PAI-1).6,7 
PAI-1/tPA ratios were calculated. Insulin resistance (IR) was estimated using the 
homeostasis model assessment (HOMA) method [IR = insulin (µmol/ml)×glucose 
(mmol/l)/22.5].8 Office blood pressure was measured using a Dinamap Vital Signs 
Monitor. Blood pressure was measured twice supine and once in upright position. 
Mean supine office blood pressure was calculated. Subsequently, ambulatory blood 
pressure was monitored for 24 hours (SpaceLabs model 90207). On the second day, 
participants returned to the hospital for disconnection of the ambulatory blood 
pressure monitoring device.
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Statistics
For calculations and statistical analyses, the SPSS personal computer software 
package was used and P<0.05 was considered statistically significant. Abnormally 
distributed data were log-transformed. Differences between CAH patients and 
controls were statistically tested using unpaired Student’s t-test or the Mann-Whitney 
U-test, as appropriate. Results are expressed as mean ± SEM, unless otherwise 
indicated.
Results
A total of 27 patients were included in this study. 20 patients had the salt-wasting 
type of CAH, 6 patients were simple virilizers and 1 patient had a non-classic type of 
CAH. The control group was well matched for age, sex and BMI. Key parameters of the 
selected population were similar to the whole population of adult CAH patients 
treated in our medical center. At the time of the investigation twenty-three patients 
were treated with hydrocortisone as the only glucocorticoid. One patient was treated 
with dexamethasone only, one patient was treated with cortisone acetate only and 
two patients received a combination of dexamethasone and hydrocortisone. Gluco-
corticoid doses were converted into hydrocortisone equivalents using anti-inflammatory 
equivalents (hydrocortisone 30 mg = cortisone acetate 37.5 mg = dexamethasone 0.75 mg). 
Hydrocortisone equivalents are also presented as mg/m2. Five patients had plasma 
renin levels <5 mU/l, consistent with overtreatment. Characteristics of our study 
population, including current daily hydrocortisone and fludrocortisone dosage, are 
shown in table 1.
Blood pressure profiles
Office blood pressure measurements during hospital visit showed no significant 
differences in supine and upright systolic and diastolic blood pressure between CAH 
patients and controls. Supine and upright heart rates during hospital visit were not 
different in CAH patients compared to controls  (table 1).
 Mean 24-hour systolic (mean ± SD, 126.3±15.5 mmHg vs 124.8±15.1 mmHg, 
P = 0.019) and diastolic (76.4±12.7 mmHg vs 73.5±12.4 mmHg, P<0.001) blood 
pressure was significantly elevated in CAH patients compared to the control 
population. Mean arterial pressure (MAP, 92.7±12.9 mmHg vs 90.0±12.3 mmHg in 
controls, P<0.001) and heart rate (77.1 bpm±17.9 vs74.2 bpm±15.5 in controls, 
P<0.001) also showed significantly higher levels in CAH patients than in controls. 
Measured blood pressure values and differences between day- and nighttime are 
shown in figure 1.
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When analyzed separately for day and night, systolic blood pressure was not 
significantly elevated during the day (08.00 h to 22.00 h) nor during the night (22.00 
h to 08.00 h), but diastolic blood pressure was elevated both during day- (P<0.001) 
and nighttime (P = 0.001) in CAH patients compared to controls. CAH patients thus 
had a similar blood pressure dip during the night as compared to controls.
Urinary cardiovascular risk markers
Albumin excretion was comparable in CAH patients and controls (data not shown).
Table 1  Characteristics of the study population
Patients (n=27) Controls (n=27)
Gender (M/F) 12/15 12/15
Age (years) 30.2 ± 8.0 32.5 ± 11.7
Height (m) 1.67 ± 0.10 1.75 ± 0.09#
Weight (kg) 75.4 ± 13.1 83.3 ± 14.5#
BMI (kg/m2) 27.2 ± 4.6 27.3 ± 4.8
Waist circumference (cm) 86.9 ± 11.5 88.3 ± 12.0
Hip  circumference (cm) 101.6 ± 9.7 103.9 ± 9.4
Waist/hip ratio 0.86 ± 0.08 0.85 ± 0.08
Office systolic blood pressure (mmHg)
    Supine
    Upright
133 ± 12
128 ± 13
133 ± 12
131 ± 12
Office diastolic blood pressure (mmHg)
    Supine
    Upright
83 ± 10
91 ± 10
80 ± 10
90 ± 10
Office heart rate (bpm)
    Supine
    Upright
67 ± 13
78 ± 14
66 ± 11
79 ± 14
Daily hydrocortisone dosage (mg)* 23.4 ± 8.0 -
Daily hydrocortisone dosage (mg/m2) 12.6 ± 4.48 -
Daily fludrocortisone dosage (mg)** 0.11 ± 0.06 -
Plasma renin level (mE/l) 34.9 ± 69.9 -
Mean values ± 1 SD are given. M=male; F=female; bpm=beats per minute, # P<0.05, *Glucocorticoid 
doses were converted into hydrocortisone equivalents using anti-inflammatory equivalents **25 
patients were treated with fludrocortisone
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Lipid profile
HDL cholesterol concentration was higher in CAH patients compared to controls. No 
significant differences in total cholesterol, LDL cholesterol and triglycerides between 
CAH patients and controls were observed (Table 2).
Figure 1  Mean 24-hour ambulatory blood pressure measurements (±1SD) in CAH patients 
(opens squares) and matched controls (closed squares).
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Table 2  Lipid profile in adult CAH patients and healthy, matched controls
CAH patients 
(n=27)
Controls  
(n=27)
P-value
Total cholesterol (mmol/l) 4.6 ± 1.0 4.2 ± 1.0 0.22
Triglycerides (mmol/l) 1.0 ± 0.6 1.0 ± 0.6 0.93
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.1 ± 0.2 < 0.01
LDL cholesterol (mmol/l) 2.8 ± 0.7 2.7 ± 0.9 0.87
Mean values ± 1 SD are given.
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Insulin sensitivity
Fasting plasma glucose levels did not differ between CAH patients and controls 
(4.6±0.6 vs 4.8±0.6 mmol/L, P = not significant). Insulin levels also were comparable in 
CAH patients and controls (9.4±4.6 vs 10.1±4.8 pmol/L, P = not significant), as was 
calculated HOMA-IR (2.0±1.2 vs 2.2±1.0, P = not significant).
Circulating cardiovascular risk markers
A trend toward elevated adiponectin levels in CAH patients compared to controls was 
observed (Table 3). Significantly lower hsCRP levels were found in CAH patients 
compared to controls (P = 0.03). PAI-1, uPA, tPA, tPA/PA1-complex, PAI-1/tPA ratio, 
IL-6, IL-18 and leptin levels were not significantly different in CAH patients and controls 
(Table 3).
Clinical characteristics
Average BMI was high in CAH patients (27.2±4.6 kg/m2). Waist and hip circumference 
and waist/hip ratio were not different in CAH patients compared to controls (data 
shown in table 1). It was not possible to evaluate BMI as an individual cardiovascular 
risk marker because controls were matched for BMI in our study.
Table 3  Circulating cardiovascular risk markers in adult CAH patients and healthy, 
matched controls
CAH patients  
(n=27)
Controls  
(n=27)
P-value
IL-18 (pg/mL) 57±24 53±26 0.56
IL-6 (pg/mL) 1.31±1.50 1.37±1.26 0.89
Adiponectin(ug/mL) 4.17±3.03 2.93±1.33 0.06
Leptin (ng/mL) 24±20 (n=26) 24±18 0.92
hsCRP (mg/L)* 1.06±1.49 1.79±1.83 0.03
uPA (ng/mL) 0.99±0.52 0.92±0.54 0.63
PAI-1 (ng/mL) 55±29 51±19 0.51
tPA (ng/mL) 4.86±2.13 6.01±3.74 0.17
tPA-PAI-1 complex (ng/mL) 6.95±3.67 9.11±5.52 0.10
PAI-1/tPA ratio 12.53±7.72 10.19±4.23 0.17
Mean values ± 1 SD are given. 
*As hsCRP values were not distributed normally, we have calculated log(CRP) values
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Discussion
The present study shows that the cardiovascular risk profile of adult CAH patients is 
relatively unaffected compared to a carefully BMI, sex and age matched control 
group; only slightly elevated 24-hour blood pressure levels were found.
 Our finding of an elevated 24-hour blood pressure profile in adult CAH patients 
was not reported in earlier studies in adult CAH patients.9,10 However, studies in 
young adult and pediatric CAH patients did show a tendency towards hypertension.5 
Elevated blood pressure in CAH patients may be caused both by glucocorticoid and 
mineralocorticoid therapy, as glucocorticoid as well as mineralocorticoid excess is 
known to result in high blood pressure.11,12 As 24-hour blood pressure is only slightly 
elevated it is hard to predict the clinical importance of this finding for the individual 
patient. Therefore, it is uncertain if the elevation in 24-hour blood pressure profile 
found in our population will lead to an increased cardiovascular mortality. The increase 
was found in ambulatory blood pressure, not in office blood pressure, suggesting 
that a given office blood pressure in a CAH patient may reflect slightly higher 24 h 
hypertensive burden and thus more risk compared to control subjects.
 The finding of a tendency toward elevated adiponectin levels in adult CAH 
patients is in line with the study by Völkl et al. who reported significantly elevated 
adiponectin levels in 51 children and adolescents with CAH.13 Adiponectin has insulin 
sensitizing and anti-inflammatory properties and high adiponectin levels are 
associated with lower risk of myocardial infarction and a reduced risk of type 2 
diabetes.14,15 Adiponectin levels are known to be decreased in obesity, insulin 
resistance and type 2 diabetes,16 and administration of glucocorticoids and androgens 
have been shown to decrease adiponectin levels.17,18 The higher adiponectin level 
found in CAH patients treated with glucocorticoids is thus somewhat surprising. With 
respect to their cardiovascular risk profile, elevated adiponectin levels might have a 
beneficial effect concerning the development of type 2 diabetes and myocardial 
infarction.
 In contrast to earlier studies,5 including one of our own,19 our adult CAH patients 
were not insulin resistant when evaluated by the HOMA-IR method. The probable 
explanation for this finding is the careful matching in BMI. Alternatively, the HOMA 
method may not have been sensitive enough to detect differences in our population. 
The lipid profile of adult CAH-patients showed no unfavorable changes. This finding is 
in line with earlier studies evaluating lipid profiles.5 In the present study we found 
significantly elevated HDL-cholesterol levels; Falhammer et al. showed a tendency 
towards higher HDL-cholesterol in female CAH patients 30 years of age or older.9
 To our knowledge hsCRP levels have not been studied before in CAH patients. 
The trend towards lower hsCRP levels in CAH patients may be explained by the 
chronic treatment with glucocorticoids. It is well known that glucocorticoids have 
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anti-inflammatory effects, but data on the direct effect of glucocorticoid treatment 
on CRP levels are lacking.20
 Most studies evaluating cardiovascular risk factors in CAH patients have focused 
on one or several risk factors. Recently, the CaHASE study evaluated the health status, 
including cardiovascular and metabolic risk, in a large British cohort of 199 adult CAH 
patients due to 21-hydroxylase deficiency.21 Results were compared to Health Survey 
for England data. Similar to our study they showed elevated diastolic but not systolic 
blood pressure. Differences in blood pressure results between our study and the 
CaHASE study may be explained by the fact that in the CaHASE study no 24-hour 
ambulatory blood pressure measurement was performed and that the results were 
compared to reference values of the general population. Furthermore they report 
high frequencies of obesity (41%), hypercholesterolemia (46%), insulin resistance 
(29%) and osteopenia (40%) compared to reference values. As data in the CaHASE 
study are only compared to age- and sex-matched reference data it is hard to compare 
their results with those obtained in our study, using an age-, sex- and BMI-matched 
cohort, as increased BMI plays an important role in both cardiovascular and metabolic 
risk. Falhammar et al. recently evaluated cardiovascular and metabolic risk in adult 
male CAH patients.22 Their findings are partly in agreement with ours: increased fat 
mass and similar lipid profiles, but no increased blood pressure, which may be due to 
the small (sub) sample sets.
 Our study had limitations. We have used the HOMA-IR method to evaluate insulin 
sensitivity instead of the gold standard, the euglycemic clamp. Furthermore, the fact 
that we have chosen to use a BMI-matched control group, precludes us to evaluate 
the role of obesity as a cardiovascular risk factor in CAH patients. This may be relevant 
as the CAH group was on average overweight. Evaluation of the cardiovascular risk 
profile depends on the evaluated markers. In this study we did not evaluate 
endothelial dysfunction, endothelial vasodilative capacity and the endothelial 
response to glucocorticoid and mineralocorticoids. As we did not control for the 
effects of environmental and physiological factors like stress and health behavior we 
could not evaluate the role of these factors on blood pressure levels and other 
cardiovascular risk factors.
 In summary, this study shows that adult CAH patients have an elevated 
ambulatory blood pressure, but otherwise a normal cardiovascular risk profile 
compared to healthy BMI, age and sex matched controls. One may speculate that 
elevated adiponectin and HDL-cholesterol and decreased hsCRP levels may even have 
some protective effect on the development of cardiovascular disease in these 
patients.
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Abstract
Context: Patients with congenital adrenal hyperplasia (CAH) are chronically treated 
with supraphysiological doses of glucocorticoids, which are known to induce insulin 
resistance. Thiazolidinediones might reverse this effect and improve insulin sensitivity.
Objectives: To assess insulin sensitivity in CAH patients and the effect of pioglitazone 
treatment on insulin sensitivity in CAH patients. Secondary objectives were the effects 
of treatment with pioglitazone on blood pressure, body fat distribution, lipid, and 
steroid profiles.
Design: Randomized placebo controlled crossover trial.
Participants: Twelve CAH patients and 12 body mass and age-matched control 
subjects.
Intervention: Sixteen-week treatment with pioglitazone (45 mg/day) or placebo.
Main outcome measure: Insulin sensitivity measured by euglycemic clamp and oral 
glucose tolerance test. Further measures were 24-h blood pressure profiles, body fat 
distribution measured by magnetic resonance imaging, dual energy x-ray absorptiometry 
(DEXA) and bioimpedance procedures, liver fat by magnetic resonance spectroscopy, 
lipid, and steroid profiles.
Results: CAH patients were insulin resistant compared with healthy controls. 
Treatment with pioglitazone significantly improved insulin sensitivity in CAH patients 
(glucose infusion rate (GIR) from 28.5±11.6 to 38.9±11.0 μmol/kg per min, P=0.000, 
GIR in controls 46.2±23.4 μmol/kg per min, P<0.05 versus CAH). Treatment with 
pioglitazone decreased blood pressure (systolic: 124.0±13.6 vs 127.0±14.9 mmHg, 
P<0.001, diastolic: 72.8±11.5 vs 77.4±12.6 mmHg, P<0.001). No changes in body fat 
distribution, lipid, and steroid profiles were observed.
Conclusions: CAH patients are insulin resistant compared with matched control subjects. 
Treatment with pioglitazone improves insulin sensitivity and decreases blood pressure 
in CAH patients.
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Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive condition, which is in 
more than 95% of the cases caused by a mutation in the gene for 21-hydroxylase.1 
This defect results in increased secretion of ACTH, adrenal hyperplasia and increased 
production of androgens, but glucocorticoid deficiency. Current treatment comprises 
glucocorticoid (and, if necessary, mineralocorticoid) administration to prevent adrenal 
crises and suppress the abnormal secretion of androgens. However, because glucoco-
rticoids are given in slightly supraphysiological doses and the therapeutic range for 
glucocorticoids is narrow, patients are at risk of developing iatrogenic Cushing’s 
syndrome.1
 Glucocorticoids induce insulin resistance in humans,2 and may precipitate diabetes 
in susceptible subjects. Chronic exogenous or endogenous oversupply with glucocor-
ticoids is associated with changes in fat distribution, typically toward more central/
visceral fat. Whether the observed insulin resistance is related to these changes in 
body fat distribution is not known.
 The use of supraphysiological doses of glucocorticoids and androgen excess in 
CAH patients are associated with the development of an unfavorable cardiovascular 
risk profile.3 Data on the prevalence of cardiovascular morbidity or life expectancy 
in CAH patients are not yet available. In this respect, it is of interest that a recent 
population- based study in Sweden has showed that patients with Addison’s disease 
have a clearly increased mortality rate. The excess mortality in both males and 
females was for a major part caused by cardiovascular disease. The authors of this 
study suggested that the increased cardiovascular mortality in Addison’s patients is 
caused by excess glucocorticoid exposure.4
 Of the few studies that have explored insulin sensitivity in CAH, most have 
concluded that CAH patients are indeed characterized by insulin resistance.5-11 Many 
different methods have been used to assess insulin sensitivity, but studies using the 
euglycemic hyperinsulinemic clamp method, the gold standard to assess insulin 
sensitivity, are lacking. It has also been reported that CAH patients are at risk of 
developing other components of the metabolic syndrome.3,12,13
 CAH patients are characterized by insulin resistance and have an unfavorable 
cardiovascular risk profile, so it might be a rational option to improve their insulin 
sensitivity with insulin sensitizers. Improving their cardiovascular risk profile might 
also improve their life expectancy. Thiazolidinediones (TZDs) improve insulin sensitivity 
in several conditions associated with insulin resistance. The improvement of insulin 
sensitivity is associated with beneficial changes in several parameters, like lipids, 
blood pressure, and vascular function, and changes in inflammatory markers.14,15 
Therefore, TZDs might be a rational therapeutic option in glucocorticoid-induced 
insulin resistance, as has been suggested by earlier studies.16,17 Such improvement in 
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insulin sensitivity might have a twofold benefit: first, glucose tolerance in patients 
with limited β-cell function will improve and hence the chance to develop overt type 
2 diabetes will decrease. Secondly, cardiovascular risk factors associated with insulin 
resistance will improve.18
 In the present study, we tested the hypotheses that CAH patients who are 
chronically treated with glucocorticoids are insulin resistant and that treatment with 
pioglitazone improves insulin sensitivity in this group. Insulin sensitivity was assessed 
using the euglycemic clamp procedure. We also measured the effect of pioglitazone 
treatment on body fat distribution, including liver fat content, blood pressure, and 
lipid profile.
Materials and methods
Patients
Adult subjects with biochemically and genetically proven CAH on a stable cortico-
steroid replacement dose for 3 months were included in the study. Characteristics of 
the study population are shown in Table 1. Gender, phenotype, results of mutation 
analysis, medication, and mean salivary androstenedione levels of the study 
population are shown in Table 2. Exclusion criteria were as follows: age <18 years, 
inability to give informed consent, significant cardiovascular disease (defined as 
myocardial infarction or stroke 6 months preceding the study), significant renal 
disease (defined as a glomerular filtration rate (GFR) <30 ml/min), significant liver 
disease (defined as alanine aminotransferase and aspartate aminotransferase levels 
of more than three times the upper limit of normal), and mental disease. All patients 
were fully informed about the aim and design of the study and all the methods 
involved. They consented with the study protocol which was approved by the 
institutional review board of the Radboud University Nijmegen Medical Centre.
 Insulin sensitivity in CAH patients treated with glucocorticoids was compared to 
insulin sensitivity measured in a group of body mass index (BMI) and age-matched 
normal subjects. These subjects were selected in a case–control design from a larger 
cohort earlier described.19 Characteristics of the control group are shown in Table 1.
Methods
At screening, all patients underwent a full physical examination and electrocardiog-
raphy. Blood was drawn for determination of liver function and renal function. To 
estimate GFR, the MDRD–GFR equation was used.20
 After a 4-week run-in phase, patients were randomized to treatment with either 
placebo for 16 weeks, followed by pioglitazone (45 mg/day) for 16 weeks, or treatment 
with pioglitazone for 16 weeks, followed by placebo for 16 weeks in a randomized 
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crossover design. Patients visited the clinic every 2 months for medication checks, 
adverse events, and measurement of weight, blood pressure, and edema formation. 
Safety measures included assessment of weight, blood pressure, and edema. At the 
end of the respective study periods, fasting glucose, lipid, and hormone levels (insulin, 
ACTH, cortisol, aldosterone, renin, 17-OH progesterone and androstenedione in 
serum, and 17-OH progesterone and androstenedione in saliva in the morning, 
afternoon, and evening) were assessed and insulin sensitivity was measured using a 
euglycemic hyperinsulinemic (steady-state plasma insulin level ~600 pmol/l) clamp. 
Glucose tolerance was measured using an oral 75-g glucose load. Blood glucose and 
insulin samples were collected at 30, 60, 90, and 120 min after the test load. Glucose 
tolerance was evaluated using the criteria of WHO.21 Body fat distribution was 
assessed by two different methods, magnetic resonance imaging (MRI) and DEXA 
scanning. Total body DEXA scanning was performed using a Hologic QDR 4500 
densitometer (Hologic, Bedford, MA, USA) to determine total bone mineral content 
(BMC, g), total areal bone mineral density (g/cm2), fat mass, and lean mass. Twenty-
four-hour ambulatory blood pressure measurement was performed using the 
Table 1  Characteristics of patients and controls
CAH patients Control subjects
Gender (M/F) 5/7 5/7
Age (yrs) 35.7 ± 8.9 37.6 ± 6.5
Height (m) 1.64 ± 0.11 1.73 ± 0.09
Weight (kg) 72.6 ± 15.1 79.5 ± 14.3
BMI (kg/m2) 26.9 ± 4.7 26.6 ± 5.1
Waist (cm) 87.1 ± 10.7
Hip (cm) 101.3 ± 10.5
Waist/hip 0.86 ± 0.09
Systolic blood pressure (mmHg)
   Supine 
   Upright
134 ± 14
125 ± 12
124 ± 11
Diastolic blood pressure (mmHg)
   Supine
   Upright
83 ± 8
87 ± 11
78 ± 12
Heart rate (bpm)
   Supine
   Upright
68 ± 6
77 ± 8
70 ± 10
M=male, F=female, bpm=beats per minute
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ambulatory SpaceLabs model 90207 blood pressure monitoring system. Mean 
salivary androstenedione levels were calculated from six samples: three samples 
after placebo treatment and three samples after pioglitazone treatment (same time 
points as after placebo treatment). Undertreatment was defined as the presence of a 
mean level of salivary androstenedione above the upper reference morning (0800 h) 
level, i.e. more than 0.63 nmol/l in males and 1.1 nmol/l in females. Overtreatment 
Table 2  Age, gender, phenotype, mutation analysis, medication and mean 
salivary  androstenedione levels in 12 included congenital adrenal hyperplasia 
(CAH) patients
P Age 
(years)
Gender Phenotypea Allele 1b Allele 2b BMI  
(kg/m2)
1 28 F non-classic c.841G>T (p.Val281Leu) c.841G>T (p.Val281Leu)
c.920-921insT(c.923dup)
c.952C>T (p.Gln318X)
c.1066C>T(p.Arg356Trp)
19.2
2 37 F SW del/conv del/conv 37.6
3 33 M SW del/conv c.290-13A/C>G 29.9
4 52 M SV c.515T>A (p.Ile172Asn) del/conv 29.6
5 45 M SV c.290-13A/C>G del/conv 26.2
6 28 F SW del/conv c.IVS2-13A/C>G 25.7
7 27 F SW c.290-13A/C>G c.329-336del (p.Gly110fs) 23.4
8 42 F SW c.290-13A/C>G c.952C>T (p.Gln318X) 29.5
9 28 F SW c.1066C>T (p.Arg356Trp) c.1066C>T (p.Arg356Trp) 24.5
10 28 M SW del/conv del/conv 23.6
11 48 M SV del/conv c.515T>A (p.Ile172Asn) 24.4
12 32 F SW c.707T>A (p.Ile236Asn), 
c.710T>A (p.Val237Glu),
c.716T>A (p.Met239Lys)
del/conv 29.5
P = patient number; F = female; M = male; del = deletion; conv = conversion; HC = hydrocortisone; DXM = 
dexamethasone
aSW = classic salt wasting CAH; SV = classic simple virilising CAH
bNucleotides are numbered according to the HGVS guidelines using Genbank entry NM_000500.5 
as reference sequence, where the A of the first ATG is 1. The variable Leucine stretch in exon 1 was 
counted as 4, not 5 Leucines to comply with the widely accepted numbering used in the literature. 
cMineralocorticoid medication (9-α-fluorohydrocortisone acetate) was taken in one to two doses. 
dSalivary levels of androstenedione are mean levels from six samples (see Materials and Methods)
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was defined as the presence of a mean level of salivary androstenedione below the 
lower reference morning (0800 h) level, i.e. lower than 0.14 nmol/l in males and 
0.16 nmol/l in females.
 In control subjects insulin sensitivity was measured using the same euglycemic 
hyperinsulinemic clamp procedure as in CAH patients.
Daily glucocorticoid therapy Daily  
mineralocorticoid  
therapyc
Mean salivary 
androstenedione 
levels (nmol/l)d
HC: 20 – 5 mg (8 a.m. – 11 p.m.) - 0.07
HC: 25 – 10 mg (9 a.m. – 5 p.m.) 0.1 mg 0.08
HC: 15 – 5 – 7.5 mg (9.00 a.m. – 0.30 p.m. – 11.30 p.m.) 0.2 mg 0.51
HC: 17.5 – 10 mg (7.30 a.m. – 6.30 p.m.) - 0.83
HC: 10 – 10 mg (8 a.m. – 11 p.m.) 0.0625 mg 0.14
HC: 6 – 4 – 4 mg (08 a.m. – 14 a.m. – 23 p.m.) 0.0625 mg 0.02
HC: 6 – 6 – 6 mg (6.30 a.m. – 4 p.m. – 10 p.m.) 0.1 mg 0.18
HC: 17.5 – 15 mg / HC: 15 – 15 mg (every other day,  
6.30 a.m. – 5.30 p.m.)
0.150 mg 0.17
HC: 10 – 10 mg (8.30 a.m. – 10.30 p.m.) 0.0625 mg – 0.125 mg 
(every other day)
0.03
HC: 10 – 15 mg (6 a.m. – 9 p.m.), DXM: 0.25 mg  
(ante noctem)
0.4 mg 0.08
HC: 15 – 5 mg (8.30 a.m. – 11.30 p.m.) - 0.50
DXM: 0.1 – 0.1 mg (7.30 a.m. – 11 p.m) 0.3 mg 0.44
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Procedures
Euglycemic clamp
Experiments were performed in the morning after an overnight (10 h) fast. Two i.v. 
cannula were inserted. One positioned retrogradely into a dorsal vein of the hand 
that was placed in a Plexiglas box, ventilated with heated air, for sampling of 
arterialized venous blood.22 The second cannula was inserted in an antecubital vein 
of the contralateral arm for infusion of insulin and glucose. Insulin (Actrapid, 
NovoNordisk, Bagsvaerd, Denmark; diluted in NaCl of 0.9% to a concentration of 1 U/ml, 
with the addition of 2 ml whole blood per 50 ml) was infused at a rate of 60 mU/min 
per m2 body surface area (360 pmol/min per m2). Arterialized venous plasma glucose 
was measured in duplicate at 5-min intervals by the glucose oxidation method 
(Beckman Glucose Analyser II, Beckman, Fullerton, CA, USA). Plasma glucose was 
clamped at the fasting level by a variable infusion of glucose 20% solution. Plasma 
insulin was measured in all samples with an in-house RIA at the start of the clamp 
procedure and after 90 and 120 min.23 Whole body glucose disposal was determined 
by glucose infusion rate (GIR) as: (mean glucose infusion 90–120 min (mg/min)/weight 
(kg))×(1000/180 g/mol) μmol/min per kg.
Magnetic resonance imaging and spectroscopy
Liver fat content and abdominal fat distribution were determined by proton magnetic 
resonance spectroscopy (MRS) and imaging (MRI) on a clinical 3T whole body MR 
system (Siemens Magnetom Tim Trio, Erlangen, Germany). All measurements were 
carried out during breath-holding for 15 s. Liver fat content was determined by 
single-voxel proton MR spectra with STEAM localization (echo time 20 ms; repetition 
time 3 s). Hepatic fat percentage was calculated without correction for differences in 
relaxation times by dividing the lipid methylene signal intensity at 1.3 ppm by the sum 
of the methylene lipid and water signal intensities and multiplying the result by 100. 
Abdominal fat distribution was derived from 16 T1-weighted FLASH-2D axial MR 
images from a region extending from 4 cm above to 4 cm below the fourth and fifth 
lumbar interspaces. Subcutaneous and visceral fat volumes were determined based 
on signal intensity.
Statistical analysis
For calculation and statistical analyses, the SPSS personal computer software package 
was used (SPSS Inc., Chicago, IL, USA) and P<0.05 was considered statistically 
significant. Differences between pioglitazone and placebo were statistically tested 
using Student’s t-test or the Wilcoxon–Mann–Whitney test as appropriate. According 
to power calculations, detecting a 20% change in insulin sensitivity with a power of 
80% at a significance level of 0.05 would require 11 subjects completing the study.
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Results
A total of 12 CAH patients completed the study, seven females and five males. All patients 
had a biochemically and genetically proven CAH and were treated with stable 
corticosteroid doses for at least 3 months. Eight patients had the classic salt wasting 
type of CAH, three patients had the classic simple virilizing type of CAH and one 
patient had a nonclassical type of CAH. Evaluation of mean salivary androstenedione 
levels showed that six patients were adequately treated, five patients were over- 
treated and one patient was undertreated (data shown in Table 2).
Insulin sensitivity
CAH patients were insulin resistant compared with the control group using the 
euglycemic clamp procedure (GIR 28.5±11.6 vs 46.2±23.4 μmol/kg per min, CAH 
patients versus controls respectively, P=0.04, Fig. 1). Similarly, the insulin sensitivity 
index in CAH patients was significantly lower compared with control subjects 
(0.35±0.16 vs 0.56±0.30 μmol/kg per min (mU/l), P=0.03).
During treatment with pioglitazone, GIR significantly increased compared with 
placebo treatment (38.9±11.0 vs 28.5±11.6 μmol/kg per min, P=0.000, Fig. 1). 
Similarly, insulin sensitivity index improved during pioglitazone treatment compared 
with placebo (0.53±0.16 vs 0.35±0.16 μmol/kg per min (mU/l, P<0.001).24 A non- 
significant decrease in homeostasis model assessment (HOMA)-estimated insulin 
Figure 1  Glucose infusion rate (GIR, μmol/kg per min) in control subjects, CAH patients during 
placebo treatment and CAH patients during pioglitazone treatment, measured during a euglycemic 
clamp procedure. Mean values for each cluster are shown by the different boxes.
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resistance (HOMA-IR) was observed after the use of pioglitazone (1.97±1.40 vs 
1.80±0.99, P=0.34).25 Plasma glucose and insulin levels during the clamps were similar 
during both treatments and in both groups.
 Oral glucose tolerance test (OGTT) showed no significant differences in glucose 
levels after the use of pioglitazone compared to placebo. Insulin levels were lower, 
although nonsignificantly, after the use of pioglitazone. The insulinAUC(mU/l per h) for 
the whole test period (0–120 min) was significantly lower after the use of pioglitazone 
compared with placebo (81±33 vs 111±69 mU/l per h, P<0.05), with no significant 
difference in glucoseAUC (mmol/l per h) for the whole test period (13.8±2.5 vs 
13.1±3.1 mlU/l per h, P=0.31).
Body fat distribution
The MRI–MRS data showed no statistically significant changes in subcutaneous fat, 
visceral fat, the visceral–subcutaneous fat ratio, and the percentage of liver fat after 
the use of pioglitazone compared to placebo (Table 3). Most patients had relatively 
low amounts of liver fat. The only patients with a high liver fat content during placebo 
(32.7%) showed a strong decrease in the percentage of liver fat after the use of 
pioglitazone (19.3%). Other patients did not show a decrease in the percentage of 
liver fat after the use of pioglitazone.
DEXA scanning showed no relevant changes in total body BMC, total lean mass, total 
fat mass, lean and fat mass in trunk, arms and legs, and the distribution of the fat 
mass after use of placebo or pioglitazone compared to baseline data.
Table 3  Magnetic resonance imaging-magnetic resonance spectroscopy 
measurements of fat distribution, during placebo or pioglitazone in congenital 
adrenal hyperplasia patients
Placebo Pioglitazone P-value
Subcutaneous fat (l) 1.98 ± 0.83 2.00 ± 0.75 0.76
Visceral fat (l) 0.58 ± 0.30 0.58 ± 0.25 0.93
Visceral:subcutaneous fat ratio 0.3 ± 0.2 0.3 ± 0.2 0.45
% liver fat 4.2 ± 9.0 3.6 ± 5.6 0.65
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Blood pressure profiles
Ambulatory 24-h blood pressure was significantly lower during pioglitazone compared 
with placebo treatment (systolic: 124.0±13.6 vs 127.0±14.9 mmHg, P<0.001, diastolic: 
72.8±11.5 vs 77.4±12.6 mmHg, P<0.001, Fig. 2 and Table 4).
Clinical characteristics, lipid profile, and steroid profile
Clinical characteristics, like weight, BMI, waist, hip, and waist/hip ratio were not 
significantly different after the use of placebo or pioglitazone. No significant changes 
in lipid profile and levels of steroids, ACTH, and renin were observed after the use of 
pioglitazone compared to placebo.
Figure 2  Twenty-four-hour ambulatory blood pressure during pioglitazone (open squares) 
or placebo treatment (closed squares) in CAH patients.
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Discussion
The main findings of the present study are that CAH patients who are chronically 
treated with glucocorticoids are insulin resistant as compared with body mass and 
age-matched normal subjects and that treatment with pioglitazone improves insulin 
sensitivity in this group of patients.
 The finding that CAH is associated with insulin resistance is in line with earlier 
studies. These prior studies suggest that both overproduction of androgens and 
treatment with (supraphysiological doses of) glucocorticoids can induce insulin 
resistance.5-11,26,27
 In our study, we document a significantly lower insulin sensitivity index and GIR 
in adult CAH patients who were chronically treated with glucocorticoids. The 
observed insulin resistance may well be the result of treatment with glucocorticoids. 
Table 4  Twenty-four-hour ambulatory blood pressure during pioglitazone or 
placebo treatment in congenital adrenal hyperplasia patients
Placebo Pioglitazone P-value
24-h SBP 127.0 ± 14.9 124.0 ± 13.6 0.000
24-h DBP 77.4 ± 12.6 72.8 ± 11.5 0.000
24-h HR 77.1 ± 13.9 75.1 ± 13.5 0.007
24-h MAP 93.4 ± 12.5 89.4 ± 11.1 0.000
Daytime SBP 129.9 ± 13.4 127.7 ± 12.1 0.017
Daytime DPB 79.9 ± 11.5 75.3 ± 11.0 0.000
Daytime HR 78.9 ± 12.9 78.1 ± 12.9 0.396
Daytime MAP 95.9 ± 11.3 91.9 ± 10.3 0.000
Nighttime SBP 116.5 ± 15.0 111.8 ± 11.9 0.010
Nighttime DBP 68.3 ± 12.6 62.6 ± 9.2 0.000
Nighttime HR 70.2 ± 13.3 66.6 ± 10.0 0.048
Nighttime MAP 84.3 ± 12.6 79.5 ± 9.2 0.000
Nocturnal drop in SBP (% fall) 10.7 12.2 0.341
Nocturnal drop in DBP (% fall) 14.5 16.5 0.390
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, MAP = mean arterial pressure
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Glucocorticoids are known to induce insulin resistance, although the mechanisms 
involved are incompletely understood.28 Supraphysiological doses of glucocorticoids 
also increase lipolysis and plasma free fatty acids (FFA), which may lead to insulin 
resistance in muscles.16,29
 Insulin resistance is known to be a risk factor for the development of cardiovascular 
disease and to precede the development of type 2 diabetes.30,31 Therefore, CAH 
patients might be at risk to develop type 2 diabetes or cardiovascular disease later in 
life. Because CAH patients need to continue glucocorticoid treatment to suppress 
overproduction of androgens and as substitution of cortisol, we reasoned that an 
intervention with insulin-sensitizing drugs, like TZDs, might have a favorable effect on 
insulin sensitivity in CAH patients and as a result improve their cardiovascular risk 
profile.15
 We observed a significant improvement of insulin sensitivity (measured both by 
clamp and by insulin response during OGTT) in CAH patients treated with pioglitazone, 
although not to the level of the healthy control group. Pioglitazone is known for its 
ability to improve insulin sensitivity in several conditions associated with insulin 
resistance. It has been hypothesized that TZDs have an insulin-sensitizing effect 
because of alterations in adipokine release, which modulates insulin sensitivity 
outside adipose tissue.15 TZDs also promote the uptake and the storage of fatty acids 
in adipose tissue, which does lead to an increase in adipose tissue mass, but in this 
way TZDs spare other insulin-sensitive tissues as the liver and the skeletal muscle 
form the harmful metabolic effect of high concentrations of FFA.15
 During pioglitazone treatment, ambulatory 24-h systolic and diastolic blood 
pressures decreased significantly. It has been noticed before that TZDs can improve 
blood pressure profiles, although the exact mechanism is not yet known. Insulin 
resistance is known to be a risk factor for the development of hypertension, so one 
may hypothesize that improvement of insulin sensitivity may also decrease blood 
pressure. Insulin resistance contributes to the development of hypertension through 
several mechanisms like angiotensin II and aldosterone actions, enhanced sympathetic 
nervous system activity, dyslipidemia, atherosclerosis, left ventricular hypertrophy 
and changes in renal function and structure, like glomerulosclerosis.32 The anti-hy-
pertensive effects of pioglitazone have been studied in Japanese male patients with 
type 2 diabetes.33 This study showed a significant decrease in mean blood pressure 
(109±14 to 101±10 mmHg) after 3 months of treatment with pioglitazone (30 mg/day). 
Results of the present study are in line with these findings. Anti-hypertensive effects 
of pioglitazone have also been described in type 2 diabetics with difficult-to-control 
hypertension, nondipping diabetic patients, and in diet-induced obese rats.34-36
 Although our study shows favorable effects of pioglitazone on insulin sensitivity 
and blood pressure in adult CAH patients, it has become uncertain whether 
pioglitazone is a valuable addition to current treatment strategies. Recent studies 
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have questioned the long-term safety of TZDs, especially with respect to long-term 
cardiovascular outcome. Frequently noticed side effects of TZDs include edema, 
weight gain, macular edema, and heart failure. Furthermore, TZDs tend to increase 
low-density lipoprotein cholesterol levels.37 Rosiglitazone may even be associated 
with a higher risk of myocardial infarction and death due to cardiovascular causes,38 
but the RECORD study only confirmed the increased risk of heart failure.39 The 
PROactive Study showed favorable effects of pioglitazone on reduction of all-cause 
mortality, nonfatal myocardial infarction, and stroke in type 2 diabetes patients.40 
Longer follow-up of treatment with TZDs is needed to evaluate their effects on 
congestive heart failure and cardiovascular death.41 Treatment with TZDs also 
decreases bone formation and bone mass, possibly as a result of promoting 
adipogenesis above osteoblastogenesis.42 This side effect seems particularly relevant 
in our group of patients, against the background of the already ongoing adverse 
effect of corticosteroids on the bone. Over this short treatment period, we did not 
observe any changes in BMC during treatment with pioglitazone. Nevertheless, with 
the currently available data on adverse effects of TZDs, the routine use of pioglitazone 
in CAH patients seems not to be indicated in a clinical setting.
 Our study has limitations. Inherent to the short 16-week treatment period, we 
were not able to evaluate long-term effects of pioglitazone in our population. 
Furthermore, insulin sensitivity was used as a surrogate outcome, but no data on the 
prevalence of diabetes mellitus or cardiovascular disease are available. Furthermore, 
our study was probably underpowered to detect changes in fat distribution, fat mass, 
and liver fat.
 In summary, this study shows that adult CAH patients treated with glucocorti-
coids are insulin resistant. Treatment with pioglitazone significantly improves insulin 
sensitivity and decreases blood pressure in CAH patients compared with the use of 
placebo. Despite these findings, there is currently not enough evidence to warrant 
the routine use of pioglitazone in this group of patients.
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Abstract
Aims: Evaluation of blood pressure in the first year of life in children with congenital 
adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. 
Methods: Twenty-four children were included. Retrospective blood pressure values, 
fludrocortisone dosages, and serum renin, 17-hydroxyprogesterone (17-OHP) and an-
drostenedione levels in the first year of life were evaluated. Blood pressure values 
were compared to reference values. Correlations between blood pressures and 
serum renin levels, and the dosage of fludrocortisone were calculated. 
Results: Mean peak systolic blood pressure values were generally not elevated, most 
values were around the 50th percentile, except incidentally higher mean peak systolic 
blood pressure values most below the 95th percentile. No significant correlations 
between blood pressure and serum renin, androstenedione and 17-OHP levels and 
fludrocortisone dosage were found. 
Conclusion: In this pilot study in CAH patients, blood pressure values do not seem to 
be elevated in the first year of life. Further investigations are necessary to evaluate 
blood pressure in the first year of life in CAH patients in more detail.
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Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder of adrenal 
steroidogenesis. In 95% of cases, it is caused by 21-hydroxylase deficiency.1,2 
A deficiency in 21-hydroxylase results in impaired adrenal synthesis of cortisol, and 
often aldosterone as well, leading to increased secretion of ACTH by the pituitary 
gland, and consequently adrenal hyperplasia and excessive production of adrenal 
androgens. In utero, the increased synthesis of adrenal androgens leads to virilization 
of the external female genitalia. Medical treatment consists of substitution of gluco-
corticoids and mineralocorticoids with resulting suppression of ACTH production and 
thereby adrenal androgen production. In most patients, supraphysiological dosages 
of glucocorticoids are necessary to suppress adrenal androgen production.
 Nowadays, the classic type of CAH is generally diagnosed in the first weeks of life 
as a result of the neonatal screening program, and most children reach adulthood 
without serious complications. However, it has been suggested that treatment with 
supraphysiological dosages of glucocorticoids and mineralocorticoids may lead to hyper- 
tension, obesity and other cardiovascular risk factors.3 Studies on blood pressure in 
children with CAH have been performed mostly in children older than 5 years of 
age.4-8 In some of these studies, a tendency towards hypertension in pediatric CAH 
patients was shown. Studies on the incidence of hypertension in CAH patients in the 
first year of life are lacking.
 The aim of this retrospective study was to evaluate the blood pressure in the first 
year of life in patients with the classical types of CAH (salt wasting, SW, and simple 
virilizing, SV) due to 21-hydroxylase deficiency. Furthermore, we evaluated the 
correlations between the blood pressure and serum renin levels, 17-hydroxyproges-
terone (17-OHP) and androstenedione levels and dosage of fludrocortisone.
Patients and Methods
Patients
All patients who were born after the introduction of the neonatal screening on CAH 
in the Netherlands in 2000 and who were treated in the Radboud University Nijmegen 
Medical Centre because of a classic type of CAH (SW or SV) due to 21-hydroxylase 
deficiency were retrospectively studied. Diagnosis was confirmed by mutation 
analysis.9 All patients were treated according to the local CAH treatment protocol: in 
the neonatal period medical treatment was started with hydrocortisone 3 mg per day 
in 3 doses (neonates 2–5 kg) and fludrocortisone 30 µg up to 62.5 µg twice a day. 
The dosage fludrocortisone was further increased when SW was suspected. The dosage 
of fludrocortisone and salt supplementation was further adapted to weekly measured 
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serum sodium and serum renin concentrations in the first weeks of life. The dosage 
of hydrocortisone was generally not changed until the age of 8–9 months. All patients 
received NaCl supplementation from the neonatal period up to 12 months of life 
(starting dosage NaCl 10%: 2 ml/kg/day).
Data Collection
Data on blood pressure measurements, serum renin, 17-OHP and androstenedione 
concentrations and fludrocortisone dosage during the first year of life were collected. 
Blood pressure measurements were performed using a Dinamap Pro 300 vital sign 
monitor (GE Healthcare, Finland) or incidentally by manual cuff blood pressure 
recording during clinical visits to the outpatient clinic. The blood pressure was measured 
by an experienced nurse with parents calming or feeding the child. When the child 
could not be calmed, we measured the blood pressure again at the end of the clinical 
visit when the infant was calmed or sleeping.
 The mean arterial blood pressure (MAP) was calculated using the formula MAP = 
[(2 × diastolic pressure) + systolic pressure]/3.
Statistical Analysis
The collected data on blood pressures during the first year of life were compressed 
into 8 time periods (weeks 0–2, 3–8, 9–16, 17–24, 25–32, 33–40, 41–48 and 49–52) 
and presented as mean peak values.
 SPSS (Windows, v. 16.0) was used for all statistical analyses. To compare peak 
systolic blood pressure values with reference values the one-sample t test was used. 
Blood pressure values were compared with reference values of 50th and 95th 
percentile systolic blood pressures as described by the Second Task Force on Blood 
Pressure Control in Children and by Flynn.10,11 Correlation coefficients (c.c.) between 
blood pressure values (systolic, diastolic and MAP) on the one hand, and serum renin, 
17-OHP and androstenedione concentrations and fludrocortisone dosage on the 
other hand were calculated using Spearman’s rho. A value of p < 0.05 was considered 
significant (2-sided). Because of the rapidly changing reference values in the first 
8 weeks of life, further statistical analyses were not performed in this period in our 
small population.
Results
Twenty-four patients were included in the study: 14 females and 10 males. All females 
presented with CAH at birth with ambiguous genitalia, except 1 patient (No. 22) who 
presented 17 days after birth with a positive neonatal screening. She had a mild 
enlargement of the clitoris that had not been noticed before. All males were diagnosed 
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Table 1  Gender, age at presentation, mutation analyses and type of CAH
Patient Gender Age at 
presentation 
(days)
DNA analysis allele 1 DNA analysis allele 2 CAH-
type
1 F 0 del/conv c.293-13A/C>G SV/SW
2 F 0 del/conv c.293-13A/C>G SV/SW
3 F 0 c.518T>A (p.Ile173Asn) c.1069C>T (p.Arg357Trp) SV
4 F 0 del/conv del/conv SW
5 M 9 del/conv c.293-13A/C>G SV/SW
6 M 9 del/conv c.293-13A/C>G SV/SW
7 M 8 del/conv c.293-13A/C>G SV/SW
8 F 0 del/conv c.293-13A/C>G SV/SW
9 F 0 del/conv c.1069C>T (p.Arg357Trp) SW
10 M 8 c.293-13A/C>G c.518T>A (p.Ile173Asn) SV
11 M 6 del/conv c.1451G>C (p.Arg484Pro) SV/SW
12 M 9 c.1069C>T (p.Arg357Trp) c.1069C>T (p.Arg357Trp) SW
13 M 6 c.293-13A/C>G c.332-339del8 
(p.Gly111fs)
SV/SW
14 F 0 c.293-13A/C>G c.293-13A/C>G SV/SW
15 M 13 del/conv c.293-13A/C>G SV/SW
16 F 0 c.293-13A/C>G c.293-13A/C>G SV/SW
17 F 0 del/conv c.1451G>C (p.Arg484Pro) SV/SW
18 M 8 del/conv c.955C>T (p.Gln319X) SW
19 F 0 del/conv c.332-339del8 
(p.Gly111fs)
SW
20 M 7 c.332-339del8 
(p.Gly111fs)
c.955C>T (p.Gln319X) SW
21 F 0 c.293-13A/C>G c.293-13A/C>G SV/SW
22 F 17 c.518T>A (p.Ile173Asn) c.518T>A (p.Ile173Asn) + 
c.710T>A (p.Ile237Asn) + 
c.713T>A (p.Val238Glu) + 
c.719T>A (p.Met240Lys) + 
c.844G>T (p.Val282Leu) + 
c.923dup (p.Leu308fs)
SV
23 F 0 c.293-13A/C>G c.710T>A (p.Ile237Asn)+  
c.713T>A (p.Val238Glu)+ 
c.719T>A (p.Met240Lys)
SV/SW
24 F 0 c.293-13A/C>G c.332-339del8 
(p.Gly111fs)
SW
DNA-mutation analyses performed as described by Higashi et al.9
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with a positive neonatal screening and had no clinical symptoms. None of our patients 
developed hyponatremia. All patients started treatment with hydrocortisone and 
fludrocortisone within the first 2 weeks of life, with exception of patient No. 22 who 
was treated from day 18. The gender, age at presentation and mutation analysis of all 
patients are shown in table 1. Three patients had the SV genotype of CAH, 7 patients 
had the SW genotype and 14 patients had a genotype with a residual enzyme activity 
of 1–5%, usually described as SV-SW CAH.2 Data on body weight, renin levels and 
dosage of fludrocortisone during the first year of life are shown in table 2.
 A total of 189 blood pressure measurements in all 24 patients during the first 
year of life have been included in this study. Mean peak systolic blood pressure values 
for male and female CAH patients are shown in figure 1. Mean peak systolic blood 
pressure values were within the normal range, most measured around the 50th 
percentile, except mean peak systolic blood pressure values in females in weeks 9–16 
(p = 0.035). Rapidly changing variable blood pressure values were measured in the 
first 8 weeks of life. 
A positive correlation between mean peak systolic (c.c. 0.606, p = 0.048) and mean 
peak diastolic (c.c. 0.723, p = 0.018) blood pressures and serum renin concentrations 
in week 0–2 and a negative correlation between mean peak systolic blood pressure 
and serum renin concentrations in week 25–32 (–0.554, p = 0.026) were found. In all 
other time periods, there were no significant correlations between mean peak 
systolic or diastolic blood pressure values and renin levels (data not shown). No 
significant correlation was found between MAP, systolic or diastolic blood pressure 
Table 2  Means (ranges) for weight, renin levels and daily dosage of fludrocortisone 
during the first year of life in 24 CAH patients
Time period (weeks) Weight, kg Renin level, mE/l Daily dosage of 
 fludrocortisone, µg
0-2 3.44 (2.73–4.48) 1,368 (37–16,136) 140 (62.5–200)
3-8 4.93 (3.19–5.35) 308 (3–1,808) 150 (62.5–187.5)
9-16 6.02 (4.36–7.08) 104 (3–562) 130 (62.5–200)
17-24 7.29 (5.10–8.60) 83 (3–426) 110 (50–187.5)
25-32 8.05 (5.59–9.40) 213 (3–1,113) 110 (50–150)
33-40 8.78 (6.30–11.0) 176 (3–585) 110 (50–150)
41-48 9.28 (6.70–11.1) 232 (3–988) 120 (60–200)
49-52 9.85 (7.70–12.1) 211 (3–1,379) 100 (60–150)
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on the one hand and dosage fludrocortisone, serum 17-OHP and androstenedione 
concentrations on the other hand.
Figure 1  Mean peak systolic blood pressure values of male (A) and female (B) CAH patients 
in the first year of life.
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Discussion
This report is the first to study blood pressure in the first year of life in children with 
CAH due to 21-hydroxylase deficiency. This pilot study shows that blood pressure 
values in the first year of life measured in our patient population are not significantly 
elevated compared with reference values.
 Studies on the incidence of hypertension in older children with CAH showed 
variable outcomes. In one study, de Silva et al. showed that none of the CAH patients 
(n = 11, age 8.5–27.2 years, mean age 14.5 years) had a blood pressure above the 95th 
percentile, using a 24-hour ambulatory blood pressure measurement.4 Roche et al. 
concluded that CAH patients (n = 38, age 6.1–18.2 years) had significantly elevated 
mean systolic blood pressures, and 58% of the investigated patients had systolic 
hypertension defined as systolic blood pressure measurements ≥95th percentile for 
age and sex.5 Völkl et al. showed altered 24-hour blood pressure profiles with 
elevated systolic blood pressure values in CAH patients (n = 55, age 5.3–19.0 years).6 
Hoepffner et al. found average blood pressure values in the upper normal range in 
pediatric CAH patients (n = 23, age 6–17 years).7 Only one study by Nebesio and 
Eugster focused also on blood pressure in children younger than 5 years of age.8 That 
study showed higher blood pressure levels in children with CAH. Five out of 91 (5.5%) 
CAH patients had hypertension defined as blood pressure >95th percentile for age 
and gender (age 58 days to 12.6 years). The differences in outcome in these studies 
may be explained by the choice of method, age and type of CAH, differences in dosage 
of hydrocortisone and fludrocortisone, and other unknown factors that may influence 
the blood pressure in the study population.
 Several risk factors may contribute to changes in blood pressure in children with 
CAH already in the first year of life. It is well known that mineralocorticoid excess 
leads to hypertension, e.g. in patients with primary aldosteronism or types of CAH 
with elevated levels of steroid metabolites with mineralocorticoid activity such as 
11-hydroxylase deficiency.12 Therefore, excessive treatment with mineralocorticoids 
might lead to elevated blood pressure. However, in our study we did not find any 
correlation between blood pressure on the one hand and type of CAH or fludrocorti-
sone dosage on the other hand. These findings are in line with other studies on blood 
pressure values in pediatric CAH patients who showed no correlation between dosage 
of fludrocortisone and blood pressure levels either.5-8 In our population, we measured 
incidentally elevated blood pressure in patients with decreasing renin levels. The 
absence of correlation between serum renin levels and blood pressure may be 
explained by the fact that we adapted the dosage of fludrocortisone very quickly 
when serum renin levels decreased or blood pressure increased. Therefore, normal 
blood pressure values as observed in our study may be the result of adaptation of the 
dosage of fludrocortisone to serum renin and blood pressure levels.
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Treatment with supraphysiological doses of glucocorticoids may also play a role in the 
development of high blood pressure in CAH patients as glucocorticoid excess,13 e.g. 
in patients with Cushing’s syndrome, is known to result in high blood pressure as 
well.14 Therefore, monitoring of the glucocorticoid treatment is essential not only to 
avoid undertreatment but also to detect overtreatment.
 Our study has several limitations. A limited number of patients were included, 
complicating statistical analyses in subgroups of patients. Blood pressure measurements 
and laboratory examinations were not performed following a standardized study 
protocol. However, even considering suboptimal circumstances (e.g. stress during 
the measurements) that would probably lead to higher blood pressures, most blood 
pressure measurements were within normal range. A 24-hour blood pressure 
measurement giving more detailed information about diurnal changes was not 
performed, as ambulatory blood pressure measurement in children below 1 year is 
not possible. This retrospective study did not allow us to precisely study the 
correlation between blood pressure and mineralocorticoid or glucocorticoid dosage. 
Therefore, further prospective studies are needed to evaluate more accurately the 
incidence and consequences of hypertension in the first year of life.
 In summary, in this retrospective pilot study, children with CAH did not show 
significantly elevated blood pressures in the first year of life. The correlation between 
blood pressure levels in the first year of life and the dosage of fludrocortisone and 
glucocorticoids should be carefully evaluated in prospective studies in order to detect 
and consequently prevent early cardiovascular risk factors in CAH children.
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Abstract
Background: The aim of the study was to evaluate the cardiovascular and metabolic 
risk profile in pediatric patients with congenital adrenal hyperplasia (CAH).
Methods: A cross-sectional study was performed in 27 CAH patients (8–16 years). 
Blood samples were taken to evaluate circulating cardiovascular risk (CVR) markers. 
Insulin resistance (IR) was evaluated by homeostatic model assessment (HOMA)-IR. 
Blood pressure (BP) was evaluated by office BP measurements and 24-h ambulatory 
BP measurements (24-h ABPM). Dual energy X-ray absorptiometry (DXA) scans were 
performed in patients >12 years.
Results: Body mass index (BMI) standard deviation score (SDS) was elevated (0.67), 
with seven patients being overweight and four obese. DXA scans showed percentage 
body fat SDS of 1.59. Office BP levels were higher than reference values. Twenty-four 
hour ABPM showed systolic hypertension (n=5), while 11 patients had a non-dipping 
BP profile. HOMA-IR was >75th percentile in 12 patients.
Conclusions: CAH patients develop an unfavorable CVR profile already in childhood 
with increased BMI, increased fat mass, elevated BP levels, a non-dipping BP profile 
and IR compared to population reference values.
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Introduction
Studies in adult patients with congenital adrenal hyperplasia (CAH) showed that they 
seem to have a high risk of clustering of a number of cardiovascular risk factors: 
elevated blood pressure (BP), insulin resistance (IR), increased body mass index (BMI), 
increased fat mass 1-9 and an increased intima-media thickness (IMT).10,11 Data on 
cardiovascular and metabolic risk factors in pediatric CAH patients are relatively 
scarce. Previous studies showed that pediatric CAH patients may already show signs 
of elevated BP, elevated BMI, increased fat mass, IR, hyperlipidemia and an increased 
IMT.4,5,9,12-21 The unfavorable changes in the cardiovascular risk profile may be due to 
the effects of both treatment (with supraphysiological doses of glucocorticoids and in 
most cases mineralocorticoids) and high androgen levels. However, most of the 
studies on cardiovascular risks in pediatric CAH patients were performed in small 
patient groups or focused on one or several risk factors only.
 The aim of this cross-sectional study was to investigate the cardiovascular and 
metabolic risk profile in pediatric CAH patients due to 21-hydroxylase deficiency by 
evaluating multiple cardiovascular risk factors.
Patients and methods
Patients
CAH patients with biochemically and genetically proven CAH due to 21-hydroxylase 
deficiency, aged 8–16 years were invited to this study. Exclusion criteria were known 
co-morbidities, such as cardiac disease, renal disease, or co-medication that interferes 
with BP. For patients aged 8–12 years, their parents consented with the study protocol, 
while for patients aged 12–16, both patients and parents consented according to the 
recommendations of the Local Medical-Ethical Committee.
Methods
Each participant visited the hospital on two consecutive days, combined with a 
regular visit to the outpatient clinic. Data on the current hydrocortisone and fludro-
cortisones dosages were collected from the medical record of the patient.
 On the first day, participants visited the hospital at 8.30 am after an overnight 
fast. Before taking their morning medication, blood was drawn to assess the 
concentrations of androstenedione, 17-OHP, fasting glucose, HbA1c, insulin, lipid 
profile (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides), renin, 
and selected circulating cardiovascular risk (CVR) markers (leptin, adiponectin, hsCRP, 
tPA, PAI-1, and tPA-PAI-1 complex).
130
Chapter 3
Glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were 
measured using an Architect c16000 (Abbott, Wiesbaden, Germany). Renin was 
measured by a radioimmunoassay (RIA) (Renin III, CisBio, Codolet, France) and hsCRP 
on a BN II nephelometer (Siemens, The Hague, The Netherlands). Total adiponectin 
was measured by a RIA (Millipore, St. Charles, MO, USA) with a LOQ of 0.5 mg/L, an 
intra-assay CV <5%, and an inter-assay CV <9% in the whole range. Leptin was 
measured using a RIA (Millipore, St Charles, MO, USA) with a lower limit of quantitation 
of 0.5 g/L. The inter-assay variation of this assay was <6% for the whole concentration 
range. Androstenedione and 17-OHP were measured by an in-house LCMS-MS 
method. The inter-assay variations and LOQs were 4.1% (at 3.6 nmol/L) and 0.05 
nmol/L (10% CV), respectively, for androstenedione and 3.7% (at 3.0 nmol/L) and 0.10 
nmol/L, respectively, for 17-OHP. Plasma concentrations of tPA, PAI-1 and tPA-PAI-1 
complex were assayed with enzyme-linked immunosorbent assay procedures as 
described before.22,23 In-house laboratory reference values for adults were available 
for PAI-1 (14.9±10.0 ng/mL) and tPA (2.93±1.16 ng/mL).
 IR was estimated using the homeostasis model assessment (HOMA) method 
(IR=insulin [μmol/mL]×glucose [mmol/L]/22.5).24 HOMA-IR data obtained were 
compared to the commonly used reference ranges for normal weight and obese 
Caucasians.25 A HOMA-IR above the 75th percentile has been suggested to be 
associated with an unfavorable cardiometabolic risk.25 Fasting total plasma 
cholesterol, LDL cholesterol and triglycerides <75th percentile for age and sex were 
considered normal, values in the 75th through 95th percentile range as borderline, 
and values >95th percentile as elevated.26 For leptin and adiponectin, we compared 
our results with the concentrations in healthy controls, aged 6–16 years, using the 
same laboratory test by calculating standard deviation scores (SDS).27
 Anthropometric measurements: All participants received a complete physical 
examination including anthropometric measurements and hip and waist 
circumferences. BMI and height SDS scores were calculated using Dutch national 
reference data based on the 5th national growth study by TNO Child Health, Leiden, 
The Netherlands (https://groeiweb.pgdata.nl/calculator.asp). Patients with BMI SDS 
>1 were classified as being overweight, while patients with BMI SDS >2 were classified 
as obese. Hip and waist circumferences and waist/hip ratio were measured and 
compared to reference values for Dutch children as well.28
	 Evaluation	of	BP: Office BP was measured using a Dinamap vital signs monitor (GE 
Healthcare, Hoevelaken, The Netherlands). BP was measured 3 times in an upright 
position and mean supine office BP was calculated. The systolic and diastolic office 
BPs were corrected for age, sex and height and expressed as SDS using published 
reference data.29 Systolic (SBP) and/or diastolic BPs (DBP) >95th percentile for sex, 
age and height was classified as hypertensive. BP values in the 90th through 95th 
percentile range were classified as “pre-hypertensive”. Subsequently, ambulatory BP 
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was monitored for 24 h using a SpaceLabs 90217-A monitor (SpaceLabs Healthcare, 
Snoqualmie, WA, USA). BP was measured every 15 min between 08.00 am and 08.00 
pm, and once every hour between 08.00 pm and 08.00 am. During the 24 h BP 
measurements, patients and their parents registered physical activities and time of 
going to sleep and waking up in a diary. Sex-specific SDSs for both age and height 
were calculated for the 24-h ABPM data using the published algorithm and reference 
values.30 For all patients, the dip in “sleeping” BP compared to daytime BP was 
calculated for SBP, DBP and mean arterial pressure (MAP). A non-dipping BP profile 
was defined as a BP decrease of less than 10% during sleep.31
	 Evaluation	of	intima	media	thickness: Ultrasound evaluation of the IMT of the left 
and right carotid artery was performed on one of the 2 days the participant visited 
the hospital by a specially trained ultrasound technician. We used a Vivid E9 for the 
IMT measurements of the common carotid artery (CCA) with a Linear array transducer 
(GE 9LD, GE, Vingmed Ultrasound, Horten, Norway). Acquisitions were made in the 
longitudinal view through the center of the lumen. IMT measurements of the CCA, 
within 2 cm of the bifurcation, were performed using the IMT module in the EchoPAC 
workstation version 112 (GE Medical Systems, Horten, Norway). One researcher 
(CFM) was trained and performed the offline analysis of the images, being double 
checked by an experienced pediatric cardiologist (LK). The results were compared to 
carotid IMT (cIMT) measurements in healthy German children.32
	 Evaluation	of	body	composition: A dual energy X-ray absorptiometry (DXA) scan 
was performed to evaluate body composition in patients older than 12 years on one 
of the 2 days. A DXA total-body scanner (Hologic Discovery A type, Hologic Inc, 
Bedford, MA, USA) was used to obtain regional and whole body composition 
measurements using a three-compartment model of body composition: lean tissue 
mass (LTM), fat tissue mass (FTM) and bone mineral content (BMC). LTM, FTM and 
BMC were determined using software algorithms based on regression equations. 
Percentage of body fat was calculated using the formula: 100·FTM/(FTM+LTM+BMC). 
The data obtained were compared to available reference values for both Canadian 
and Dutch children by calculating Z-scores. Reference values in healthy Canadian 
children were obtained by Hologic densitometers for BMC, LTM and FTM. Z-scores 
were calculated using the published formula and reference values.33 Reference 
values in healthy Dutch children measured by Lunar were obtained for bone mineral 
density (BMD), BMC, LTM and % body fat.34 As a different fan-beam instrument was 
used in the latter study,34 we converted our data using the known conversion factors 
from Hologic to Lunar prodigy,35 before calculating Z-scores for BMC, LTM, and 
percentage body fat. Because the data in healthy Dutch children were obtained using 
a different fan-beam instrument, we compared our data to both the Canadian and 
converted Dutch reference values.
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Statistical analysis
All data were collected and stored in a secure database (Castor, www.castoredc.
com), complying with the regulations of the Local Medical-Ethical Committee. For the 
statistical analyses, the SPSS personal computer software package version 22 (IBM 
SPSS Inc., Chicago, IL, USA) was used. Using descriptive statistics, we checked whether 
the study variables were normally distributed. If not, we presented median values 
plus ranges. Otherwise, we calculated mean absolute and SDS values with 95% 
confidence intervals (CI). If the 95% CI for an SDS value did not contain the zero value, 
we considered the values in our cohort to be different from the reference values 
used. Linear regression analyses were performed to evaluate the associations 
between different cardiovascular risk markers, treatment (daily dosages of 
hydrocortisone and fludrocortisones), and disease control (levels of 17-OHP, andro-
stenedione, and renin). B-coefficients with 95% CIs above or below 0 were considered 
to indicate relevant associations.
Results
Patient characteristics
A total of 27 patients (17 boys/10 girls), aged 8.8–16.0 years (median 11.7 years) 
participated in this study. Twenty-four patients were classified as salt wasting CAH 
patients, two as simple virilizing CAH patients, and one as a non-classic CAH patient. 
A complete description of the anthropomorphic evaluation and the biochemical 
analysis is given in Table 1. The B-coefficients showing the associations between the 
different parameters are shown in Table 2. BMI SDS for the cohort was clearly higher 
compared to the reference population (BMI SDS 0.67; 95% CI: 0.16–1.18), with seven 
patients (25.9%; four boys, three girls) being overweight and four patients (14.8%; 
three boys; one girl) being obese.28 BMI SDS was positively associated with the 
17-OHP and androstenedione concentrations.
BP profiles
The office BP measurements showed a mean SBP SDS of 0.83 (95% CI: 0.49–1.18) and 
a mean DBP SDS of 0.56 (95% CI: 0.34–0.78). Five of the patients (18.5%) had systolic 
hypertension and four patients (14.8%) were pre-hypertensive. None of the patients 
showed diastolic hypertension, but three patients (11.1%) had a pre-hypertensive 
DBP. Office SBP SDS and DBP SDS were not associated with BMI SDS, therapy control, 
treatment, or HOMA-IR.
 The 24-h ABPM values for SBP and DBP and MAP are shown in Table 3. Mean 24-h 
SBP and DBP SDSs in the cohort were within the normal range compared to both age- 
and height-specific reference values for each sex, although the 24-h SBP SDS and DBP 
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Table 1  Patient characteristics, current dosages of hydrocortisone and fludro-
cortisone, and results of biochemical analysis of fasting pre-morning medication 
blood concentrations of androstenedione, 17-OHP, renin, and several circulating 
cardiovascular risk markers in a cohort of 27 pediatric CAH patients aged 8 – 16 years
Mean (95% CI) Minimum  
value 
Maximum  
value 
Anthropometric measure
Height (cm) 156.0 (150.5 – 161.4) 131.8 183.1
Height SDS -0.04 (-0.45 – 0.36) -1.83 1.60
Target height SDS -0.01 (-0.31 – 0.30) -2.06 1.48
Weight (kg) 48.9 (41.9 – 55.8) 26.2 100.2
BMI (kg/m2) 19.5 (17.8 – 21.3) 14.7 33.3
BMI SDS 0.67 (0.16 – 1.18) -1.14 3.72
Waist circumference (cm) 64.7 (59.8 – 69.5) 50.0 107.5
Hip circumference (cm) 73.4 (68.5 – 78.4) 57.0 106.0
Waist-hip ratio 0.88 (0.86 – 0.90) 0.82 1.01
Current treatment dosages
Daily hydrocortisone dosage (mg/m2) 12.2 (11.2 – 13.2) 8.5 17.4
Daily fludrocortisone dosage * (µg/m2) 98.5 (75.8 – 121.1) 46 276
Hormonal evaluation
Androstenedione (nmol/l) 4.0 (median) 0.05 32.10
17-OHP (nmol/l) 83.0 (median) 0.68 740.00
Renin (mU/l) 52.0 (median) 3.0 1900.0
Circulating cardiovascular risk markers
Leptin (µg/l) 6.8 (median) 1.1 27.2
Leptin SDS 1.14 (0.45 – 1.88) -0.83 4.33
Adiponectin (mg/l) 13.5 (11.2 – 15.8) 4.1 26.0
Adiponectin SDS 0.25 (-0.16 – 0.66) -1.45 2.51
High sensitive CRP (mg/l) 1.13 (0.28 – 1.98) 0.16 8.06
tPA (ng/ml) 13.07 ( 9.36 – 16.79) 1.28 40.54
PAI-1 (ng/ml) 11.56 (9.61 – 13.52) 3.95 22.47
Complex tPA/PAI-1 (ng/ml) 34.03 (22.71 – 45.34) 4.02 129.36
PAI1/tPA ratio 1.34 (0.76 – 1.92) 0.48 8.07
* Only patients with salt wasting CAH (n=24) were treated with fludrocortisone.
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SDS were higher than in the reference population. Four of the patients (14.8%) had 
systolic hypertension compared to both age- and height-specific references, one 
additional patient was hypertensive compared to height-specific references (total 
n=5; 18.5%). Three of these five patients were also classified as hypertensive based 
on the office BP measurement. In one patient (3.7%), 24-h diastolic hypertension was 
found compared to both age- and height-specific references. As shown in Table 3, the 
mean sleeping SBP and DBP SDSs and the MAP SDSs were increased by approximately 
0.5 and 0.8 SDS, respectively, compared to the normal ranges for both age and height. 
The mean dip in BP during sleep in the cohort as a whole was just >10%. However, 13 
patients (48.1%) had a dip <10% in SBP during sleep, and 11 patients (40.7%) had a dip 
<10% in MAP during sleep.
Table 2  Associations among parameters in a cohort of 27 pediatric CAH patients.
Parameters Daily dosage 
 hydrocortisone
17-OHP
BMI SDS 0.6 (-0.2 – 1.4) 62.3 (2.5 -122.2)*
24h Diastolic BP SDS (height) -0.28 (-1.52 – 0.97) -77.6 (-170.3 – 15.1)
Sleeping diastolic BP SDS (age) -0.67 (-1.93 – 0.59) -71.2 (-167.5 – 25.1)
Sleeping diastolic BP SDS (height) -0.62 (-1.73 – 0.49) -66.7 (-151.4 – 18.0)
Daytime diastolic BP SDS (age) -0.09 (-1.31 – 1.12) -70.4 (-160.9 – 20.2)
Daytime diastolic BP SDS (height) -0.06 (-1.25 – 1.13) -73.0 (-161.2 – 15.2)
Percentage of the nocturnal dip in MAP 0.03 (-0.14 – 0.20) -5.5 (-18.3 – 7.3)
Total cholesterol concentration -0.74 (-2.04 – 0.57) -41.3 (-144.8 – 62.2)
HOMA-IR 0.75 (0.11 – 1.39)* 28.4 (-25.7 – 82.6)
Leptin concentration (SDS) 0.26 (-0.32 – 0.87) 10.1 (-37.4 – 57.6)
Percentage bodyfat SDS (Dutch references) 1.7 (-0.4 – 3.8) 179.1 (5.3 – 353.0)*
Fat tissue mass SDS (Canadian references) 0.45 (-0.79 – 1.69) 97.3 (5.1 – 189.5)*
Percentage bodyfat on DXA scan 0.10 (-0.12 – 0.32) 7.3 (-12.3 – 26.9)
Bone mineral content SDS (Dutch references) -0.42 (-2.30 – 1.45) 139.6 (-0.2 – 279.3)
Bone mineral content SDS (Canadian references) -0.30 (-2.11 – 1.51) 134.3 (-0.01 – 268.5)
Lean tissue mass  SDS (Dutch references) -0.06 (-1.31 – 1.19) 87.6 (-6.2 – 181.4)
Lean tissue mass  SDS (Canadian refences) 0.37 (-1.59 – 2.33)  134.2 (-16.0 – 284.3)
B-coefficients of linear regression analysis are presented with 95% CI. B-coefficients with 95% CI excluding 
the zero-value are marked with an asterisk (*).
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No associations were found between 24-h SBP or MAP and dosage of hydrocortisone 
or fludrocortisone, therapy control, HOMA-IR and body composition. In contrast, 
24-h DBP SDS to height was negatively associated with androstenedione level (Table 2). 
DBP SDS during sleep was also negatively associated with androstenedione 
concentrations, while daytime diastolic BP SDS was negatively associated with 
HOMA-IR. The percentage of the dip in MAP during sleep was negatively associated 
with BMI SDS. The dip in BP was not associated with dosage of hydrocortisone, flud-
rocortisone, HOMA-IR, or therapy control.
Biochemical evaluation
The lipid profiles of our 27 CAH patients are shown in Table 4. These were normal in 
the vast majority of patients, with 63%–78% of our population having triglyceride, 
total cholesterol, and/or LDL cholesterol levels below the 50th percentile. Total 
Androstenedione Renin HOMA-IR BMI SDS
2.99 (0.22 – 5.77)* -13.5 (-127.9 – 100.8) 0.59 (0.17 – 1.01)*
-4.3 (-8.5 – -0.1)* -49.2 (-220.4 – 122.1) -0.61 (-1.29 – 0.08) -0.50 (-1.09 – 0.08)
-4.5 (-8.8 – -0.2)* -67.8 (-242.5 – 106.9) -0.61 (-1.29 – 0.08) -0.07 (-0.71 – 0.56)
-4.1 (-7.9 – -0.3)* -50.0 (-205.2 – 105.1) -0.23 (-0.97 – 0.51) -0.10 (-0.66 – 0.47)
-3.7 (-7.9 – 0.5) -69.0 (-233.7 – 95.7) -0.7 (-1.3 – -0.05)* -0.53 (-1.09 – 0.03)
-3.7 (-7.8 – 0.4) -52.3 (-214.6 – 110.1) -0.7 (-1.3 – -0.03)* -0.53 (-1.07 – 0.02)
-0.14 (-0.75 – 0.48) 0.84 (-22.0 – 23.7) -0.06 (-0.16 – 0.03) -0.1(-0.17 – -0.03)*
-5.0 (-9.5 – -0.6)* -100.3 (-280.0 – 79.4) -0.06 (-0.84 – 0.72) -0.16 (-0.82 – 0.51)
1.8 (-0.6 – 4.3) 112.1 (26.4 – 197.9)* 0.43 (0.12 – 0.73)*
-0.61 (-1.60 – 2.82) 57.3 (-23.1 – 137.7) 0.53 (0.26 – 0.81)* 0.50 (0.28 – 0.72)*
7.1 (-0.2 – 14.5) 156.3 (-255.1 – 567.8) 0.95 (-0.18 – 2.07) 1.03 (0.09 – 1.98)*
3.4 (-0.7 – 7.5) 3.0 (-223.8 – 229.8) 0.55 (-0.04 – 1.13) 0.81 (0.50 – 1.13)*
0.11 (-0.72 – 0.95) 9.4 (-30.8 – 49.7) 0.11 (0.02 – 0.21)* 0.11 (0.03 – 0.20)*
6.0 (0.4 – 11.7)* -223.5 (-526.9 – 79.9) 0.14 (-0.87 – 1.16) 0.78 (0.01 – 1.55)*
6.0 (0.6 – 11.4)* -162.1 (-468.4 – 144.2) 0.19 (-0.79 – 1.16) 0.81 (0.10 – 1.52)*
3.5 (-0.5 – 7.4) -171.8 (-362.7 – 19.1) 0.04 (-0.64 – 0.71) 0.60 (0.13 – 1.06)*
5.4 (-0.9 – 11.7) -220.5 (-540.3 – 99.3) 0.24 (-0.81 – 1.29) 1.04 (0.36 – 1.72)*
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cholesterol levels were negatively associated with androstenedione levels (Table 2). 
All other cholesterol and triglyceride levels were not associated with therapy control, 
dosage of hydrocortisone, BMI SDS, or HOMA-IR.
 Fasting glucose concentrations (mean 4.49 mmol/L; 95% CI: 4.35–4.62) and 
HbA1c concentrations (mean 36.0 mmol/mol; 95% CI: 35.2–36.8) were normal in all 27 
patients. The range in fasting insulin concentrations was wide (4.50–28.4 mU/L; 
median 11.0 mU/L). The mean HOMA-IR level in the cohort was 2.64 (95% CI: 
2.05–3.24). We compared the HOMA-IR of our patients with BMI SDS <1 to reference 
values of non-overweight children and the HOMA-IR of patients with BMI SDS >1 to 
reference values for children with BMI SDS >1. Twelve patients (44.4%; seven boys, 
five girls) had a HOMA-IR above the 75th percentile, and eight patients (29.6%; four 
boys, four girls) had a HOMA-IR above the 90th percentile for sex and age. HOMA-IR 
levels were positively associated with the daily dosage of hydrocortisone, BMI SDS 
and renin concentration (Table 2).
 The mean concentrations of CVR markers in our CAH patients are shown in Table 2. 
Adiponectin levels were on average similar to the selected reference values. Only one 
patient had an adiponectin SDS >2. Adiponectin levels were not associated with BMI 
SDS, hydrocortisone dosage or HOMA-IR.
 The median leptin level in our cohort (6.8 μg/L; SDS 0.30) was similar to the 
average of 5.29 μg/L in healthy Polish children,27 while the mean leptin SDS in our 
cohort was 1.14 (95% CI: 0.45–1.88). In 9 CAH patients (33.3%; four of these patients 
were classified as obese and three as overweight), the leptin SDS was >2. Leptin levels 
were positively associated with BMI SDS, HOMA-IR values, (for B-coefficients see 
Table 2) percentage of body fat SDS on the DXA scan (B-coefficient 3.8; 95% CI: 
2.5–5.2), and FTM on the DXA scan (B-coefficient 0.52; 95% CI: 0.13–0.90). Leptin 
levels were not associated with daily hydrocortisone dose.
 The high sensitivity CRP levels were normal in all patients according to the 
reference values of our laboratory. Compared to our laboratory reference values for 
adults, mean PAI-1 values in our cohort were comparable (−0.33 SDS; 95% CI: −0.53 to 
−0.14), but mean tPA values were increased (8.74 SDS; 95% CI: 5.54–11.95).
Intima media thickness
The cIMT was normal in our cohort (n=24) with a mean cIMT of 0.50±0.03 mm. 
Compared to reference values in healthy children, only one patient had a cIMT >75th 
percentile for age and sex.
Body composition
Data on body composition obtained by DXA scans are shown in Table 5. Compared to 
both Canadian and Dutch reference children, the CAH patients in our cohort had 
more body fat. No associations were found between fat mass or fat percentage and 
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hydrocortisone dosage. Percentage body fat SDS (compared to Dutch references) was 
positively associated with BMI SDS, 17-OHP and androstenedione concentrations 
(Table 2). Positive associations were seen between FTM SDS (compared to Canadian 
references) and BMI SDS and 17-OHP concentrations and tentative associations 
between FTM SDS and androstenedione concentrations and HOMA-IR. The 
percentage body fat in our patients was positively associated with BMI SDS and 
HOMA-IR. LTM was positively associated with BMI SDS compared to both Dutch and 
Canadian references. No associations were observed between data on body 
composition and dosage of hydrocortisone per m2 (BSA). The SDSs for BMC were 
positively associated with BMI SDS and with the androstenedione concentrations.
Discussion
This study showed that, compared to population reference values, a number of 
unfavorable changes in the cardiovascular risk profile of our CAH patients already 
occur in childhood, i.e. overweight and obesity, an increased fat mass, elevated BP 
levels, a non-dipping BP profile, and increased IR. The lipid profile and cIMT were 
within the normal range. Only elevated HOMA-IR values were positively associated 
with the daily dosage of hydrocortisone per m2. The prevalence of overweight and 
obesity in our studied pediatric CAH patients is higher (25.9% overweight; 14.8% 
obese) than in the healthy pediatric population suggesting that additional CAH-related 
factors may play a role.
Table 5  Body composition of pediatric CAH patients evaluated by DXA scan 
compared to healthy Dutch and Canadian children
CAH patients (n = 13)
(Mean ± 95% CI)
SDS compared 
to healthy Dutch 
children*
(Mean + 95% CI)
SDS compared  
to healthy Canadian 
children
(Mean + 95% CI)
Lean tissue mass 41582.1 (36472.7 – 46691.5) g -1.21 (-2.13 – -0.28) -0.31 (-0.90 – 0.27) 
Fat tissue mass 18762.4 (12806.7 – 24718.1) g 0.94 (0.04 – 1.85)
Fat percentage 29.0 (23.9 – 34.0) % 1.59 (1.10 – 2.07) **
Bone mineral content 2048.11 (1843.83 – 2252.38) g -0.06 (-0.67 – 0.54) 0.60 (-0.03 – 1.24) 
BMC Z-score 0.63 (0.22 – 1.04)
Bone mineral density 1.05 (1.01 – 1.09) g/cm2
* After correction of data for the type of fanbeam used according to published conversion ratio’s.35
** After converting to natural logarithm of fat percentage as used by van der Sluis et al.34
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First of all, treatment with glucocorticoids, both in physiological and supraphysio logical 
doses, has been associated with (central) obesity in adult CAH patients in several 
studies.4,15,36 However, we did not find an association between BMI SDS and current 
hydrocortisone dose. Secondly, obesity is associated with high serum leptin 
concentrations, suggesting leptin resistance.37 Leptin acts via a specific receptor in 
the brain, the long form of the leptin receptor (OB-Rb) in the hypothalamic regions 
and the arcuate nucleus to regulate energy balance and body weight. Glucocorticoids 
and insulin are known to increase leptin secretion and catecholamines suppress 
leptin secretion. Our pediatric CAH patients had increased leptin levels, associated 
with BMI SDS, HOMA-IR and fat mass. This finding is in line with previous studies 
evaluating leptin levels in CAH patients.4,9,12 Finally, an increased prevalence of 
obesity in adult CAH patients may be due to hyperandrogenism38 which is known to 
cause IR, and consequently may lead to obesity and centralization of body fat. We 
found positive associations between BMI SDS and the 17-OHP and androstenedione 
concentrations. It may be expected that undertreated patients, with higher 17-OHP 
and androstenedione levels, will be treated with higher dosages of hydrocortisone to 
suppress androgens with consequently increased BMI due to high glucocorticoid 
dosages. In contrast, Reinehr et al. showed that otherwise healthy prepubertal obese 
children had significantly increased levels of androstenedione and other androgens.39 
Weight loss significantly lowered androstenedione concentrations suggesting that 
elevated precursors rather are the consequence than the cause of obesity.39 Several 
hypotheses for the increased glucocorticoid and androgen levels in healthy obese 
prepubertal children were proposed, including an increased activation of the hypothalamic 
pituitary adrenal axis and an adrenal fasciculata-reticularis cell refractoriness to the 
inhibitory effect of leptin on ACTH-stimulated glucocorticoid production. The increased 
leptin concentrations in our cohort fit within this hypothesis. In CAH patients, a vicious 
circle may exist: alimentary obesity due to unhealthy lifestyle causes an increased 
ACTH stimulated secretion of androgens due to the above proposed mechanisms. 
In CAH patients, this may be more pronounced due to the enzymatic defect. 
A consequent increase in glucocorticoids to supraphysiological dosages further 
induces obesity.
 The finding of increased fat mass, found by DXA scan, in our pediatric CAH 
patients is in line with previous studies using different methods (skin-fold thickness, 
bioelectrical impedance analysis and DXA scan) to evaluate body composition in 
both pediatric and young adult CAH patients.9,16,40-42 In contrast to our findings, 
Falhammar et al.6,43 found normal fat mass with the DXA scan in young adult CAH 
patients compared to controls. They explained the normal fat mass in young adults as 
a consequence of lowering glucocorticoid dosage over the years. Despite relatively 
low hydrocortisone dosage, we still found an increased fat mass in our pediatric 
population. The increased fat mass contributes to the increased BMI SDS in our 
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population, as BMI SDS scores were associated with the fat percentage SDS and 
FTM SDS.
Increased BP levels and a non-dipping BP profile
The prevalence of hypertension in pediatric CAH has been described in up to 58% of 
patients. 4,5,20,21,44-48 In our study, the prevalence of systolic hypertension was lower 
(18.5% in both office BP and 24-h ABPM). In previous studies, BP levels were associated 
with BMI, dose of glucocorticoids, dose of fludrocortisone, or suppressed plasma 
renin activity.4,20,21,44,45 Both our study and the study by Subbarayan et al.5 did not 
find these associations. However, regular control of renin levels to prevent mineralo-
corticoid overtreatment, as a cause of elevated BP, remains important in clinical care.
 Data on the nocturnal dip in BP in pediatric CAH patients are scarce and the 
results vary.44,46,49 A non-dipping SBP profile was described previously in 84% of the 
CAH patients (n=32).44 Another study showed that the nocturnal dip in BP was 
maintained in all studied CAH patients (n=20), despite a higher BMI SDS (1.05) and 
higher daily hydrocortisone dose compared to our study.46 The percentage dip in 
sleeping BP in our cohort was associated with BMI SDS. It is well known that obesity 
is associated with a non-dipping BP profile, an independent cardiovascular risk 
factor.31 Further research in larger cohorts is needed to establish the presence of a 
non-dipping BP profile in pediatric CAH, and its association with BMI. All our patients 
were treated with hydrocortisone in a reverse circadian rhythm, that may affect 
sleeping BP and cause the absence of the nocturnal dip.50 In the future, treatment 
with slow release hydrocortisone, mimicking a physiological cortisol secretion in CAH 
patients,51 may have a favorable outcome on 24-h BP profiles in CAH patients.
Insulin resistance
IR in our cohort was associated with the daily hydrocortisone dose.52 Lowering the 
hydrocortisone dose, if possible, may lead to reduction of IR as suggested by 
Subbarayan et al.5 In contrast to previous studies,1 we did not find an association 
between hyperandrogenism and IR.
 The main limitation of our study is that we could not include a control group with 
healthy matched controls, due to regulations of the medical ethical committee in our 
center. Therefore, we carefully selected the reference groups used in this study, to 
use reference groups that are as similar as possible to the Dutch population. We were 
unable to calculate the cumulative steroid dosages, which may elucidate associations 
between long-term treatment and unfavorable changes in the cardiovascular risk profile. 
Furthermore, the size of our study population was too small to perform subgroup 
analyses. A future long running study evaluating the cardiovascular risk profile over 
many years from childhood into adulthood could give additional insights in the 
long-term effect of the current treatment regimen and unfavorable cardiovascular 
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risk factors in pediatric patients on the cardiovascular morbidity in adulthood, as 
current cross-sectional studies in adult CAH patients reflect the outcomes of the 
treatment regimens of several decades ago.
 In conclusion, our study shows that CAH patients already develop an unfavorable 
cardiovascular and metabolic risk profile in childhood compared to population 
reference values. Increased BMI seems to play an essential role in the increased 
cardiovascular risk. Lifestyle interventions to lower BMI may lead to better hormonal 
control and a reduced risk of cardiovascular morbidity in adult life. Further studies 
are necessary to evaluate the role of lifestyle interventions on the cardiovascular risk 
profile of pediatric CAH patients.
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Summary
Background: Hyperandrogenism and exogenous glucocorticoid excess may cause 
unfavorable changes in the cardiovascular risk profile of patients with congenital 
adrenal hyperplasia (CAH).
Objective: To evaluate the cardiac function in pediatric patients with CAH.
Patients and methods: Twenty-seven pediatric patients with CAH, aged 8-16 years, 
were evaluated by physical examination, electrocardiogram (ECG), conventional 
echocardiography, tissue Doppler imaging and two-dimensional (2D) myocardial 
strain (rate) imaging. Results were compared to 27 age- and gender- matched healthy 
controls.
Results: No signs of left ventricular hypertrophy or dilatation were detected on echo-
cardiography. ECG revealed a high prevalence (25.9%) of incomplete right bundle branch 
block. Left ventricular posterior wall thickness in diastole (LVPWd) was significantly 
lower in patients with CAH compared to controls (5.55 vs 6.53 mm; P = .009). 
The LVPWd Z-score was significantly lower in patients with CAH yet within the normal 
range (−1.12 vs −0.35; P = .002). Isovolumetric relaxation time was significantly lower in 
patients with CAH (49 vs 62 ms; P = .003). Global longitudinal, radial and circumferential 
strain was not significantly different compared to controls. Global radial strain rate 
was significantly higher compared to healthy controls (2.58 vs 2.06 1/s; P = .046). 
Global longitudinal strain was negatively correlated with 24-hour blood pressure 
parameters.
Conclusion: Cardiac evaluation of pediatric patients with CAH showed no signs of left 
ventricular hypertrophy or ventricular dilatation. LVPWd was lower in patients with 
CAH than in controls but within the normal range. A shorter isovolumetric relaxation 
time in patients with CAH may be a sign of mild left ventricular diastolic dysfunction.
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Introduction
Congenital adrenal hyperplasia (CAH) due to 21 hydroxylase deficiency (21OHD) is a 
disorder of adrenal steroidogenesis. 21OHD is characterized by androgen excess and 
cortisol deficiency, and depending on the residual enzyme activity also aldosterone 
deficiency.1 Treatment consists of glucocorticoids and, if necessary, mineralocorticoids 
to prevent adrenal crises and to suppress abnormal secretion of adrenal androgens. 
In most cases, supraphysiological doses of glucocorticoids are needed to suppress 
androgen levels.
 Both androgen excess and treatment with supraphysiological doses of glucocor-
ticoids are associated with an unfavorable cardiovascular and metabolic risk profile in 
patients with CAH.2,3 Several studies performed in adult and pediatric patients with 
CAH showed that they indeed cluster a number of cardiovascular risk factors: obesity, 
increased fat mass, insulin resistance and high blood pressure.2,4,5 These unfavorable 
changes in the cardiovascular risk profile may cause cardiovascular morbidity later in 
life. This hypothesis was confirmed by a population-based national cohort study in 
Sweden.6
 Few studies have previously evaluated the cardiac function in patients with CAH. 
One study evaluated the cardiac function in untreated newborn patients with CAH 
(n = 9), reporting cardiac dysfunction that had been reversed with glucocorticoid 
treatment.7 Seven of the nine patients had an abnormal fractional shortening and 
rate-corrected velocity of circumferential fiber shortening at baseline that was 
improved in six of the patients after glucocorticoid treatment. The other previous 
studies on cardiac function in patients with CAH evaluated cardiac function in 
pediatric and adolescent patients, mean age ranges of 6.3-13.6 years, using 
conventional echocardiography and, in most studies, tissue Doppler imaging.8-12 
None of the studies used the newer echocardiographic technique, for example 
myocardial deformation, for the detection of early signs of myocardial damage. Left 
ventricular diastolic dysfunction was described in Italian adolescent male patients 
with CAH (n = 10)8 and in pediatric patients with CAH from Cameroon (n = 19),9 Egypt 
(n = 32)10 and Turkey (n = 25).11 The finding of impaired left ventricular diastolic 
function was based on the presence of a lower ratio of Doppler-derived E/A wave, 
prolonged mitral deceleration time and isovolumetric deceleration times in studied 
patients with CAH compared to controls. Left ventricular diastolic dysfunction was 
associated with testosterone levels and the late age of diagnosis in three of the 
studies;9-11 in one study, no correlation with androgen levels was found.11 Left 
ventricular hypertrophy, indicated by an increased left ventricular mass index, was 
described by two studies.9,10 In both these studies, levels of left ventricular 
hypertrophy correlated with testosterone levels.9,10 In addition, a study in Italian 
pediatric patients with CAH (n = 20) showed an association between left ventricular 
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mass and testosterone concentrations; however none of the studied patients had 
myocardial hypertrophy.12 Marra et al compared the cardiac parameters in patients 
with CAH with a group of patients receiving a similar dose of glucocorticoids for 
juvenile idiopathic arthritis.8 In none of the above studies, a correlation between the 
glucocorticoid dose and cardiac function was reported, which may be surprising as 
supraphysiological doses of glucocorticoids may also impair cardiac function.13
 In this study, we systematically evaluated the cardiac function, and its correlations 
with the blood pressure, glucocorticoid and fludrocortisone doses and the 
concentrations of 17-OHP and androstenedione, in pediatric patients with CAH due 
to 21OHD by electrocardiography (ECG), by conventional echocardiography, by tissue 
Doppler imaging, and by 2D myocardial strain (rate) imaging. Echocardiographic data, 
including tissue Doppler and 2D myocardial strain, were compared to healthy gender- 
and age- matched controls.
Patients and methods
Patients
Patients with CAH, with biochemically and genetically proven 21OHD, aged 8-16 years 
and treated at a single tertiary hospital were included in this study. Exclusion criteria 
were known comorbidities as congenital cardiac disease, renal disease and comedication 
that might interfere with blood pressure measurements. As part of the routine clinical 
care, all patients were followed every 3 months at our outpatients clinic. All patients 
and their parents were fully informed about the aim and design of the study and the 
methods involved. Informed consent with the study protocol was obtained in all 
cases according to the recommendations of the local medical ethical committee. Full 
data on the cardiovascular and metabolic risk profile in the same group of patients 
with CAH were recently published by our group.14 As a control group, we included 27 
healthy age-and gender- matched children who were routinely referred for echocar-
diographic evaluation of an asymptomatic, innocent heart murmur or for screening 
purposes. In the controls, medical history, electrocardiogram and echocardiogram 
were not indicative of cardiac disease and no medication was used.
 Data regarding the current hydrocortisone and fludrocortisone dosage of the 
patients with CAH were collected from their medical records. Serum levels of 
17-OH-progesterone (17OHP), androstenedione and renin were measured in blood 
withdrawn after an overnight fast and before the patients took their morning 
medication as a part of our recent study evaluating the cardiovascular risk profile in 
pediatric 21OHD patients.14 These data were used to evaluate possible correlations 
between these serum levels and the cardiac function. Data on 24-hour ambulatory 
blood pressure measurement (24-hour ABPM) were collected in the same study and 
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used to evaluate possible correlations between 24-hour ABPM values and cardiac 
function.14
Methods
Each patient visited the hospital on two consecutive days; cardiac assessment was 
carried out on one of these days by an ultrasound technician and supervised offline 
by one experienced pediatric cardiologist (LK). A 12-lead ECG was performed in rest 
in supine position. All patients and controls underwent a transthoracic 2D echo-
cardiogram in supine and lateral position, in rest, according to the recommendations 
of the American Society of Echocardiography.15 Images were obtained with a 3.0 MHz 
or a 5.0 MHz phased-array transducer, depending on the patient’s age and weight, 
using a Vivid 7 echocardiographic scanner (GE, Vingmed Ultrasound, Horton, Norway).
 Quantification of cardiac chamber size, ventricular mass and systolic and diastolic 
left ventricular function was measured in accordance with the recommendations for 
chamber quantification by the American Society of Echocardiography’s Guidelines 
and Standard Committee and the Chamber Quantification Writing Group.15
 Left ventricular systolic function was determined using fractional shortening (FS), 
ejection fraction (EF), end-systolic wall stress (ESWS) and rate-corrected velocity of 
circumferential fiber shortening (VCFc). FS was calculated by the following formula: 
((LVIDd-LVIDs)/LVIDd)/100. Fractional shortening above 27% and EF 54% and higher 
were considered normal. The modified formula of Rowland and Gutgesell was used 
for calculating left ventricular end-systolic wall stress (ESWS).16 Velocity of circumfer-
ential fiber shortening (VCFc) was calculated with the formula from Colan et al.17
 An M-mode echocardiogram was performed in the parasternal long- and 
short-axis views to measure the internal dimensions of the left ventricle at end-diastole 
(LVIDd) and end-systole (LVIDs), the posterior and septal wall thickness at end-diastole 
(LVPWd, IVSd) and the left ventricular mass (LVM).
 LVM was calculated using the following formula: LVM = 0.8{1.04[({LVIDd + IVSd + 
LVPWd]3 − LVIDd3)]} + 0.6;18 and was afterwards indexed by the body mass surface 
area (BSA). Z-scores for LVIDd, LVIDs, IVSd and LVPWd were calculated using an online 
calculator (parameterz.blogspot.com).
 Left ventricular diastolic function was evaluated using early (E) and late (A) 
diastolic transmitral peak flow velocity (E/A ratio), the systolic to diastolic pulmonary 
vein peak flow velocity (PV S/D ratio), early diastolic transmitral peak flow velocity (E) 
to early diastolic myocardial Doppler velocity (e′) ratio (E/e′ ratio) and isovolumetric 
relaxation time (IVRT). The E/A ratio and S/D ratio were obtained by pulse Doppler at 
the mitral valve inflow and the pulmonary vein inflow, respectively.
 The myocardial strain, a measure for the deformation of the myocardium 
throughout the cardiac cycle, was determined using 2D speckle-tracking strain 
analysis in accordance with a previously published protocol.19 Offline analysis was 
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performed using software for echocardiographic quantification (EchoPAC 6.1.0; GE 
Medical Systems, Horten, Norway). Timing of aortic valve closure (AVC) and mitral 
valve opening (MVO) was used to indicate end of systole and start of diastole, 
respectively. Myocardial segments were named and localized according to the 
statement of the Cardiac Imaging Committee of the Council on Clinical Cardiology of 
the American Heart Association.20 Manual tracking of the endomyocardial borders 
was performed at the end-systolic frame. An automatic generation of the second 
epicardial tracing was created by the software, which also automatically divided the 
image into six equal segments. Quality of the tracking was verified for each segment 
and adjusted if needed. Three consecutive cardiac cycles were analyzed separately. 
Strain and strain rate curves were then exported for postprocessing in a custom-made 
tool in which the curves can be aligned, detrended and averaged for final global strain 
(rate) values estimates according to the consensus paper of Voigt et al21 and to create 
a fully automated workflow to avoid errors by user interaction.
 Strain values are dimensionless and are expressed in percentage. Strain rate is 
the temporal derivative of strain and is expressed as 1/s. The average values of peak 
systolic longitudinal, radial and circumferential strain, and strain rate of the three 
imported curves were calculated without correction for the length of the cardiac 
cycle as it is known that the systolic phase is relatively constant if heart rate changes 
<10%.22 Global longitudinal myocardial strain (GLS) and strain rate (GLSR) were 
calculated by averaging the six segments of the 4-chamber long-axis view. Global 
radial and circumferential myocardial strain (GRS, GCS) and strain rate (GRSR, GCSR) 
were calculated by averaging four up to six present segments of the mid-cavity 
short-axis view.
 For the matched controls, conventional echocardiography and myocardial strain 
data were obtained following the same protocol as described above.
Statistical analysis
All data were collected and stored in a secure database (Castor, www.castoredc.com), 
complying with the regulations of the local medical ethical committee. For the 
statistical analyses, the spss personal computer software package version 22 (IBM 
SPSS Inc., Chicago, IL, USA) was used. Student’s t test (independent samples) was 
used to compare the cardiac function parameters between patients with CAH and 
the gender- and age- matched controls assuming a normal distribution of the data. 
Pearson and Spearman correlation tests were performed to evaluate the strength of 
the association between different cardiac function parameters, treatment (current 
daily dosages of hydrocortisone and fludrocortisone per m2 BSA), levels of 17OHP, 
androstenedione and renin and 24-hour ambulatory blood pressure measurement 
SD scores in patients with CAH. A P-value of <.05 was considered statistically 
significant. Z-scores between −2 and 2 were interpreted as being normal.
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Results
Twenty-seven patients with CAH (17 boys/10 girls; 24 patients were classified as salt 
wasting, two as simple virilizing and one as nonclassic), aged 8.8-16.0 years (median 
11.7 years), participated in this study. Twenty-seven age- and gender-matched 
healthy controls were included. Patient characteristics, including daily dosages of 
hydrocortisone, fludrocortisone and data on the biochemical evaluation of 17OHP 
progesterone, androstenedione and renin levels, are shown in Table 1.
Cardiac function evaluated by electrocardiogram
ECGs showed a high prevalence of 25.9% (n = 7) of an incomplete right bundle branch 
block (IRBBB). A sinus rhythm was seen in 25 of the patients, with one patient having 
atrial rhythm and one patient with sino atrial rhythm. Conduction durations (PR 
Table 1  Characteristics of 27 studied patients with CAH and gender and age 
matched controls
Patients with CAH 
(Mean ± SD)
Controls  
(Mean ± SD)
P-value 
Gender 17 males / 10 females 17 males / 10 females
Age (years) 12.15 ± 2.29 12.25 ± 2.45 0.536
Anthropometric measure
Height (cm) 156.0 ± 13.9 157.6 ± 15.6 0.425
Weight (kg) 48.9 ± 17.6 45.6 ± 15.3 0.315
BMI (kg/m2) 19.5 ± 4.4 17.8 ± 2.6 0.066
BMI SDS 0.67 ± 1.29 0.04 ± 1.00 0.054
Current treatment dosages
Daily hydrocortisone dosage (mg/m2) 12.2 ± 2.6 -
Daily fludrocortisone dosage * (µg/m2) 98.5 ± 53.6 -
Hormonal evaluation
Androstenedione (nmol/l) 4.0 (median;  
range 0.05 - 32.10)
-
17OHP (nmol/l) 83.0 (median;  
range 0.68 - 740.00)
-
Renin (mU/l) 52.0 (median;  
range 3.0 - 1900.0)
-
* Only patients with salt wasting CAH (n=24) were treated with fludrocortisone.
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interval, QRS interval and QTc interval) were normal in all patients with CAH. No ST 
segment abnormalities were found. Based on ECG, none of the patients met the 
criteria for left ventricular (LV) or right ventricular (RV) hypertrophy.
Cardiac function evaluated by conventional echocardiography and tissue 
Doppler imaging
The echocardiographic parameters evaluated by conventional echocardiography for 
both the patients with CAH and the controls are shown in Table 2. One patient had 
increased LVIDd (Z-score 3.07), with a normal LVIDs (Z-score 1.32), resulting in 
re-evaluation by the pediatric cardiologist within 1 year. All other echocardiographic 
parameters were within the normal range in all studied patients with CAH.
Table 2  Cardiac function evaluated by conventional echocardiography in  
27 pediatric patients with CAH and 27 age and gender matched controls
Echocardiographic parameter Patients with CAH  
(mean ± SD) 
Controls  
(mean ± SD) 
P-value 
FS (%) 37 ± 4 36 ± 4 (n=24) 0.638 
EF (%) 66 ± 6 67 ± 5 0.701 
LVIDd (mm) 46.4 ± 4.5 45.2 ± 4.9 0.226 
LVIDd (Z) 0.95 ± 0.98 0.63 ± 0.75 0.197 
LVIDs (mm) 29.3 ± 3.8 28.5 ± 3.9 0.323 
LVIDs (Z) 0.57 ± 0.97 0.31 ± 0.95 0.330 
IVSd (mm) 5.50 ± 0.87 5.70 ± 1.17 0.359 
IVSd (Z) -1.42 ± 0.76 -1.15 ± 1.01 0.200 
LVPWd (mm) 5.55 ± 0.82 6.53 ± 1.70 0.009 
LVPWd (Z) -1.12 ± 0.59 -0.35 ± 1.05 0.002 
LVM (g) 77 ± 24 75 ± 34 0.691 
LVMI (g/m2) 53 ± 10 52 ± 14 0.615 
IVRT (ms) 49 ± 18 62 ± 11 0.003 
MV E/A ratio 2.05 ± 0.63 (n=26) 2.36 ± 1.06 (n=26) 0.328 
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Compared to controls, a significantly lower LVPWd was found (5.55 ± 0.82 vs 6.53 ± 
1.70 mm, P = .009) in patients with CAH. However, the average LVPWd Z-score of -1.12 
in patients with CAH was within the normal range. A shorter IVRT was found in 
patients with CAH compared to controls (49 ± 18 vs 62 ± 11 ms, P = .003). All other 
evaluated echocardiographic parameters were similar for patients with CAH and controls.
 No correlations were found between left ventricular parameters and BMI standard 
deviation score (SDS), hydrocortisone dose, androstenedione and 17OHP levels, 
respectively. LVPWd Z-score (not in mm) was weakly correlated with the daily dose of 
fludrocortisone (r = .386; P = .042). All other evaluated echocardiographic parameters 
did not correlate with the daily dose of fludrocortisone. The MV E/A ratio was 
significantly but weakly correlated with the systolic blood pressure during sleep SDS 
for age (correlation coefficient (r = .416; P = .035), the systolic blood pressure during 
sleep SDS for height (r = .423; P = .031), the diastolic blood pressure during sleep SDS 
for age (r = .393; P = .047) and the diastolic blood pressure during sleep SDS for height 
(r = .389; P = .049). LVIDs (in mm, not Z-score) was negatively correlated with the 
24-hour diastolic blood pressure SDS for height (r = −.386; P = .047), the diastolic 
blood pressure in sleep SDS for age (r = −.432; P = .024) and the diastolic blood 
pressure in sleep SDS for height (r = −.441; P = .021). All other evaluated echocardio-
graphic parameters did not correlate with 24-hour ambulatory blood pressure 
measurement parameters in our patients with CAH.
Myocardial deformation evaluated by 2D speckle tracking-derived  
strain imaging
2D speckle tracking-derived strain (rate) parameters of patients with CAH and controls 
are shown in Table 3. No relevant signs of myocardial deformation abnormalities were 
seen in our patients with CAH compared to controls. No correlations were found 
between 2D strain (-rate) parameters and BMI SDS, hydrocortisone dose, andro-
stenedione and 17OHP levels, respectively. Global circumferential strain was 
weakly correlated with the daily dose of fludrocortisone (r = .539; P = .008). All other 
2D speckle tracking-derived myocardial deformation (strain and strain rate) 
parameters were not correlated with the daily dose of fludrocortisone. Global 
longitudinal strain was negatively correlated with systolic 24-hour blood pressure 
SDS for height (r = −.400, P = .039), systolic daytime blood pressure SDS for height 
(r = −.412, P = .033), diastolic 24-hour blood pressure SDS for both age and height 
(r = −.428, P = .033; r = −.438, P = .022), diastolic daytime blood pressure SDS for both 
age and height (r = −.425, P = .027; r = −.426, P = .027). Time to peak GCS was correlated 
with systolic sleeping blood pressure SDS for age (r = .419; P = .047). All other 2D 
speckle tracking-derived myocardial deformation (strain and strain rate) parameters 
were not correlated with 24-hour ambulatory blood pressure measurement 
parameters in the studied patients with CAH.
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Discussion
This study was the first to evaluate cardiac function in a group of pediatric patients 
with CAH by both electrocardiogram, conventional echocardiography, tissue Doppler 
imaging and 2D myocardial strain (rate) imaging. Compared to healthy controls, the 
conventional echocardiographic parameters showed a significantly thinner LVPWd 
and significantly shorter IVRT. Electrocardiogram showed a high prevalence of 25.9% 
of an ICRBBB in patients with CAH.
Left ventricular characteristics in patients with CAH
The LVPWd (both in mm and as Z-score) was significantly lower in the patients with 
CAH when compared to the controls. As the mean Z-score of the LVPWd of our 
patients was −1.12, we believe it should be considered as normal without clinical 
relevance. Our finding was in contrast to the study by Metwalley et al, who reported 
a significantly higher left ventricular posterior wall thickness (without the international 
Z-scores) and LVM index indicating LV hypertrophy in a cohort of 32 Egyptian pediatric 
patients with CAH as compared to their controls.10 The increased LVM index was 
positively correlated with testosterone levels,10 supporting the hypothesis that 
increased levels of androgens may have an unfavorable effect on the development of 
ventricular hypertrophy in patients with CAH. The diagnosis of CAH was made at an 
older age in the Egyptian study compared to our patients. The longer exposure to 
high androgen levels in the Egyptian study might explain the difference on the left 
ventricular structure between our studies. Early diagnosis, as a result of the newborn 
Table 3  Myocardial deformation evaluated by 2D speckle tracking in 27 pediatric 
patients with CAH and 27 age and gender matched controls
Strain (rate) parameters Patients with CAH  
(mean ± SD) 
Controls  
(mean ± SD)
P-value 
Global longitudinal strain (GLS) (%) -20.4 ± 2.0 -19.5  ± 2.1 0.093 
Global longitudinal strain rate (1/s) -1.24 ± 0.15 -1.21 ± 0.16 0.520 
Global radial strain (GRS) (%) 53 ± 14 (n=23) 46 ± 10 (n=20) 0.253 
Global radial strain rate (1/s) 2.58 ± 0.79 (n=22) 2.06 ± 0.29 (n=20) 0.046 
Global circumferential strain (GCS) (%) -17.5 ± 4.2 (n=23) -19.1 ± 3.3 (n=22) 0.350 
Glocal circumferential strain rate (1/s) -1.55 ± 0.26 (n=22) -1.43 ± 0.25 (n=20) 0.264 
Time to Peak GLS (%) 35 ± 2 35 ± 3 0.755 
Time to Peak GRS (%) 33 ± 4 (n=23) 33 ± 4 (n=20) 0.631 
Time to Peak GCS (%) 34 ± 4 (n=23) 32 ± 3 (n=22) 0.305 
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screening for CAH in the Netherlands with consequent initiation of treatment within 
the first weeks of life, may reduce the level and duration of androgen excess and 
perhaps help to prevent LV hypertrophy.
 In several reports on cardiac function in pediatric patients with CAH, unfavorable 
changes in left ventricular function and left ventricular mass were correlated to 
testosterone levels partly also due to late age of diagnosis with longer exposure to 
elevated androgen levels.8-10,12 We did not find an increased left ventricular mass 
(index) in our well-controlled group of patients with CAH in which treatment was 
started immediately after diagnosis based on positive newborn screening for 21OHD 
or directly after birth in female patients with ambiguous genitalia. Furthermore, we 
did not find any correlation between androgen levels and the other studied cardiac 
parameters. Preventing long-term androgen excess by early diagnosis and consequently 
early start of treatment may therefore be beneficial in reducing the incidence of left 
ventricular hypertrophy in patients with CAH. The role of neonatal screening in early 
diagnosis of 21OHD (male) patients is essential and may not only contribute to the 
prevention of Addisonian crisis but may also lead to reduction in morbidity, such as 
impaired cardiac function, later in life. During treatment with  glucocorticoids, one 
should prevent overtreatment with glucocorticoids as cortisol excess also is 
associated with left ventricular hypertrophy.23,24 Besides an increased left ventricular 
mass, also negative effects on the left ventricular systolic and diastolic function in 
patients with increased cortisol levels have been described.23,25-29 It has been 
suggested that cortisol also acts directly on the myocard, as glucocorticoid receptors 
have been reported in the human heart.30 An association between the degree of 
glucocorticoid excess (hypercortisolism) and cardiac changes has been reported, 
supporting the hypothesis of glucocorticoid excess-related cardiac alterations.23,25,31
Impaired left ventricular diastolic function in patients with CAH
A shorter IVRT was found in our patients with CAH compared to controls. A shortened 
IVRT may be the result of increased left atrial pressure.32 Both a prolonged and 
shortened IVRT may be a sign of impaired left ventricular diastolic function. Mild left 
ventricular dysfunction has been described previously,8-11 with both Metwalley et al 
and Marra et al reporting a prolonged IVRT. Marra et al 8 found a significant negative 
correlation between serum testosterone concentrations and IVRT with a prolonged 
IVRT being reported mainly in men, where Metwalley et al suggest that both high and 
low levels of androgens and/or high blood pressure may play a role in the etiology of 
left ventricular dysfunction.10 IVRT in our patients was not correlated with androgen 
levels or 24-hour ABPM parameters. Although we did not find a correlation between 
blood pressure and the shortened IVRT in our patients, the increased blood pressure 
levels in our studied patients14 may explain an increased atrial pressure resulting in a 
shortened IVRT as a sign of mild diastolic dysfunction.
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Elevated blood pressure levels and cardiac function in patients with CAH
Twenty-four-hour ABPM evaluation showed a prevalence of systolic hypertension of 
18.5%, with an absence of the nocturnal dip in blood pressure in 40.7% of the 
patients.14 On the long-term, elevated blood pressure levels are associated with 
cardiovascular events and impaired cardiac function. Although this study did not 
show clear unfavorable effects of blood pressure on cardiac function, one may 
hypothesize that ongoing elevated blood pressure levels may cause impaired cardiac 
function later in life. In this context the weak, but significant, negative correlation 
between 24-hour blood pressure levels and the global longitudinal strain in our 
patients is interesting. Previous studies in adult hypertensive patients with preserved 
left ventricular ejection fraction showed that global longitudinal strain is significantly 
decreased in hypertensive adults compared to healthy controls.33,34 Global 
longitudinal strain is known to be a more sensitive predictor of left ventricular 
dysfunction than left ventricular ejection fraction and may identify subclinical left 
ventricular dysfunction at an earlier stage.35,36 Although at the time of our study, the 
global longitudinal strain was normal compared to controls, we suggest to perform a 
longitudinal follow-up study of this strain parameter to identify subclinical left 
ventricular dysfunction in adult patients with CAH. In addition, this study may further 
evaluate the correlation between the doses of fludrocortisone on the global 
longitudinal strain, as we found a weak, but significant, correlation between them.
IRBBB in patients with CAH
The prevalence of IRBBB in the studied patients with CAH is much higher than 
previously reported in cohorts of healthy children and adolescents (0.32%-7.0%).37-39 
An IRBBB in children is considered as a benign conduction disturbance of unknown 
etiology, and this conduction pattern usually normalizes in adulthood. There are no 
previous data on the association between elevated androgen levels and/or 
glucocorticoid treatment and IRBBB. It is not clear whether this ECG pattern will be 
clinically relevant in future. However, this particular finding had no clinical implications 
for our pediatric patients with CAH.
 The main limitation of this study was the relatively small sample size of patients. 
Furthermore, the development of left ventricular dysfunction and other impairments 
in cardiac function over time was not evaluated. As patients with CAH are exposed to 
a number of cardiovascular risk factors, such as elevated blood pressure, one may 
hypothesize that later in life, the effects on the cardiac function may be more 
prevalent. Further (longitudinal) studies are needed to evaluate the cardiac function 
in adult patients with CAH with long exposure to elevated androgen levels and/or 
exogenous glucocorticoid excess.
 In conclusion, we thoroughly evaluated the cardiac function in pediatric patients 
with CAH by multiple techniques showing normal left ventricular mass and systolic 
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function, with a shortened IVRT that may be a sign of mild left ventricular diastolic 
dysfunction. Based on the current study, there is no indication to routinely evaluate 
the cardiac function pediatric patients with CAH. Further studies are needed to 
evaluate the cardiac function in well-controlled patients with CAH in adolescence and 
adulthood.
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Abstract
Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency 
leads to accumulation of steroid precursors and adrenal androgens. These steroids 
may have a biological effect on the steroid receptor with clinical consequences on 
diagnostics and treatment in CAH patients. Therefore, we analyzed the effect of 
accumulated steroids [17-hydroxyprogesterone (17OHP), progesterone, androstene-
dione and testosterone] on aldosterone-mediated transactivation of the human 
 mineralocorticoid receptor (hMR). 
Methods: A transactivation assay using transiently transfected COS-7 cells was 
employed. Cells were co-transfected with hMR-cDNA, MMTV-luciferase and renilla- 
luciferase expression vectors. Transfected cells were incubated with six different 
steroid concentrations in addition to aldosterone (10-10M). Luciferase and renilla 
activities were measured to quantify hMR transactivation. 
Results: Linear regression analysis showed statistically significant linear inhibition of 
transactivation of the hMR by 10-10M aldosterone in the presence of increasing 
17OHP [F(1,5) = 11.34, p = 0.019] and progesterone [F(1,5) = 11.08, p = 0.021] 
concentrations. In contrast, neither androstenedione nor testosterone affected hMR 
transactivation by aldosterone at a concentration of 10-10M. 
Conclusion: Our study shows for the first time that neither androstenedione nor 
testosterone has a biological effect on aldosterone-mediated transactivation of 
the hMR. 17OHP and progesterone have an anti-mineralocorticoid effect in vitro 
that may clinically lead to an increased requirement of mineralocorticoids in poorly 
controlled CAH patients.
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Introduction
Congenital adrenal hyperplasia (CAH) is a group of disorders affecting adrenal ste-
roidogenesis. The incidence of classic CAH varies between 1 in 10,000 and 1 in 15,000 
live births in most Caucasian populations.1 In about 95% of the cases, CAH is caused 
by 21-hydroxylase deficiency,2 resulting in impaired adrenal synthesis of cortisol. 
Cortisol deficiency triggers a counter-regulatory increase in pituitary ACTH secretion 
leading to accumulation of adrenal steroid precursors before the deficient enzymatic 
step and increased adrenal androgen production. 21-hydroxylase converts 17-hydroxy-
progesterone (17OHP) to 11-deoxycortisol, the penultimate step in cortisol synthesis. 
Hence, 17OHP accumulates and is used as a marker for 21-hydroxylase deficiency.
 Classic CAH is commonly subdivided in the salt wasting and simple virilizing forms 
depending on the residual enzymatic activity. Salt wasting patients have no residual 
21-hydroxylase activity leading to severe salt loss, typically after the first week of life, 
and prenatal virilization of the female external genitalia. Patients with the simple 
virilizing form of CAH have a residual enzyme activity of 1-2% and usually have 
sufficient aldosterone production to prevent severe salt loss, whereas glucocorticoid 
synthesis is severely impaired. In both salt wasting and simple virilizing forms, 
elevated adrenal androgens cause prenatal virilization of the female external genitalia 
and postnatal androgen excess in both sexes.2,3 Current treatment of CAH consists of 
lifelong glucocorticoid and, if necessary, mineralocorticoid treatment.4 Treatment 
with glucocorticoids restores feedback within the hypothalamus-pituitary-adrenal 
axis, consequently achieving downregulation of adrenal androgen production. In 
many patients, however, supraphysiological doses of glucocorticoids are needed to 
normalize androgen levels.
 Untreated and poorly controlled CAH patients are characterized by elevated 
levels of steroid hormone precursors, including progesterone and 17OHP, and 
androgens such as androstenedione and testosterone.3,5-8 It has been shown that 
progesterone and 17OHP have antagonistic properties on the human mineralocorti-
coid receptor (hMR), and therefore may contribute to mineralocorticoid deficiency in 
classic CAH patients.9 The aim of our study was to evaluate the effects of 17OHP, 
progesterone, androstenedione and testosterone on aldosterone-mediated transac-
tivation and translocalization of the hMR. Furthermore, we studied the effect of the 
frequent mineralocorticoid receptor p.Ile180Val single nucleotide polymorphism 
(SNP) on transactivation of the hMR.
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Material and Methods
Construction of Plasmids
The hMR cDNA was PCR amplified from the previously used pcDNA3.1-NR3C2 construct10 
using specific primers with HindIII and EcoRV restriction sites for directional cloning 
into pcDNA6/V5-His-B vector (Invitrogen Corp., Carlsbad, Calif., USA). The p.Ile180Val 
SNP was recreated in the pcDNA6-hMR construct by site-directed mutagenesis using 
the QuikChange XL Site-Directed Mutagenesis Kit according to the manufacturer’s 
protocol (Stratagene, Amsterdam, The Netherlands). The correct insertion of the 
hMR construct and the p.Ile180Val SNP as well as the integrity of the cDNA was 
checked by direct DNA sequencing. For intracellular localization assays Green 
Fluorescent Protein (GFP), an autofluorescent genetic reporter, was cloned into 
pcDNA6. The hMR cDNA and the hMR p.Ile180Val (hMR-I180V) construct were 
cloned into the pcDNA6-GFP vector using the same restriction enzymes as described 
above.
In vitro Transactivation Assays
Transactivation of hMR and hMR-I180V by different concentrations of aldosterone 
was investigated using a MMTV-luciferase assay. Approximately 2.5 × 104 COS-7 cells 
were grown in 500 ml of Dulbecco’s minimal essential medium (DMEM) high glucose 
(4.5 g/l) with L-glutamine (PAA Laboratories GmbH, Pasching, Austria) supplemented 
with 10% fetal bovine serum (PAA Laboratories GmbH) and penicillin/streptomycin 
(PAA Laboratories GmbH) in 24-well plates, and transiently transfected 24 h after 
seeding using FuGene® HD transfection reagent (Roche Applied Sciences, Burgess 
Hill, UK). Cells were transfected with 300 ng of pcDNA6-V5/HisB-hMR or pcDNA6-V5/
HisB-hMR variant (p.Ile180Val) in the presence of 300 ng of a mouse mammary tumor 
virus (MMTV)-luciferase reporter construct (MMTV-luc) driving the firefly luciferase 
gene. Co-transfection with 50 ng of pRL-TK (Promega, Madison, Wisc., USA), a renilla 
luciferase vector, was performed to normalize data for transfection efficiency. In 
each set of experiments, 3 wells with COS-7 cells were co-transfected with 300 ng of 
pcDNA-hMR and 300 ng of pGL3-Basic (Promega) for data normalization and 
interassay comparison purposes as pGL3-Basic contains a coding region for firefly 
luciferase for monitoring transcriptional activity in transfected cells. Two days after 
transfection, cells were treated with aldosterone (Sigma Aldrich, Gillingham, UK) for 
24 h in different concentrations (final concentrations made up in total of 500 μl full 
DMEM media: 10-6, 10-8, 10-10, 10-12 and 10-14M), or in a 10-10M concentration in 
addition to different concentrations of 17OHP (range 5-1,000 nM), progesterone 
(2.5-100 nM), androstenedione (1-250 nM) or testosterone (0.5-60 nM) (Sigma 
Aldrich). Concentrations of 17OHP, progesterone, androstenedione and testosterone 
used in the assays were based on biochemical findings in CAH patients.5,6,7,8
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To evaluate the transactivational potential of 17OHP, progesterone, androstenedione 
and testosterone on the hMR in the absence of aldosterone, transfected cells were 
also incubated in 500 μl of full DMEM supplemented with different concentrations of 
these steroids.
 Cells were lysed in 100 μl of passive lysis buffer (Promega). Consequently, 30 μl 
of cell lysate was used for the measurement of firefly and renilla luciferase activity, 
with a luminometer (Berthold, Bad Wildbad, Germany), using the Dual-Luciferase® 
Reporter Assay System (Promega) according to manufacturer’s standard protocol. 
The hMR transactivation was calculated by the ratio of the steroid-dependent (firefly) 
luciferase and the steroid independent renilla (luciferase). Luciferase/renilla ratios 
were normalized for luciferase activity driven by pGL3-Basic. Data were normalized 
for the transactivation by a 10-10M aldosterone concentration and are presented as fold 
transactivation compared to the transactivation by 10-10M aldosterone (transactivation 
by 10-10M aldosterone was set as 1.0-fold transactivation). All assays were performed 
in triplicate (n = 9). Statistical analysis was performed using GraphPad Prism software 
version 5.0 (GraphPad Software, San Diego, Calif., USA). Results were analyzed by 
both linear regression analyses and ANOVA with Bonferroni adjustment for multiple 
comparisons (all possible comparisons were analyzed). Differences between the hMR 
wild type and the p.Ile180Val construct were analyzed using a t test. p < 0.05 was 
considered significant.
Intracellular Localization
The transactivational potential of the hMR-GFP construct was evaluated to ensure 
comparable transactivational potential to the hMR construct in the presence of 
10-10M concentrations of aldosterone. The hMR-GFP construct was used for an 
intracellular localization assay. Approximately 2 × 105 COS-7 cells were grown on glass 
coverslips in 6-well plates containing 2 ml of DMEM high glucose (4.5 g/l) with 
L-glutamine (PAA Laboratories GmbH) supplemented with charcoal stripped fetal 
bovine serum (Sigma Aldrich) and penicillin/streptomycin (PAA Laboratories GmbH). 
Twenty-four hours after seeding, the cells were transiently transfected using FuGene® 
HD transfection reagent (Roche Applied Sciences) with 2 μg of hMR-GFP or 2 μg of 
hMR-I180V-GFP. Forty-eight hours after transfection, cells were treated for 120 min 
with a combination of 10-10M aldosterone and different concentrations of other 
steroids (17OHP, progesterone, androstenedione and testosterone) to study the 
effect of these steroids on the intracellular localization of the receptor. Cells were 
washed three times in 1× phosphate buffered saline (PBS) and fixed in 1 ml 100% 
methanol at -20°C for 15 min. Fixed cells were further washed three more times in 1× 
PBS and mounted on Vectorshield with 4’, 6-diamidino-2-phenylindole (DAPI; 
exclusively nuclear staining). Results were obtained from three independent 
transfection experiments in which 150 transfected cells were classified in 4 categories: 
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(1) nuclear, (2) mainly nuclear, (3) equal nuclear and cytoplasmic, and (4) mainly 
cytoplasmic. Representative images were taken using confocal microscopy (Nikon 
Instruments Inc., Melville, N.Y., USA). To evaluate if treatment causes a difference in 
the number of cells counted as nuclear, mainly nuclear, equal nuclear or mainly 
cytoplasmic, respectively, one-way ANOVA was performed. Statistical analysis was 
performed using GraphPad Prism software version 5.0.
Results
Transactivation of the Mineralocorticoid Receptor by Aldosterone
Increasing concentrations of aldosterone caused an increase in potent transactiva-
tion of both the hMR and hMR-I180V. The dose-dependent effects on the transacti-
vation are shown in a dose-response curve (fig. 1). An estimated concentration for 
50% transactivation (EC-50) of the hMR of around 10-10M aldosterone was calculated 
for both the wild type (2.4 × 10-11M) and the p.Ile180Val SNP (1.2 × 10-11M).
Figure 1  Dose-response curves showing the transactivation of the hMR (wild type) and the 
hMR-I180V SNP by different concentrations of aldosterone using a luciferase assay. The results 
are expressed as the ratio of (firefly) luciferase and renilla (luciferase) activity. Data are means 
± SEM for each concentration (n = 9). MR = Mineralocorticoid receptor.
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Effect of 17OHP, Progesterone, Androstenedione and Testosterone on  
hMR Transactivation
Increasing concentrations of 17OHP and progesterone inhibited aldosterone-mediat-
ed transactivation of the hMR in a dose-dependent fashion (fig. 2). Linear regression 
analyses showed a linear inhibition of transactivation of the hMR by 10-10M 
aldosterone in the presence of increasing concentrations of 17OHP [F(1,5) = 11.34, p 
= 0.019] and progesterone [F(1,5) = 11.08, p = 0.021]. Variable concentrations of 
17OHP [F(6,48) = 111.9, p < 0.0001] and progesterone [F(6,48) = 62.11, p < 0.0001] 
have a significant effect on transactivation of the hMR by aldosterone in the presence 
of 10-10M aldosterone, as shown by ANOVA (suppl. tables 1, 2).
Figure 2  The effect of different concentrations of 17OHP (A), progesterone (B), testosterone 
(C) and androstenedione (D) on the transactivation of hMR by 10-10M aldosterone concentration. 
The transactivation activity of 10-10M aldosterone was set as 1.0. Results are expressed as 
x-fold transactivation of MMTV (firefly) luciferase (MMTV-luc). Data are means ± SEM for each 
concentration (n = 9). Significant differences in transactivation between two concentrations 
closest to each other are indicated by an asterisk (p < 0.05).
A
C
B
D
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In contrast, treatment with increasing concentrations of androstenedione and 
testosterone did not have any measureable effect on hMR transactivation (fig. 2). 
No linear effect of increasing concentrations of androstenedione [F(1,5) = 0.709, 
p = 0.438] or testosterone [F(1,5) = 1.57, p = 0.265]on transactivation of the hMR by 
aldosterone was found. In addition, ANOVA showed that different concentrations of 
androstenedione or testosterone did not affect transactivation of the hMR by 
aldosterone (online suppl. tables 3, 4).
 The effect of three different concentrations of 17OHP on the aldosterone-mediated 
transactivation of the hMR was also evaluated in the p.Ile180Val SNP construct (fig. 3). 
The inhibitory effect of 17OHP on hMR-I180V was found to be similar to its effect on 
the wild-type hMR (p > 0.05).
Intracellular Localization of the hMR
The transactivation potential of both the hMR-GFP and the hMR construct were 
compared to assess whether the GFP had altered transactivational properties of the 
construct prior to performing an intracellular localization assay. The hMR-GFP 
construct was shown to have equal transactivational properties as the hMR construct 
(suppl. fig. 1).
Figure 3  The effect of different concentrations of 17OHP on the transactivation of hMR by 
10-10M aldosterone concentration compared to the effect of different concentrations of 17OHP 
on the transactivation of the hMR-I180V SNP. The transactivation activity of 10-10M aldosterone 
on the hMR (wild type) was set as 1.0. Results are expressed as x-fold transactivation of MMTV 
(firefly) luciferase (MMTV-luc). Data are means ± SEM for each concentration (n = 9)
173
Steroid metabolism in congenital adrenal hyperplasia
4
Figure 4  A Cellular localization of the hMR without the presence of aldosterone and in the 
presence of aldosterone with or without different concentrations of 17OHP and progesterone. 
Cells were localized using confocal microscopy as (1) nuclear (black bars), (2) mainly nuclear 
(dark grey bars), (3) equal nuclear-cytoplasmic (light grey bars) and (4) mainly cytoplasmic 
(white bars). B Images showing the four possible cellular localizations of the hMR: (1) nuclear, 
(2) mainly nuclear, (3) equal nuclear and cytoplasmic, (4) mainly cytoplasmic. Images were 
taken with a confocal microscope. Different images were taken showing DAPI staining, GFP and 
a merged image. C Cellular localization of the hMR-I180V without the presence of steroids and 
in the presence of aldosterone with or without different concentrations of 17OHP. Cells were 
localized using confocal microscopy as (1) nuclear (black bars), (2) mainly nuclear (dark grey 
bars), (3) equal nuclear - cytoplasmic (light grey bars) and (4) mainly cytoplasmic (white bars).
A C
B
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In untreated cells, the hMR was localized only in the cytoplasm or equally distributed in 
nucleus and cytoplasm (fig. 4a). Treatment with aldosterone for 120 min resulted in a 
clear translocation of the hMR with a predominantly nuclear localization.
 17OHP and progesterone did not influence the translocation of the hMR to the 
nucleus in the presence of aldosterone (fig. 4b). Treatment with 17OHP, progesterone, 
androstenedione or testosterone did not result in significant differences in the intra -
cellular localization of the hMR.
 In the presence of aldosterone, the hMR-I180V-GFP was also mainly localized in 
the nucleus. 17OHP did not inhibit the translocation of the hMR-I180V-GFP to the 
nucleus in the presence of aldosterone (fig. 4c).
Discussion
We studied the effects of different adrenal steroid hormone precursors and androgens 
on the transactivational potential and localization of the hMR. Our study shows for 
the first time that excess concentrations of androstenedione and testosterone do not 
have a biological effect on the aldosterone-mediated transactivation of the hMR in 
vitro. Furthermore, 17OHP and progesterone have a strong anti-mineralocorticoid 
effect in vitro, which confirms previous findings.9 This study highlights the anti- 
mineralocorticoid effect of elevated 17OHP concentrations as found in poorly controlled 
CAH patients.
 These findings may have important implications for the clinical care provision. 
Based on our results, it can be suggested that elevated 17OHP and progesterone 
concentrations are likely to have an adverse effect on the mineralocorticoid effect in 
untreated and poorly treated CAH. This may potentially lead to increased requirement 
of mineralocorticoids and suboptimal control. In contrast, elevated androgens did 
not influence the mineralocorticoid transactivation in vitro. We therefore hypothesize 
that elevated androgens per se do not have a clinical relevant effect on mineralocor-
ticoid treatment in the clinical care of CAH.
 The current treatment strategy is based on normalizing adrenal androgens to 
prevent adverse effects of hyperandrogenism. Slightly elevated 17OHP concentrations 
are generally accepted because of the possible side effects of high dosages of gluco-
corticoids needed to achieve physiological 17OHP concentrations. Based on our 
results it can be suggested that lowering of highly elevated 17OHP concentrations 
may also have an additional positive effect on the dosage of mineralocorticoid 
treatment and consequently decrease the potential risk of adverse effects of 
mineralo corticoid treatment such as hypertension. Unfortunately, supraphysiologi-
cal doses of glucocorticoids are generally necessary to lower 17OHP levels that may 
lead to adverse effects and long-term complications. Therefore, the treatment goal in 
CAH patients is normalization of adrenal androgens with slightly elevated 17OHP 
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levels.4 Elevated renin levels may indicate the need for higher mineralocorticoid 
doses. However, based on our data, elevated renin concentrations may also reflect 
the anti- mineralocorticoid effect of elevated 17OHP concentrations. A fine balance 
between the use of supraphysiological dosages of glucocorticoids, mineralocorticoid 
treatment and normalizing 17OHP levels has to be achieved to prevent long-term 
complications of overtreatment with glucocorticoids on one hand and overtreatment 
with mineralo corticoids on the other hand.
 The antagonistic properties of progesterone on the human, rat and sheep 
mineralo corticoid receptor have been previously described.9,11-15 A 50% inhibition of 
the maximum transactivation of the mineralocorticoid receptor is caused by 
progesterone concentrations between 2 and 11 nM.9,16-18 The inhibitory effect of 
progesterone described in our study is in line with those described in the studies 
mentioned above. Minor differences between the results of those studies may be 
explained by different cells and different luciferase constructs used.
 The effect of slightly elevated 17OHP concentrations on the hMR have been 
studied previously.9 The previously reported concentration of 135 nM, causing a 50% 
inhibition of transactivation of the hMR by a 10-9M aldosterone, is in line with the 
antagonistic effect of 17OHP on aldosterone-mediated transactivation described in 
our study. In our study we evaluated the effect of even higher 17OHP concentrations, 
as found in untreated or poorly controlled CAH patients.
 In contrast to the effect on transactivation, the translocation to the nucleus 
seems not to be affected by 17OHP or progesterone. The physiological human ligand 
of the hMR is aldosterone. After binding to aldosterone, the hMR undergoes a 
conformational change and partial dissociation of the ligand binding complex occurs, 
leading to translocation of the hMR to the nucleus. Within the nucleus, the activated 
receptors regulate transcription by different pathways including transactivation of 
target genes.19-23 Intracellular localization studies on the hMR have shown that in the 
absence of steroids the hMR is localized in the cytoplasm and in the nucleus, 
aldosterone causes a rapid nuclear accumulation of the hMR.19,24-27 Binding of 
aldosterone to the hMR causes dissociation of several associated proteins from the 
receptor, followed by dimerization and finally nuclear translocation of the activated 
receptor. The translocation assay performed in this study showed a similar subcellular 
localization with a predominant localization of the hMR in the cytoplasm in the 
absence of steroids. Treatment of the COS-7 cells expressing the hMR-GFP construct 
with aldosterone causes a quick translocation of the hMR to the nucleus of the cells. 
However, different concentrations of 17OHP and progesterone in addition to an 
aldosterone concentration of 10-10M do not have an impact on the translocation of 
the hMR to the nucleus. This finding is in contrast to the described effects of hMR 
antagonists, such as spironolactone and eplerenone, which inhibit the translocation 
of the hMR to the nucleus.19
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The mechanism of the inhibition of aldosterone-mediated transactivation of the hMR 
by progesterone and 17OHP remains unclear. It has been shown that 17OHP has a 
relatively high binding affinity for the hMR.9 Therefore, competitive binding of the 
hMR between 17OHP and aldosterone, such as in patients with poorly controlled 
CAH, is very likely. We showed that 17OHP does not inhibit the translocation of the 
hMR to the nucleus. Therefore, we hypothesize that the anti-mineralocorticoid effect 
of 17OHP on the hMR is not due to an effect on the translocation of the hMR, 
but might be caused by effects on the transcription after translocation to the nucleus. 
It has been suggested by Hellal-Levy et al.20 that binding of an antagonist to the hMR 
leads to an inactive conformation of the hMR. Due to instability, this complex of 
the mineralocorticoid receptor and its antagonist will not be converted into a tran-
scriptionally active conformation.20 This hypothesis may explain the antagonistic 
properties of 17OHP and progesterone on the hMR.
 The mineralocorticoid receptor p.Ile180Val SNP (rs5522) is one of the most 
frequent SNPs in the hMR with a frequency of 10.2% of the G allele in a European 
population (HapMap project, www.hapmap.org). The mineralocorticoid receptor p.
Ile180Val SNP has been associated with an increased hypertension risk.28 As CAH 
patients have a tendency to develop elevated blood pressure,29,30 the role of this SNP 
in CAH patients might be important with respect to their cardiovascular risk profile. 
We showed that the hMR p.Ile180Val SNP does not affect transactivation of the hMR 
by aldosterone. These findings are in line with the results by DeRijk et al.31 In addition, 
17OHP has the same antagonistic effect on the hMR-I180V SNP as on the wild-type 
hMR. Thus, the results of this study do not explain the increased hypertension risk in 
p.Ile180Val.
 In conclusion, our study shows for the first time that neither androstenedione 
nor testosterone have a significant biological effect on the aldosterone-mediated 
transactivation of the hMR. In contrast, increased 17OHP and progesterone 
concentrations have an anti-mineralocorticoid effect due to an inhibition of aldoste-
rone-mediated transactivation of the hMR. However, unlike hMR blockers, neither 
17OHP nor progesterone inhibits the translocation of the hMR to the nucleus. Further 
studies are needed to explain the mechanism of this inhibition of transactivation by 
17OHP.
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Supplementary table 1  Results of Bonferroni’s Multiple Comparison Test for all 
comparisons in the experiment evaluating the effect of different concentrations of 
17OHP on the aldosterone mediated transactivation of the hMR
Comparison Mean difference. t P < 0.05?
1000 nmol/l vs 500 nmol/l -0,09818 2,176 No
1000 nmol/l vs 250 nmol/l -0,1691 3,748 Yes
1000 nmol/l vs 100 nmol/l -0,3538 7,841 Yes
1000 nmol/l vs 20 nmol/l -0,6562 14,54 Yes
1000 nmol/l vs 5 nmol/l -0,7723 17,12 Yes
1000 nmol/l vs 0 nmol/l -0,8160 18,09 Yes
500 nmol/l vs 250 nmol/l -0,07093 1,572 No
500 nmol/l vs 100 nmol/l -0,2556 5,664 Yes
500 nmol/l vs 20 nmol/l -0,5581 12,37 Yes
500 nmol/l vs 5 nmol/l -0,6741 14,94 Yes
500 nmol/l vs 0 nmol/l -0,7179 15,91 Yes
250 nmol/l vs 100 nmol/l -0,1846 4,092 Yes
250 nmol/l vs 20 nmol/l -0,4871 10,80 Yes
250 nmol/l vs 5 nmol/l -0,6032 13,37 Yes
250 nmol/l vs 0 nmol/l -0,6469 14,34 Yes
100 nmol/l vs 20 nmol/l -0,3025 6,704 Yes
100 nmol/l vs 5 nmol/l -0,4186 9,277 Yes
100 nmol/l vs 0 nmol/l -0,4623 10,25 Yes
20 nmol/l vs 5 nmol/l -0,1161 2,573 No
20 nmol/l vs 0 nmol/l -0,1598 3,542 Yes
5 nmol/l vs 0 nmol/l -0,04373 0,9692 No
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Supplementary table 2  Results of Bonferroni’s Multiple Comparison Test for all 
comparisons in the experiment evaluating the effect of different concentrations of 
progesterone on the aldosterone mediated transactivation of the hMR
Comparison Mean difference t P < 0.05?
100 nmol/l vs 75 nmol/l -0,04790 0,9424 No
100 nmol/l vs 50 nmol/l -0,1382 2,719 No
100 nmol/l vs 25 nmol/l -0,09753 1,919 No
100 nmol/l vs 10 nmol/l -0,3455 6,797 Yes
100 nmol/l vs 2.5 nmol/l -0,5654 11,12 Yes
100 nmol/l vs 0 nmol/l -0,7384 14,53 Yes
75 nmol/l vs 50 nmol/l -0,09030 1,776 No
75 nmol/l vs 25 nmol/l -0,04963 0,9763 No
75 nmol/l vs 10 nmol/l -0,2976 5,855 Yes
75 nmol/l vs 2.5 nmol/l -0,5175 10,18 Yes
75 nmol/l vs 0 nmol/l -0,6905 13,58 Yes
50 nmol/l vs 25 nmol/l 0,04067 0,8001 No
50 nmol/l vs 10 nmol/l -0,2073 4,078 Yes
50 nmol/l vs 2.5 nmol/l -0,4272 8,405 Yes
50 nmol/l vs 0 nmol/l -0,6002 11,81 Yes
25 nmol/l vs 10 nmol/l -0,2480 4,878 Yes
25 nmol/l vs 2.5 nmol/l -0,4679 9,205 Yes
25 nmol/l vs 0 nmol/l -0,6408 12,61 Yes
10 nmol/l vs 2.5 nmol/l -0,2199 4,327 Yes
10 nmol/l vs 0 nmol/l -0,3929 7,729 Yes
2.5 nmol/l vs 0 nmol/l -0,1729 3,402 Yes
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Supplementary table 3  Results of Bonferroni’s Multiple Comparison Test for all 
comparisons in the experiment evaluating the effect of different concentrations of 
testosterone on the aldosterone mediated transactivation of the hMR
Comparison Mean difference t P < 0.05?
60 nmol/l vs 30 nmol/l -0,3613 2,501 No
60 nmol/l vs 15 nmol/l -0,3361 2,326 No
60 nmol/l vs 7.5 nmol/l -0,3316 2,295 No
60 nmol/l vs 2.5 nmol/l -0,1137 0,7870 No
60 nmol/l vs 0.5 nmol/l -0,3324 2,301 No
60 nmol/l vs 0 nmol/l -0,2067 1,431 No
30 nmol/l vs 15 nmol/l 0,02527 0,1749 No
30 nmol/l vs 7.5 nmol/l 0,02973 0,2058 No
30 nmol/l vs 2.5 nmol/l 0,2476 1,714 No
30 nmol/l vs 0.5 nmol/l 0,02890 0,2001 No
30 nmol/l vs 0 nmol/l 0,1546 1,070 No
15 nmol/l vs 7.5 nmol/l 0,004459 0,03086 No
15 nmol/l vs 2.5 nmol/l 0,2224 1,539 No
15 nmol/l vs 0.5 nmol/l 0,003627 0,02511 No
15 nmol/l vs 0 nmol/l 0,1294 0,8955 No
7.5 nmol/l vs 2.5 nmol/l 0,2179 1,508 No
7.5 nmol/l vs 0.5 nmol/l -0,0008315 0,005755 No
7.5 nmol/l vs 0 nmol/l 0,1249 0,8646 No
2.5 nmol/l vs 0.5 nmol/l -0,2187 1,514 No
2.5 nmol/l vs 0 nmol/l -0,09299 0,6436 No
0.5 nmol/l vs 0 nmol/l 0,1257 0,8704 No
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Supplementary table 4  Results of Bonferroni’s Multiple Comparison Test for all 
comparisons in the experiment evaluating the effect of different concentrations of 
androstenedione on the aldosterone mediated transactivation of the hMR
Comparison Mean difference t P < 0.05?
250 nmol/l vs 100 nmol/l -0,1522 1,264 No
250 nmol/l vs 50 nmol/l -0,3702 3,073 No
250 nmol/l vs 25 nmol/l -0,2441 2,027 No
250 nmol/l vs 10 nmol/l -0,1788 1,484 No
250 nmol/l vs 1 nmol/l -0,1100 0,9129 No
250 nmol/l vs 0 nmol/l -0,01177 0,09770 No
100 nmol/l vs 50 nmol/l -0,2180 1,810 No
100 nmol/l vs 25 nmol/l -0,09192 0,7631 No
100 nmol/l vs 10 nmol/l -0,02654 0,2204 No
100 nmol/l vs 1 nmol/l 0,04224 0,3507 No
100 nmol/l vs 0 nmol/l 0,1404 1,166 No
50 nmol/l vs 25 nmol/l 0,1261 1,047 No
50 nmol/l vs 10 nmol/l 0,1915 1,589 No
50 nmol/l vs 1 nmol/l 0,2602 2,160 No
50 nmol/l vs 0 nmol/l 0,3584 2,976 No
25 nmol/l vs 10 nmol/l 0,06538 0,5427 No
25 nmol/l vs 1 nmol/l 0,1342 1,114 No
25 nmol/l vs 0 nmol/l 0,2324 1,929 No
10 nmol/l vs 1 nmol/l 0,06878 0,5710 No
10 nmol/l vs 0 nmol/l 0,1670 1,386 No
1 nmol/l vs 0 nmol/l 0,09820 0,8152 No
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Supplementary figure 1  Transactivational potential of the hMR construct versus the hMR-GFP 
construct evaluated by a luciferase assay. The results are expressed as the ratio of (firefly) 
luciferase to renilla (luciferase) activity corrected for pGL3 (transfection efficiency). Data are 
means ± S.E.M. (n=9).
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Summary
Patients with congenital adrenal hyperplasia (CAH) are often clinically less severely 
affected by cortisol deficiency than anticipated from their enzymatic defect. We 
hypothesize that adrenal steroid hormone precursors that accumulate in untreated 
or poorly controlled CAH have glucocorticoid activity and partially compensate for 
cortisol deficiency. We studied the in vitro effects of 17-hydroxyprogesterone 
(17OHP), progesterone (P), 21-deoxycortisol (21DF), and androstenedione (Δ4) on the 
human glucocorticoid receptor (hGR). Competitive binding assays were performed in 
HeLa cells. Nuclear translocation of the hGR was studied by transfection of COS-7 
cells with a GFP-tagged hGR and fluorescence microscopy. Transactivation assays 
were performed in COS-7 cells and in HEK 293 cells after cotransfection with hGR and 
luciferase reporter vectors using a dual luciferase assay. 17OHP, P, and 21DF are able 
to bind to the hGR with binding affinities of 24–43% compared with cortisol. Δ4 has a 
low binding affinity. Incubation with 21DF led to complete nuclear translocation of 
the hGR, whereas treatment with 17OHP or P resulted in partial nuclear translocation. 
21DF transactivated the hGR with an EC50 approximately 6 times the EC50 of cortisol. 
17OHP and P transactivated the hGR with EC50s of more than 100 times the EC50 of 
cortisol. No hGR transactivation was detected after incubation with Δ4. 21DF, 17OHP, 
and P are able to bind, translocate, and transactivate the hGR in vitro and thus may 
have glucocorticoid activity. 21DF might have a clinically relevant agonistic effect on 
the hGR and could potentially partially compensate the cortisol deficiency in CAH 
patients.
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Congenital adrenal hyperplasia (CAH) is an autosomal-recessive disorder caused by a 
deficiency of one of the enzymes involved in adrenal steroid synthesis. Ninety-five 
percent of cases are caused by 21-hydroxylase deficiency. This results in impaired 
synthesis of cortisol. In 75% of cases patients also suffer from clinically relevant 
aldosterone deficiency.1 Due to the reduced negative feedback to the hypothalamus 
and pituitary gland, cortisol deficiency leads to increased pituitary secretion of ACTH. 
Consequently, the steroid hormone precursors prior to the enzymatic block 
accumulate and are shunted into the androgen-synthesis pathway. The presence of 
increased concentrations of adrenal steroid hormone precursors is a hallmark feature 
of patients with CAH and these precursors can be used as diagnostic markers.2 CAH 
caused by 21-hydroxylase deficiency represents a spectrum of disease depending on 
the severity of the enzymatic defect. The most severe, classic CAH, is subdivided in a 
salt-wasting form (SW-CAH) and a simple-virilizing form (SV-CAH) without aldosterone 
deficiency. Nonclassic CAH (NCAH) is less severe with generally only mild symptoms 
of hyperandrogenism.1 The treatment of classic CAH consists of lifelong replacement 
of glucocorticoids and if necessary also of mineralocorticoids. The goal of treatment 
is to prevent adrenal and salt-wasting crises and to suppress abnormal secretion of 
adrenal androgens by suppression of the pituitary gland. Treatment of NCAH is only 
indicated when there are severe symptoms of androgen excess and/or glucocorticoid 
deficiency.2
 Patients with CAH are clinically often less severely affected by cortisol deficiency 
than anticipated from their enzymatic defect. For example, patients with SW-CAH 
have a severe cortisol and aldosterone deficiency due to a residual enzymatic activity 
of less than 1%.1 They develop salt-wasting crises neonatally but only a minority 
present with hypoglycemia or conjugated jaundice, a classic symptom of infantile 
glucocorticoid deficiency.3 Patients with SV-CAH have a residual enzymatic activity of 
1–2% and a suboptimal increase of cortisol after stimulation with ACTH. In areas 
where neonatal screening is not implemented, male patients with SV-CAH often 
present with signs of androgen excess in (early) childhood, without a history of 
Addisonian crises during illness or surgery prior to their diagnosis.1 Furthermore, 
many adult patients with classic CAH who are lost to endocrine followup and are not 
adherent to treatment with glucocorticoids do not develop adrenal crises for long 
periods of time.4 Finally, between 30 and 40% of patients with NCAH diagnosed in 
adolescence or adulthood show a suboptimal cortisol response to synacthen 
stimulation, suggesting a potential risk of adrenal insufficiency during illness or 
surgery.5-7 However, these patients usually do not report a history of signs or 
symptoms consistent with adrenal insufficiency during surgery or illness.5,7
 These observations could hypothetically be explained by the presence of adrenal 
steroid hormone precursors that accumulate in patients with untreated and poorly 
controlled CAH. These precursors, such as 17-hydroxyprogesterone (17OHP), 
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progesterone (P), 21-deoxycortisol (21DF), and androstenedione (Δ4),2 have structural 
similarities to cortisol.8 We hypothesize that they may have clinically significant 
glucocorticoid activity and partially substitute for cortisol. To analyze their 
glucocorticoid properties, we studied their effects on binding, nuclear translocation, 
and transactivation of the human glucocorticoid receptor (hGR).
Materials and Methods
In vitro receptor binding assays
Competitive binding assays for the hGR were performed as described previously.9 
HeLa cells were cultured in DMEM High Glucose (4.5 g/L) with L-Glutamine 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (all PAA 
Laboratories, GmbH). Whole cells (0.2–1.0 × 106) were incubated in serum and 
 phenol-red-free RPMI medium (final volume, 150 μL) for 1.5–2 hours at 37°C in a 
series of 0.5 mL microcentrifuge tubes containing 30nM 3H-cortisol (PerkinElmer, 
Inc.) and an increasing amount of unlabeled competitor: cortisol, 17OHP, 21DF, Δ4 
(all Steraloids) or P (Sigma-Aldrich). Nonspecific binding was assessed by means of 
500-fold excess of dexamethasone (Steraloids). Radioactivity was counted in a β counter. 
Specific binding was expressed as the percentage of specific binding over binding of 
radioligand only, corrected for nonspecific binding.
In vitro nuclear translocation assays
For the intracellular localization assays, hGR DNA (pRShGRα) was PCR amplified using 
primers with BamHI and EcoRV restriction sites (Sigma-Aldrich). It was cloned into a 
pcDNA6-V5/HisB-EGFP vector (Invitrogen Corp.). The correct insertion of the hGR 
construct as well as the integrity of the cDNA was checked by direct DNA sequencing.
The assays were carried out in COS-7 cells, which is a cell line that does not contain 
endogenous glucocorticoid receptor. The COS-7 cells were cultured in DMEM High 
Glucose (4.5 g/L) with L-Glutamine supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin. COS-7 cells (n = 1.5 × 105) were grown in six-well plates on 
glass coverslips. After 24 hours the cells were transiently transfected with 2 μg of 
GFP-hGR using the TransIT-LT 1 DNA transfection reagent (Mirus Bio). Fourty-eight 
hours after transfection the cells were treated for 60 minutes with one of the steroids 
(cortisol, 17OHP, P, 21DF, Δ4) in a concentration of 10−6M. Afterward the cells were 
fixated on the coverslips in 100% methanol at −20°C for 15 minutes and mounted with 
Vectashield with DAPI (Vector Laboratories) on microscope slides. The cells were 
studied under the Zeiss Apotome Fluorescence microscope with Zeiss Axiovision 
imaging software (version 4.7.2) at a magnification of 200× for the localization of the 
hGR. Representative images were taken. The experiment was performed in duplicate.
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In vitro transactivation assays
For the transactivation assays, the hGR DNA was cloned into a pcDNA6-V5/HisB 
vector (Invitrogen Corp.) using the same restriction enzymes as described above. The 
luciferase reporter vectors used for the transactivation assays were MMTV-luc and 
pRL-TK (Promega). MMTV-luc is a firefly luciferase reporter construct. Transcription is 
controlled by glucocorticoid response elements immediately upstream from the 
luciferase sequence. pRL-TK contains a renilla luciferase. It serves as an internal 
standard to normalize firefly luciferase light emission measurements with regard to 
transfection efficiency and the number of cells in each well.
 The COS-7 cells were cultured in DMEM High Glucose (4.5 g/l) with L-Glutamine 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and 
seeded in 24-well plates in a density of 2 × 104 cells per well. Twenty-four hours after 
seeding, the COS-7 cells were transiently cotransfected using the TransIT-LT 1 DNA 
transfection reagent with 0.2 μg pcDNA6-V5/HisB-hGR, 0.3 μg MMTV-luc, and 0.01 
μg pRL-TK per well. Two days after transfection the cells were treated with one of the 
steroids (cortisol, 17OHP, P, 21DF, Δ4). Steroid solutions in ethanol were made in 
concentrations of 200× the final desired concentration (10−9 to 10−4M) and diluted 
1:200 with DMEM prior to adding them to the transfected cells. Twenty-four hours 
after adding the steroid, firefly and renilla luciferase activity were measured using the 
Dual-Luciferase Reporter Assay System (Promega) on a Fluoroskan FL luminometer 
(Thermo Scientific). Firefly luciferase/renilla luciferase ratios were calculated to 
normalize for transfection efficiency. Each experiment was performed in triplicate.
To ensure that the COS-7 cell line did not contain relevant amounts of endogenous 
steroid receptors, the transactivation activities of the different steroids were also 
measured in COS-7 cells that had not been transfected with steroid receptor 
expression vectors. Likewise, the system was tested for the presence of endogenous 
steroids by measuring the transactivation activity after transfection with the hGR 
vectors but without addition of steroids. In neither approach relevant transactivation 
was measured.
 The transactivation assay was repeated in HEK293 cells using the methods 
described above. These experiments were performed in duplicate.
Statistical analysis
Analyses were performed using GraphPad Prism software version 5.0 for Windows 
(GraphPad Software). Steroid concentrations were expressed on a log scale and 
dose-response curves were calculated using nonlinear regression. For the receptor 
binding assays, the concentration of unlabeled steroid that reduces binding of the 
radioligand by half (IC50) was determined. The relative binding affinity of the study 
steroids compared with cortisol was calculated by IC50:cortisol/IC50:test steroid × 100%. 
For the transactivation assays, the estimated concentration for 50% transactivation 
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(EC50) was determined. For calculation of the relative functional sensitivity of the hGR 
to the different steroids, the transactivation potential of cortisol was set at 100%. The 
sensitivity of the hGR to the other test compounds was calculated as EC50:cortisol/
EC50:test steroid × 100%.
Results
Receptor-binding assay
The receptor-binding curves for the studied steroids are shown in Figure 1. The IC50 
and the relative binding affinity of cortisol, 17OHP, P, 21DF, and Δ4 were calculated 
(Table 1). The results demonstrate that 17OHP, P, and 21DF bind to the hGR with 
relative binding affinities of 27, 43, and 24%, respectively. The binding affinity for Δ4 
is dramatically less than that of cortisol, 0.4%.
Nuclear translocation assay
Incubation with cortisol in a concentration of 10−6M resulted in complete nuclear 
translocation of the hGR within 60 minutes (Figure 2B). Adding 17OHP, P, and 21DF to 
the transfected cells in a concentration of 10−6M resulted in respectively almost 
complete, partial and complete transport to the nucleus (Figure 2, C–E). After 
treatment of the cells with Δ4, the location of the hGR was still predominantly 
cytoplasmic (Figure 2F).
Figure 1  Binding assay. Competition of various steroids for binding of 3H cortisol to the hGR 
in HeLa cells. Binding data are expressed as the percentage of specific binding (Bs) remaining 
after adding increasing amounts of competitor.
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hGR transactivation assay in COS-7 cells
Cortisol activated the hGR with an EC50 of 1.7 × 10−8M (Figure 3, A–D; Table 1). 
Exposure of the hGR to increasing concentrations of 17OHP, P, and 21DF resulted in 
increasing hGR transactivation, up to a maximum. A dose-response curve was fitted 
(Figure 3, A–C) and the EC50 values for these steroids were calculated. The EC50 value 
was 2.2 × 10−6M for 17OHP, 3.0 × 10−6M for P, and 1.0 × 10−7M for 21DF (Table 1). Δ4 
did not transactivate the hGR at the concentrations tested (Figure 3D).
Figure 2  Localization of the hGR in COS-7 cells transfected with the hGR, without steroids (A) 
and after incubation with various steroids in a concefitration of 10−6M (B–F). The nucleus is 
stained blue and the hGR is tagged with a green fluorescent protein. B, cortisol. C, 17-OHP. 
D, progesterone. E, 21DF. F, Δ4.
A
C
E
B
D
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hGR transactivation assay in HEK293 cells
The results for the transactivation assay in HEK293 cells are shown in Supplemental 
Figure 1 and Table 1. In these experiments, the EC50 for cortisol was 3.5 × 10−9M. 
17OHP, P, and 21DF activated the hGR with EC50 values of 1.2 × 10−6M, 2.3 × 10−6M, 
and 4.1 × 10−8M, respectively.
Figure 3  Transactivation of the hGR by 17OHP (A), P (B), 21DF (C), and Δ4 (D), in comparison 
with the transactivation of the hGR by cortisol.
A
C
B
D
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Discussion
We describe here the binding of 17OHP, P, 21DF, and Δ4 to the hGR and their effects 
on the nuclear translocation and transactivation of the hGR, in comparison with the 
effects of cortisol. We found that 21DF and to a lesser extent 17OHP and P can 
transactivate the hGR. This is consistent with the receptor-binding and nuclear 
translocation of the hGR we found after incubation with these steroids. It has 
previously been described that 17OHP and P bind to the hGR,10-12 but to the best of 
our knowledge this has not been shown for 21DF previously. These agonistic 
properties on the hGR might explain the clinical observation that CAH patients are 
often less severely affected by cortisol deficiency than anticipated from their 
enzymatic defect.
Supplemental figure 1  Transactivation of the human glucocorticoid receptor (hGR) in HEK293 
cells by 17-hydroxyprogesterone, 21-deoxycortisol and androstenedione, in comparison with 
the transactivation of the hGR by cortisol.
A
C
B
D
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Steroid hormone cross reactivity to receptors is a well-known phenomenon. For example, 
cortisol is known to have an agonistic effect on the mineralocorticoid receptor.13 
In addition, in a previous study of our group we have demonstrated that 17OHP and 
P can influence the transactivation of the human mineralocorticoid receptor: both 
have antimineralocorticoid effects in vitro.14 The occurrence of cross reactivity of 
these steroids at both the hGR and the human mineralocorticoid receptor can be 
explained by the high degree of homology at the DNA-binding domains of these 
receptors.15
 The EC50 of cortisol in our model is comparable to the EC50 previously described,16 
demonstrating the reliability of our in vitro model. Under the experimental conditions 
21DF, 17OHP, and P have the capacity to transactivate the hGR. With the concentrations 
used in our experiments we were able to reconstruct complete dose response curves, 
up to the point where maximum transactivation was reached. In the two cell lines 
studied, a comparable profile was found: 21DF has the greatest transactivational 
capacity, 17OHP and P are also able to transactivate the hGR but only at much higher 
concentrations. Δ4 does not transactivate the hGR at the concentrations tested. 
Given that there was no transactivation detectable for Δ4 even in concentrations at 
least 100 times higher than the concentrations found in untreated CAH, we do not 
expect that relevant transactivation will occur with higher concentrations.17 The fact 
that Δ4 has no agonistic effect on the hGR might be explained by the greater structural 
dissimilarity between Δ4 and cortisol compared with that of the other test compounds 
and cortisol.8
 As illustrated by the EC50 values more than 100 times higher than the EC50 of 
cortisol, 17OHP and P are less potent agonists of the hGR than cortisol. In healthy 
volunteers the 17OHP concentration is substantially lower than that of cortisol: 
reference values for serum 17OHP are 2.0–10.8 nmol/L for males and 0.45–12.7 
nmol/L for females, 0900-h reference values for serum cortisol are 190–550 nmol/L. 
In this situation cross-reactivity on the hGR will be negligible. However, in patients 
with classic CAH 17OHP concentrations can increase to very high concentrations of 
more than 1500 nmol/l.18,19 Based on the dose-response curve we constructed, 
these concentrations might be high enough to result in relevant hGR transactivation.
 Interestingly, the EC50 of 21DF is much closer to the EC50 of cortisol (approximately 
6-fold in the transactivation assays in COS-7 cells, approximately 12-fold in the 
HEK293 cells). The serum concentrations of 21DF in untreated or poorly controlled 
patients with classic CAH can exceed 400 nmol/l.18,19 Based on our results we 
hypothesize that these concentrations may lead to a clinically relevant transactivation 
of the hGR. Less transactivation can be expected in NCAH patients, given that in 
these patients the 21DF concentrations are lower and reach up to approximately 
40 nmol/L.6 We suggest that high serum 21DF concentrations in untreated or poorly 
controlled CAH patients may partially compensate for their cortisol deficiency. 
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In contrast, overtreatment with complete suppression of adrenal precursors including 
17OHP and 21DF might lead to an increased risk of adrenal crises and hypoglycemia. 
Therefore, adequate stress dosing is crucial once glucocorticoid treatment is initiated 
in patients with CAH.
 Considering that we have studied several elements of the hGR transactivation 
cascade with consistent results, we are confident that our results represent actual 
glucocorticoid properties of 21DF, 17OHP, and P. However, given that this is an in vitro 
model, our findings must be confirmed in additional studies. We have studied the 
transactivating properties of several steroids, and not the other mechanisms by 
which the glucocorticoid receptor exerts its actions: transrepression and nongenomic 
effects.13,20,21 It might also be relevant to study other steroid precursors. Despite 
these limitations, we consider our results promising and potentially relevant for a 
significant group of patients with CAH.
 In conclusion, 21DF and to a lesser extent 17OHP and P are able to transactivate 
the hGR in vitro and thus may have glucocorticoid activity. 21DF, which can be strongly 
elevated in patients with untreated or poorly controlled CAH, has the strongest 
agonistic effect on the hGR and may partially compensate for the cortisol deficiency 
in patients with CAH.
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Since the introduction of glucocorticoid and mineralocorticoid replacement therapy 
in the 1950s classic congenital adrenal hyperplasia (CAH) is no longer a potentially 
lethal condition. As a result of successful steroid hormone replacement regimens and 
careful follow up, CAH changed into a well treatable chronic condition. Consequently, 
long term health consequences, co-morbidities and quality of life became more 
important. Both CAH related factors, e.g. elevated androgen levels and chronic exposure 
to elevated steroid hormone precursor levels, and side effects of long term treatment 
with glucocorticoids and/or mineralocorticoids play a role in the current and future 
health status and quality of life of CAH patients. CAH is a unique type of adrenal 
insufficiency as it results in ACTH stimulated increased activity of the adrenal gland 
leading to the production of large amounts of steroid hormone precursors. As cardio- 
vascular disease is a potential cause of morbidity in CAH patients, it is important to 
gain more insight in the effect of steroid hormone precursors as they may also 
contribute to an increased risk profile in CAH patients. Therefore, within this thesis we 
especially focused on cardiovascular and metabolic risk in CAH and the role of steroid 
hormones and its precursors on glucocorticoid and mineralocorticoid metabolism.
Cardiovascular and metabolic risk factors in CAH
Over the last years many studies, including studies by our group (chapters 2.1, 2.2, 
3.1, 3.2, 3.3), have evaluated the cardiovascular and metabolic risk profile in both 
pediatric and adult CAH patients. The results of studies by other groups on this topic 
are summarized in chapter 1.2: unfavorable changes in the cardiovascular and 
metabolic profile of CAH patients including obesity, increased fat mass, elevated 
blood pressure and insulin resistance have been described. All studies differ regarding 
study population (different age groups, different countries), treatment regimens and 
control groups or reference data. Nevertheless, the evidence for unfavorable changes 
in the cardiovascular and metabolic risk profile in CAH patients is solid. Multiple risk 
factors contributing to the development of this unfavorable cardiovascular and 
metabolic risk profile have been suggested, and some of them were confirmed by the 
results of our studies: obesity, the use of supraphysiological doses of glucocorticoids 
and hyperandrogenism. One of the pitfalls of studying the cardiovascular risk profile 
in adult CAH patients is that the results may reflect the effects of the treatment 
regimen of decades ago. Therefore, our finding of unfavorable changes in the 
cardiovascular and metabolic risk profile in pediatric CAH patients including increased 
BMI, increased fat mass, elevated blood pressure levels, a non-dipping blood pressure 
profile and insulin resistance, is important, as it emphasizes that unfavorable changes 
in the cardiovascular risk profile of CAH patients can already occur during childhood. 
The importance of the various individual cardiovascular risk factors in the unfavorable 
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cardiovascular risk profile in CAH patients is still unclear. Based on our results at least 
three key factors can be identified playing an important role in the long term health 
consequences in CAH patients: obesity, the treatment with glucocorticoids and hyper-
androgenism.
The role of obesity in the cardiovascular risk profile in CAH 
One of the potential factors in the development of an unfavorable cardiovascular risk 
profile in CAH patients is obesity. Most studies report an increased BMI in CAH 
patients or an increased prevalence of obesity. Many of the studies by others describe 
an association between the dosage of glucocorticoids and the BMI. In contrast to 
other reports, we did not find an association between the glucocorticoid dose and 
BMI in pediatric CAH patients (chapter 3.2). Therefore, additional factors, as for 
example an unhealthy lifestyle, may explain the increased BMI in our patient group. 
It is well known that obesity plays an important role in the development of insulin 
resistance and dyslipidemia. Furthermore, positive associations between BMI and 
blood pressure levels have been described in CAH patients. Therefore, CAH patients 
with an increased BMI are at risk of BMI associated negative effects on their cardio-
vascular risk profile. The negative effects on the cardiovascular risk profile may even 
be more pronounced than in obese individuals without CAH, as other factors, like 
glucocorticoid treatment, may have an additional negative effect on the cardiovascular 
risk profile. 
 In chapter 3.2 we report a positive association between BMI SDS levels in 
pediatric CAH patients and 17-OH progesterone (17OHP) and androstenedione levels. 
In CAH patients elevated concentrations of androgens and steroid precursors before 
the enzymatic block are caused by an increased ACTH stimulated activity of the 
adrenal gland due to the lack of negative feedback on the pituitary gland by cortisol. 
In obese, but otherwise healthy individuals, an increased activation of the 
hypothalamic pituitary adrenal axis and adrenal fasciculata-reticularis cell 
refractoriness to the inhibitory effect of leptin on ACTH-stimulated glucocorticoid 
production have been described.1 In CAH patients, elevated 17OHP and androstene-
dione levels may therefore be the result of obesity due to increased stimulation of 
the hypothalamic pituitary axis in obesity, causing elevated levels of steroid precursors 
due to the enzymatic deficiency in CAH, and may not indicate undertreatment in CAH 
patients. In addition, the elevated leptin levels in our studied patients may indicate 
resistance to the inhibitory effect of leptin on ACTH-stimulated adrenal steroidogen-
esis. Our clinical observation that normalization of  17OHP and androstenedione 
levels in overweight or obese CAH patients is more difficult to achieve fits within this 
hypothesis.
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Based on the above mentioned findings we suggest that achieving a normal BMI 
(between -1 and +1 SDS for age and gender) may contribute to lowering androgen and 
17OHP levels without the need of increasing the dosage of glucocorticoids; this may 
consequently contribute to a reduced cardiovascular and metabolic risk later in life. 
Lifestyle interventions, including dietary interventions, to optimize BMI may therefore 
be an important tool in the treatment of CAH patients, especially in those with an 
increased BMI. Preferably, aiming for a normal BMI starts as early in life as possible. 
A future study evaluating the effect of BMI reduction by life style interventions on 
glucocorticoid requirements, cardiovascular and metabolic risk parameters and 
androgen and 17OHP levels in CAH patients is necessary to evaluate our hypotheses. 
The role of glucocorticoid treatment in the cardiovascular risk profile in CAH
Glucocorticoid exposure in CAH patients is associated with an unfavorable 
cardiovascular and metabolic risk profile. Over the past decades the mean daily dose 
of glucocorticoids used in the treatment of CAH patients was reduced, due to better 
treatment monitoring, to prevent overtreatment. However, supraphysiological doses 
of glucocorticoids are still required to reset the negative feedback loop on the 
pituitary gland and consequently normalize androgen levels in CAH patients. Not only 
the use of supraphysiological doses, but also the inability to mimic the physiological 
secretion pattern of cortisol, with a thrice daily treatment regimen, may negatively 
affect the cardiovascular and metabolic risk profile. The peak concentrations of glu-
cocorticoids may be higher in a thrice daily treatment regimen compared to peak 
levels in healthy subjects. Furthermore, the use of a reversed circadian rhythm 
regimen with the highest dose of hydrocortisone before the night, is associated with 
an impaired nocturnal dip in blood pressure levels (chapter 3.2). 
 It can be hypothesized that a more physiological glucocorticoid replacement 
strategy leads to a reduction of unfavorable changes in the cardiovascular risk profile. 
Currently several new treatment modalities mimicking physiological glucocorticoid 
exposure are being evaluated, including continuous hydrocortisone infusion, 
once-daily modified-release hydrocortisone and delayed and sustained absorption 
hydrocortisone formulations.2,3 However, further studies have to clarify if the use will 
lead to a significant reduction of the total daily glucocorticoid dosage and if the 
cardiovascular risk profile may improve over time as the long term effects on the 
cardiovascular and metabolic risk profile have not yet been studied. Additionally, new 
treatment modalities focusing on blocking the ACTH production, like Corticotro-
pin-Releasing Factor Receptor-1 antagonists, are currently being studied.2,4 Due to a 
complete block of ACTH production patients will undergo a chemical adrenalectomy, 
with consequently the need of only physiological glucocorticoid and mineralocorti-
coid replacement.  
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The role of hyperandrogenism in the cardiovascular risk profile in CAH
The association between elevated androgens and impaired insulin sensitivity has 
been reported in several studies.5,6  Elevated androgen levels may also have a direct 
negative effect on the cardiac function, as discussed in chapter 3.4. As the effects of 
hyperandrogenism on left ventricular function and left ventricular mass are already 
detected at a young age, these patients may  have an increased risk of cardiovascular 
morbidity and mortality later in life, especially when these effects on the heart are 
not reversible after normalizing androgen levels. We hypothesize that early diagnosis 
of CAH, and consequently reduced exposure to elevated androgen levels due to 
frequent monitoring and follow up, may explain the normal left ventricular mass in 
our studied pediatric CAH patients. The potentially negative effects of hyperandro-
genism on the heart emphasizes the need of early diagnosis, and consequently early 
start of treatment, in CAH patients. In the Netherlands, early diagnosis of CAH is 
facilitated by the newborn screening program. However, in many countries, e.g. the 
United Kingdom, there is no newborn screening program for CAH leading to later 
diagnosis and delayed start of treatment. Future studies evaluating the cardiac 
function in untreated or lately diagnosed adult simple virilizing or non-classic CAH 
patients may further elucidate the role of long term androgen exposure on the heart.
The role of steroid precursors in CAH
One of the hallmark features of 21-hydroxylase deficiency is the presence of elevated 
levels of steroid hormone precursors before the enzymatic block due to ACTH 
stimulated increased adrenal activity. The clinical role of these steroid precursors on 
glucocorticoid and mineralocorticoid action is not yet elucidated. As we know that 
both glucocorticoid and mineralocorticoid excess are associated with unfavorable 
changes in the cardiovascular risk profile, we hypothesize that glucocorticoid or min-
eralocorticoid properties of elevated concentrations of these steroid precursors may 
also affect the cardiovascular risk profile of CAH patients. Besides elevated levels of 
adrenal steroid precursors like 17OHP, recent studies showed that less frequently 
measured adrenal 11-oxygenated 19-carbon steroid concentrations are elevated in 
21OHD patients.7,8 The role of these lesser known steroid precursors in the steroid 
metabolism in CAH patients have to be further elucidated.
 In chapter 4 of this thesis we report the results of our research on the effect of 
steroid precursors on the mineralocorticoid and glucocorticoid receptor in vitro. 
Several steroid precursors, like 21-deoxycortisol and to a lesser degree, 17OHP and 
progesterone, are able to bind, translocate and transactivate the glucocorticoid 
receptor and therefore can exhibit glucocorticoid action. This may explain some of 
the clinical observations indicating residual glucocorticoid potential in CAH patients 
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mentioned in chapter 1.3 (the absence of hypoglycemia in neonates with classic CAH; 
the absence of Addisonian crises in adult patients who are lost to follow up or children 
with a delayed diagnosis in countries without neonatal screening). The glucocorticoid 
activity of the steroid precursors may have several clinical implications. Treatment 
with glucocorticoids lowers the concentrations of steroid precursors by restoring 
feedback on the pituitary leading to a decrease in ACTH levels and therefore may 
reduce endogenous glucocorticoid activity. As a result, patients may have an 
increased risk of developing an Addisonian crisis, especially in situations with 
increased stress if the combined exogenous and endogenous glucocorticoid activity 
is insufficient. In untreated CAH patients the adrenocortical function evaluated by a 
cosyntropin stimulation test is impaired with an inadequate release of cortisol after 
stimulation. However, based on the results in chapter 4.2 it may be more appropriate 
to evaluate the cumulative glucocorticoid potential after stimulation based on the 
concentrations of cortisol and steroid hormone precursors with glucocorticoid 
activity. Future research should be performed to gain insight in the cumulative 
glucocorticoid activity of present steroid hormone precursors in CAH patients. We 
suggest that both animal models and a glucocorticoid activity index based on in vivo 
concentrations of steroids and their precursors may help in elucidating glucocorticoid 
activity in CAH patients. Hypothetically, patients with sufficient endogenous 
cumulative glucocorticoid activity may not require glucocorticoid replacement 
therapy at all, or only in situations with a severely increased stress level, and treatment 
of CAH in those patients can focus on blocking androgen secretion and/or action to 
normalize androgen levels. So far, several antiandrogen treatment modalities have 
been described as alternative treatment options to reduce androgen levels in CAH. 
The described treatment options include adrenal androgen synthesis inhibitors (e.g. 
ketoconazole), androgen receptor antagonists (e.g. flutamide) and 5 alpha reductase 
inhibitors (e.g. finasteride).  Normalizing androgen levels with an alternative treatment 
modality in patients with sufficient glucocorticoid activity may not have an effect on 
the production of glucocorticoid precursors and therefore may reduce the need of 
supraphysiological glucocorticoid dosages with beneficial effects on the cardiovascular 
risk profile. It can be hypothesized that some of the patients with a mild non-classic 
phenotype do not need treatment and follow-up by a physician if the cumulative 
glucocorticoid activity is sufficient. This might potentially lead to a reduced use of 
medical care and consequently financial costs in non-classic CAH patients.
 The elevated concentrations of steroid hormones and steroid hormone precursors 
in CAH also have impact on the mineralocorticoid metabolism. The results presented 
in chapter 4.1 show that 17OHP and progesterone in vitro have antagonistic properties 
on the mineralocorticoid receptor. This may lead to a higher requirement of mineralo-
corticoid replacement therapy in poorly controlled CAH patients. 
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The fundamental studies described in chapter 4 both evaluated the in vitro effect of 
a single steroid hormone precursor on the glucocorticoid or mineralocorticoid 
receptor. However, in CAH patients generally multiple steroid hormones and steroid 
precursors are present at the same time in different concentrations. Our studies have 
not evaluated the competitive effect of these steroid precursors in the presence of 
other steroids (except for evaluating the anti-mineralocorticoid properties on the 
mineralocorticoid receptor in the co-presence of aldosterone). An important goal of 
future research on this topic is to evaluate the glucocorticoid and mineralocorticoid 
effects of these steroid hormone precursors in a more physiological situation.
Clinical recommendations and suggestions for future studies 
based on this thesis
Based on our studies and the studies by others several unfavorable changes in the 
cardiovascular risk profile of both pediatric and adult CAH patients are present. 
As mentioned previously, these unfavorable changes include increased BMI, increased 
body fat, increased blood pressure levels and insulin resistance. In our opinion the 
current knowledge on the cardiovascular risk profile of CAH patients warrants regular 
evaluation of some cardiovascular risk factors in the clinical care of both pediatric and 
adult CAH patients. We recommend regular evaluation of at least blood pressure 
levels and BMI at each follow-up appointment in pediatric and adult CAH patients, 
as it may lead to earlier detection of changes in these two major cardiovascular risk 
markers. As 24 hour ambulatory blood pressure measurement is more accurate in 
evaluating blood pressure levels compared to office blood pressure measurements 
performing a 24 hour blood pressure evaluation once every 2 - 3 years from the age 
of 12 or when office blood pressure levels are elevated can be considered. In obese 
CAH patients regular evaluation of blood pressure, insulin resistance and dyslipidemia 
is necessary and  more important compared to normal weight CAH patients, as an 
increased BMI may play a role in the development of further unfavorable changes in 
the cardiovascular risk profile. Therefore we suggest to individualize evaluation of 
cardiovascular and metabolic risk markers in CAH patients with an increased BMI 
(more than + 1 SDS for age and gender). Based on the current knowledge and possible 
consequences of unfavorable changes in the lipid profile and insulin sensitivity we 
would not recommend standard evaluation of the lipid profile and insulin resistance 
by the HOMA-IR method in pediatric CAH patients. Future studies should evaluate 
the effects of dyslipidemia and insulin resistance and potential treatment consequences 
before regular evaluation should be incorporated into standard care.
 Besides improving the screening of cardiovascular risk factors in CAH patients, 
also changes in the current treatment protocol are warranted to improve long term 
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health in CAH patients. First of all, it is of great importance to use the lowest possible 
glucocorticoid dose to reduce adverse effects of exposure to supraphysiological 
doses of glucocorticoids. Regular monitoring of salivary androstenedione can help to 
find the lowest acceptable dosage. As previously mentioned, new glucocorticoid 
treatment modalities may have beneficial effect on the cardiovascular risk profile in 
CAH patients. We furthermore propose that aiming for a normal BMI (between -1 and 
+1 SDS for age and gender) should be an independent treatment goal in CAH patients 
to improve long term health, because of the crucial role of an increased BMI in 
the unfavorable cardiovascular and metabolic risk profile. As discussed previously, 
elevated 17OHP levels may also be associated with increased BMI. Therefore, we 
hypothesize that life style interventions to lower BMI and consequently 17OHP levels 
may lead to a reduced replacement dosage of mineralocorticoids due to the anti- 
mineralocorticoid potential of 17OHP. Future studies evaluating the effect of life 
style interventions on the cardiovascular and metabolic risk profile in CAH patients, 
should also evaluate the effect of a reduced BMI on 17OHP concentrations and the 
mineralocorticoid requirement after lowering 17OHP concentrations.
 If an unfavorable cardiovascular risk profile persists despite the proposed 
interventions other treatment options should be considered to reduce cardiovascular 
morbidity and mortality. Improving insulin sensitivity and lowering blood pressure 
levels for example may reduce cardiovascular morbidity and mortality in CAH patients 
later in life. As a proof of principle we have shown that adding pioglitazone, a drug 
known to improve insulin sensitivity, to the treatment of adult CAH patients indeed 
leads to improved insulin sensitivity and also decreases blood pressure. (Chapter 2.2) 
As the long term safety of the use of pioglitazone was questioned we do not suggest 
to add pioglitazone to the treatment regimen of CAH patients with impaired insulin 
sensitivity. Future research should evaluate the safety and efficacy of adding insulin 
sensitizing and/or blood pressure lowering drugs to the treatment of CAH patients 
with unfavorable changes in their cardiovascular risk profile.
 The role of steroid precursors, and especially their combined glucocorticoid 
potential, should be one of the main points of interest for future studies within the 
field of CAH. Based on the results in chapter 4.1 and 4.2 future research should focus 
on quantifying the mineralocorticoid and especially glucocorticoid potential of 
steroid precursors in vivo and on developing a tool to calculate the combined 
glucocorticoid activity in patients with an enzymatic defect in adrenal steroidogenesis. 
The results of these studies may have important clinical implications, as discussed 
previously, as they may change the treatment regimens of CAH patients with sufficient 
combined glucocorticoid activity.
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Congenital adrenal hyperplasia (CAH) is a disorder of adrenal steroidogenesis due to 
a defect in one of the enzymes involved in steroid synthesis. In the majority of cases 
CAH is caused by 21-hydroxylase deficiency (21OHD). In this thesis we discuss CAH 
due to 21OHD. 21OHD causes impaired glucocorticoid synthesis, in some cases also 
impaired mineralocorticoid synthesis, accumulation of the precursors before the 
enzymatic block and excess of adrenal androgen production. Treatment of the most 
severe forms of CAH consists of lifelong replacement of glucocorticoids and, in cases 
with insufficient aldosterone production, also mineralocorticoids. As a result of 
the treatment with glucocorticoids and mineralocorticoids, nearly all patients with 
CAH in Western countries currently reach adulthood without severe complications. 
Therefore, long term health consequences of CAH and its treatment become more 
important. Knowledge on the role of steroid precursors in CAH on glucocorticoid and 
mineralocorticoid metabolism and its long term consequences is lacking. In this thesis 
we studied the cardiovascular and metabolic risk profile of both pediatric and adult 
CAH patients. In addition we described the role of steroid precursors on the steroid 
metabolism in CAH patients in vitro.
 Chapter 1 contains a general introduction on CAH (Chapter 1.1), a review of the 
literature on the cardiovascular and metabolic risk profile in both pediatric and adult 
CAH patients (Chapter 1.2a and Chapter 1.2b) and an introduction on the role of 
steroids and steroid precursors in CAH (Chapter 1.3).
 In chapter 2 studies evaluating the cardiovascular and metabolic risk profile of 
adult CAH patients are presented. Chapter 2.1 describes a case-control study evaluating 
the cardiovascular risk profile of adult CAH patients. The cardiovascular risk profile of 
27 adult CAH patients and 27 controls, matched for age, sex and body mass index 
(BMI) was evaluated by measuring ambulatory 24-hour blood pressure levels, insulin 
sensitivity (by HOMA-IR), lipid profiles, albuminuria and several circulating cardio-
vascular risk markers (PAI-1, tPA, uPA, tPA/PAI-1 complex, hsCRP, adiponectin, IL-6, IL-18 
and leptin). Based on 24-hour blood pressure measurement both systolic (126.3 mmHg 
± 15.5 versus 124.8 mmHg ± 15.1 in controls, P = 0.019) and diastolic (76.4 mmHg 
± 12.7 versus 73.5 mmHg ± 12.4 in controls, P<0.001) blood pressure was significantly 
elevated in CAH patients compared to controls. Furthermore, this study showed that 
CAH patients had higher HDL cholesterol levels (P<0.01), lower hsCRP levels (P = 0.03) 
and there was a trend toward elevated adiponectin levels compared to controls. 
The other evaluated cardiovascular risk factors were similar in both groups. Based on 
the results of this study we concluded that adult CAH patients have higher 24-hour 
systolic and diastolic blood pressure levels compared to healthy matched controls. 
Other cardiovascular risk markers did not differ from controls, while HDL-cholesterol, 
hsCRP and adiponectin levels tended to be more favorable in the studied adult CAH 
patients. 
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In chapter 2.2 the results of a randomized placebo controlled crossover trial 
evaluating the effect of pioglitazone on insulin sensitivity in adult CAH patients are 
presented. As it is known that glucocorticoid treatment in CAH may induce insulin 
resistance, we hypothesized that thiazolidinediones, like pioglitazone, might reverse 
this effect and improve insulin sensitivity. Twelve adult CAH patients and twelve BMI 
and age-matched control subjects were included in this study. All studied patients 
were treated with pioglitazone (45 mg/day) or placebo during sixteen weeks in 
this crossover trial. Insulin sensitivity was measured using an euglycemic clamp and 
oral glucose tolerance test. Furthermore, the effects of treatment with pioglitazone 
on blood pressure, body fat distribution, lipid, and steroid levels were evaluated. 
The studied CAH patients were more insulin resistant compared with healthy controls. 
Sixteen weeks of treatment with pioglitazone significantly improved insulin sensitivity 
in CAH patients (glucose infusion rate (GIR) from 28.5 ± 11.6 to 38.9 ± 11.0 micromol/kg 
per min, P=0.000, GIR in controls 46.2 ± 23.4 micromol/kg per min, P<0.05 versus 
CAH). An additional favorable effect of treatment with pioglitazone was lowered 
24-hour blood pressure levels (systolic: 124.0 ± 13.6 vs 127.0 ± 14.9 mmHg, P<0.001, 
diastolic: 72.8 ± 11.5 vs 77.4 ± 12.6 mmHg, P<0.001). No changes in body fat 
distribution, lipid, and steroid profiles were observed after treatment. In conclusion, 
adult CAH patients were insulin resistant compared with matched control subjects. 
Treatment with pioglitazone improved insulin sensitivity and decreased blood pressure 
in CAH patients. Although this study showed favorable effects of pioglitazone treatment 
on the cardiovascular risk profile in adult CAH patients we would not recommend its 
standard use in clinical care due to the results of other studies questioning the long 
term safety of pioglitazone.
 Chapter 3 focused on the cardiovascular and metabolic risk profile and cardiac 
function in pediatric CAH patients.  Chapter 3.1 describes the results of a pilot study 
evaluating blood pressure levels within the first year of life in CAH patients. Twenty- 
four children were included. Retrospective blood pressure values, fludrocortisone 
dosages, and serum renin, 17-hydroxyprogesterone (17OHP) and androstenedione 
levels in the first year of life were evaluated. Blood pressure values were compared to 
reference values. Mean peak systolic blood pressure values were generally normal, 
around the 50th percentile, except incidentally higher mean peak systolic office blood 
pressure values. In this study we did not find correlations between blood pressure on 
one side and serum renin, androstenedione and 17OHP levels and fludrocortisone 
dosage on the other side. In conclusion, blood pressure values do not seem to be 
elevated in the first year of life. However, further investigations are necessary to 
evaluate blood pressure in the first year of life in CAH patients in more detail.
 In chapter 3.2 we analyzed the cardiovascular and metabolic risk profile of 27 
pediatric CAH patients aged 8 to 16 years in a cross-sectional study. Blood samples 
were taken to evaluate circulating cardiovascular risk markers. Insulin resistance was 
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evaluated by HOMA-IR. Blood pressure was evaluated by office measurements and 
24-hour ambulatory blood pressure measurements (24-h ABPM). Carotid intima media 
thickness (cIMT) was evaluated as surrogate marker of atherosclerosis. Dual energy 
X-ray absorptiometry (DXA) scans were performed in patients >12 years to evaluate 
body composition. The results of this study were compared to carefully selected 
reference values. The results of this study make it clear that unfavorable changes in 
the cardiovascular risk profile in CAH patients may occur already in childhood. BMI 
standard deviation score (SDS) was elevated (0.67) in the studied CAH patients, with 
seven patients being overweight (25.9 %) and four obese (14.8 %). DXA scans showed 
unfavorable changes in body composition with a percentage body fat SDS of 1.59. 
Office blood pressure levels were higher than reference values. Twenty-four hour 
ABPM showed systolic hypertension in 18.5 % of the studied CAH patients, while 
11 patients (40.7 %) had a non-dipping blood pressure profile. The prevalence of insulin 
resistance, defined as a HOMA-IR >75th percentile for gender and age, was high (44.4 %). 
The lipid profile and cIMT were within the normal range in the studied patients. Only 
elevated HOMA-IR values were positively associated with the daily dosage of hydro-
cortisone per m2. Based on this study increased BMI seems to play an essential role 
in the increased cardiovascular risk. In summary, the data presented in this chapter 
show that the unfavorable changes in the cardiovascular risk profile of pediatric CAH 
patients include an increased BMI, increased fat mass, elevated blood pressure levels, 
a non-dipping blood pressure profile and insulin resistance compared to population 
reference values. 
 Chapter 3.3 describes the cardiac function of the same 27 pediatric CAH patients. 
Only a few studies previously evaluated the cardiac function in CAH patients. The cardiac 
function was evaluated by electrocardiogram (ECG), conventional echocardiography, 
tissue Doppler imaging and two-dimensional (2D) myocardial strain (rate) imaging. 
Results were compared to 27 age- and gender-matched healthy controls. No signs of 
left ventricular hypertrophy or dilatation were detected on echocardiography. ECG 
revealed a high prevalence (25.9%) of incomplete right bundle branch block. 
Conventional echocardiography revealed that left ventricular posterior wall thickness 
in diastole (LVPWd) was significantly lower in patients with CAH compared to controls 
(5.55 vs 6.53 mm; P=0.009). The LVPWd Z-score was significantly lower in patients 
with CAH yet within the normal range (-1.12 vs -0.35; P=0.002). Isovolumetric 
relaxation time was significantly lower in patients with CAH (49 vs 62 ms; P=0.003). 
Global longitudinal, radial and circumferential strain was not significantly different 
compared to controls. Global radial strain rate was significantly higher compared to 
healthy controls (2.58 vs 2.06 1/s; P=0.046). In conclusion, the cardiac evaluation of 
pediatric patients with CAH showed no signs of left ventricular hypertrophy or 
ventricular dilatation. LVPWd was lower in patients with CAH than in controls but 
within the normal range. A shorter isovolumetric relaxation time in patients with CAH 
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may be a sign of mild left ventricular diastolic dysfunction. Further studies are needed 
to evaluate the cardiac function in adolescence and adulthood in well-controlled CAH 
patients. Compared to the results of other studies the cardiac function in our studied 
CAH patients seemed to be better, which may be explained by a longer duration of 
androgen excess in those studies due to a later diagnosis and start of treatment. 
Therefore, we believe that early diagnosis and start of treatment in CAH patients is 
essential to lower androgen levels with consequently less negative effects on cardiac 
function.
 Chapter 4 aimed to evaluate the role of steroid precursors accumulating in CAH 
on glucocorticoid and mineralocorticoid metabolism in vitro. We hypothesized that 
the elevated concentrations of steroid precursors present in CAH patients may have 
a biological effect on the steroid receptors with clinical consequences on diagnostics 
and treatment in CAH patients. In chapter 4.1 the results of our study evaluating the 
effects of 17OHP, progesterone, androstenedione and testosterone on aldoste-
rone-mediated translocation and transactivation of the human mineralocorticoid 
receptor (hMR) are presented. A transactivation assay using transiently transfected 
COS7 cells was employed. Cells were co-transfected with hMR-cDNA, MMTV-luciferase 
and renilla-luciferase expression vectors. Transfected cells were incubated with six 
different steroid concentrations in addition to aldosterone (10-10M). Luciferase and 
renilla activities were measured to quantify hMR transactivation. A hMR-green 
fluorescent protein (GFP) construct was used for an intracellular localization assay 
evaluating translocation. Linear regression analysis showed statistically significant 
linear inhibition of transactivation of the hMR by 10-10M aldosterone in the presence 
of increasing 17OHP [F(1,5) = 11.34, P=0.019] and progesterone [F(1,5) = 11.08, 
P=0.021] concentrations. In contrast, neither androstenedione nor testosterone 
affected hMR transactivation by aldosterone at a concentration of 10-10M. Chapter 4.1 
shows that 17OHP and progesterone have anti-mineralocorticoid effects in vitro that 
may clinically lead to an increased requirement of mineralocorticoids in poorly 
controlled CAH patients.
 Chapter 4.2 focused on the effects of 17OHP, progesterone, 21-deoxycortisol 
(21DF), and androstenedione on the human glucocorticoid receptor (hGR). 
Competitive binding assays were performed in HeLa cells. Nuclear translocation of 
the hGR was studied by transfection of COS7 cells with a GFP-tagged hGR and 
fluorescence microscopy. Transactivation assays were performed in both COS7 cells 
and in HEK293 cells after cotransfection with hGR and luciferase reporter vectors 
using a dual luciferase assay. This study showed that 17OHP, progesterone, and 21DF 
are able to bind to the hGR with binding affinities of 24-43% compared with cortisol. 
Androstenedione has a low binding affinity. Incubation with 21DF led to complete 
nuclear translocation of the hGR, whereas treatment with 17OHP or progesterone 
resulted in partial nuclear translocation. 21DF transactivated the hGR with an EC50 
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approximately 6 times the EC50 of cortisol. 17OHP and progesterone transactivated the 
hGR with EC50s of more than 100 times the EC50 of cortisol. No hGR transactivation 
was detected after incubation with androstenedione. 21DF, 17OHP, and progesterone 
are able to bind, translocate, and transactivate the hGR in vitro and thus may have 
glucocorticoid activity. 21DF might have a clinically relevant agonistic effect on the hGR 
and could potentially partially compensate the cortisol deficiency in CAH patients.
 A discussion of the studies of this thesis, clinical recommendations and future 
research perspectives can be found in chapter 5. Based on the studies presented in 
this thesis and studies by others we conclude that several unfavorable changes in 
the cardiovascular risk profile of both pediatric and adult CAH patients may be 
present. Unfavorable changes in the cardiovascular risk profile of CAH patients 
include increased BMI, increased body fat, increased blood pressure levels and insulin 
resistance. We recommend regular evaluation of at least blood pressure levels and 
BMI at each follow-up appointment, as it may lead to earlier detection of changes in 
these two major cardiovascular risk markers. Obesity may play an important role in 
the development of further unfavorable changes in the cardiovascular risk profile. 
Therefore, we suggest to individualize the follow up of obese CAH patients. 
Furthermore, we have shown that adrenal steroid precursors present in CAH patients 
have effects on both glucocorticoid and mineralocorticoid action in vitro. Especially, 
the glucocorticoid activity of 21DF may have a clinically relevant role in CAH patients, 
partially compensating for the cortisol deficiency. Future research should focus on 
quantifying the mineralocorticoid and glucocorticoid potential of steroid precursors 
in vivo and on developing a tool to calculate the combined glucocorticoid activity in 
patients with an enzymatic defect in adrenal steroidogenesis.
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Congenitale bijnierhyperplasie, in Nederland ook bekend als het adrenogenitaal 
syndroom (AGS), is een aandoening waarbij er sprake is van een deficiëntie van één 
van de enzymen die betrokken zijn bij de synthese van hormonen in de bijnier. In de 
meerderheid van de gevallen wordt  AGS veroorzaakt door 21-hydroxylase deficiëntie 
(21OHD). In dit proefschrift bestuderen we AGS ten gevolge van 21OHD. 21OHD leidt 
tot een verminderde synthese van cortisol (een glucocorticoïd) en meestal ook tot 
een verminderde synthese van aldosteron (een mineralocorticoïd). Door een onvoldoende 
negatieve terugkoppeling op de ACTH secretie door de hypofyse ontstaat er over - 
matige stimulatie van de bijnier leidend tot bijnierhyperplasie (vandaar de Engelse 
benaming 'congenital adrenal hyperplasia' (CAH)). Door de overmatige stimulatie van 
de bijnier treedt er een accumulatie van voorloperhormonen (precursors) voor het 
enzymatische defect op en is er sprake van een sterk verhoogde productie van bijnier-
androgenen. De behandeling van de ernstige vormen van AGS bestaat uit levenslange 
substitutie met glucocorticoïden, en indien er tevens sprake is van onvoldoende 
aldosteron productie, ook mineralocorticoïden. Vaak zijn supra fysiologische doseringen 
glucocorticoïden noodzakelijk om de androgeen productie in de bijnier te normaliseren. 
Succesvolle behandeling met glucocorticoïden en mineralo corticoïden heeft er toe 
geleid dat bijna alle patiënten in Westerse landen de volwassen leeftijd bereiken 
zonder ernstige complicaties. Daardoor worden lange termijn gevolgen van AGS 
steeds belangrijker. De kennis over de rol van hormoonprecursors bij AGS op het 
glucocorticoïde en mineralocorticoïde metabolisme en de lange termijn effecten van 
deze precursors is nog beperkt. In dit proefschrift hebben wij het cardiovasculaire en 
metabole risicoprofiel van zowel pediatrische als volwassen AGS patiënten bestudeerd. 
Daarnaast bestudeerden wij de rol van hormoonprecursors op het hormoonmeta-
bolisme bij AGS patiënten in vitro.
 Hoofdstuk 1 omvat een algemene introductie over AGS (Hoofdstuk 1.1), een 
overzicht van de literatuur over het cardiovasculaire en metabole risicoprofiel van 
zowel pediatrische als volwassen AGS patiënten (Hoofdstuk 1.2a en Hoofdstuk 1.2b) 
en een introductie op de rol die hormonen en hormoonprecursors spelen bij AGS 
(Hoofdstuk 1.3).
 In hoofdstuk 2 worden de resultaten van twee studies gepresenteerd waarin het 
cardiovasculaire en metabole risicoprofiel van volwassen AGS patiënten is bestudeerd. 
Hoofstuk 2.1 beschrijft een case-control studie waarin het cardiovasculaire risico -
profiel van volwassen AGS patiënten is onderzocht. Het cardiovasculaire risicoprofiel 
van 27 volwassen AGS patiënten en 27 op leeftijd, geslacht en body mass index (BMI) 
gematchte controles werd in kaart gebracht door evaluatie van een 24-uurs ambulante 
bloeddrukmeting, het bepalen van de insuline gevoeligheid (via de HOMA-IR methode), 
het vetspectrum, albuminurie en het meten van verschillende circulerende cardio-
vasculaire risico markers (PAI-1, tPA, uPA, tPA/PAI-1 complex, hsCRP, adiponectine, 
IL-6, IL-18 en leptine). De 24-uurs bloeddruk metingen toonden aan dat zowel de 
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systolische (126.3 mmHg ± 15.5 versus 124.8 mmHg ± 15.1 bij controles, P = 0.019) als 
diastolische (76.4 mmHg ± 12.7 versus 73.5 mmHg ± 12.4 bij controles, P<0.001) 
bloeddruk significant verhoogd was bij AGS patiënten vergeleken met de controles. 
Verder bleken AGS patiënten een hoger HDL cholesterol (P<0.01) en lagere hsCRP 
concentratie (P=0.03) te hebben, daarnaast was er sprake van een trend wijzend op 
verhoogde adiponectine concentraties ten opzichte van controles. De andere in kaart 
gebrachte cardiovasculaire risicofactoren waren vergelijkbaar in beide groepen. 
Op basis van de resultaten van deze studie concludeerden wij dat volwassen AGS 
patiënten een verhoogde 24-uurs systolische en diastolische bloeddruk hebben 
vergeleken met gezonde gematchte controles. De andere cardiovasculaire risico -
markers verschilden niet van de controlegroep, terwijl HDL-cholesterol, hsCRP en 
adiponectine concentraties juist gunstig leken te zijn in de bestudeerde AGS patiënten.
 Hoofdstuk 2.2 beschrijft de resultaten van een gerandomiseerde placebo 
gecontroleerde cross-over trial die het effect van pioglitazone op de insuline 
gevoeligheid bij volwassen AGS patiënten heeft onderzocht. Het is bekend dat 
behandeling met glucocorticoïden kan leiden tot insuline resistentie bij AGS patiënten. 
Onze hypothese was dat thiazolidinedionen, zoals pioglitazone, dit effect konden 
omdraaien en de insuline sensitiviteit zouden verbeteren. Twaalf volwassen AGS 
patiënten en twaalf BMI en leeftijd gematchte controles werden geïncludeerd in deze 
studie. Alle geïncludeerde patiënten werden behandeld met pioglitazone (45 mg/
dag) of een placebo gedurende 16 weken. Insuline gevoeligheid werd gemeten door 
een euglycemische clamp en een orale glucose tolerantie test. Daarnaast werden de 
effecten van de behandeling met pioglitazone op de bloeddruk, lichaamsvetverde-
ling, het lipidenprofiel en steroïd concentraties geëvalueerd. De onderzochte AGS 
patiënten waren meer insulineresistent vergeleken met gezonde controles. Zestien 
weken behandeling met pioglitazone leidde tot een significante verbetering van de 
insuline gevoeligheid bij de AGS patiënten (glucose infusion rate (GIR) van 28.5 ± 11.6 
naar 38.9 ± 11.0 micromol/kg per min, P=0.000, GIR in controles 46.2 ± 23.4 micromol/
kg per min, P<0.05 versus CAH). Een bijkomend gunstig effect van de behandeling 
met pioglitazone was een verlaging van het 24-uurs bloeddruk profiel (systolisch: 
124.0 ± 13.6 vs 127.0 ± 14.9 mmHg, P<0.001, diastolisch: 72.8 ± 11.5 vs 77.4 ± 12.6 
mmHg, P<0.001). Er werden na de behandeling geen veranderingen ten aanzien 
van de lichaamsvet verdeling, lipidenprofiel en steroïd concentraties gevonden. 
Concluderend waren volwassen AGS patiënten insulineresistent vergeleken met 
gematchte controles. Behandeling met pioglitazone verbeterde de insuline gevoelig- 
heid en leidde tot een verlaging van de bloeddruk bij AGS patiënten. Ondanks de 
gunstige effecten van pioglitazone op het cardiovasculaire risicoprofiel bij volwassen 
AGS patiënten, is er geen plaats voor het gebruik van pioglitazone in de standaard 
behandeling van AGS patiënten gezien de resultaten van recentere andere studies die 
de lange termijn veiligheid van pioglitazone in twijfel trekken.
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Hoofdstuk 3 richt zich op het cardiovasculaire en metabole risicoprofiel en de cardiale 
functie bij pediatrische AGS patiënten. In hoofdstuk 3.1 beschrijven wij de resultaten 
van een pilot studie waarin de bloeddruk waarden in het eerste levensjaar van AGS 
patiënten zijn geëvalueerd. Vierentwintig kinderen werden geïncludeerd. Retrospectieve 
analyse van bloeddrukmetingen, doseringen van fludrocortison en serum concentraties 
van renine, 17-hydroxyprogesteron (17OHP) en androsteendion vond plaats. De bloed - 
druk waarden werden vergeleken met referentiewaarden. De gemiddelde piek systolische 
bloeddruk waarden waren over het algemeen normaal, rond de 50e percentiel, met 
uitzondering van incidenteel hogere gemiddelde piek systolische bloeddrukwaarden. 
In deze studie vonden wij geen correlaties tussen enerzijds de bloeddruk en anderzijds 
de dosering fludrocortison en de 17OHP, androsteendion en renine concentraties. 
Concluderend toont deze studie dat de bloeddruk niet verhoogd lijkt te zijn bij AGS 
patiënten in het 1e levensjaar. Verder onderzoek is gewenst om de bloeddruk in het 
1e levensjaar bij kinderen met AGS beter te evalueren.
 In hoofdstuk 3.2 hebben we het cardiovasculaire en metabole risicoprofiel van 
27 pediatrische AGS patiënten tussen de 8 en 16 jaar geanalyseerd in een cross- 
sectionele studie. Bloed werd afgenomen om circulerende cardiovasculaire risico 
markers te bepalen. Insulineresistentie werd bepaald middels HOMA-IR. De bloeddruk 
werd geëvalueerd door gestandaardiseerde bloeddrukmetingen in de spreekkamer 
en ambulante 24-uurs bloeddrukmetingen (24-u ABPM). De intima media dikte (IMT) 
van de arteria carotis werd bepaald als een surrogaat marker van atherosclerose. Een 
DEXA (Dual Energy X-Ray Absorptiometrie) scan werd verricht bij patiënten ouder 
dan 12 jaar om de lichaamssamenstelling in kaart te brengen. De data verkregen in 
deze studie werden vergeleken met zorgvuldig geselecteerde referentiewaarden. 
De resultaten beschreven in dit hoofdstuk maken duidelijk dat ongunstige veranderingen 
in het cardiovasculaire risicoprofiel bij AGS patiënten al op de kinderleeftijd op kunnen 
treden. De BMI standaard deviatie score (SDS) was verhoogd (0.67) in de bestudeerde 
pediatrische AGS patiënten. Zeven patiënten hadden overgewicht (25.9%) en vier 
patiënten waren obees (14.8%). DEXA scans toonden ongunstige veranderingen in de 
lichaamssamenstelling met een percentage lichaamsvet SDS van 1.59. Spreekkamer 
bloeddruk waarden waren hoger dan normaalwaarden. Vierentwintig uur ABPM 
toonde systolische hypertensie bij 18.5% van de bestudeerde AGS patiënten, terwijl 
11 patiënten (40.7%) een non-dipping bloeddruk profiel hadden. De prevalentie van 
insulineresistentie, gedefinieerd als een HOMA-IR > 75e percentiel voor geslacht en 
leeftijd, was hoog (44.4%). Het lipiden profiel en de IMT van de arteria carotis waren 
normaal in de geïncludeerde patiënten. Enkel de verhoogde HOMA-IR waarden 
waren positief geassocieerd met de dagelijkse dosering hydrocortison per m2. Het 
verhoogde BMI lijkt een essentiële rol te spelen in het verhoogde cardiovasculaire 
risico in de AGS patiënten in deze studie. Samenvattend laten de data gepresenteerd 
in dit hoofdstuk zien dat ongunstige veranderingen in het cardiovasculaire risicoprofiel 
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van kinderen met AGS een verhoogd BMI, verhoogde vetmassa, verhoogde bloeddruk 
waarden, een non-dipping bloeddruk profiel en insuline resistentie omvatten. 
 Hoofdstuk 3.3 beschrijft de cardiale functie van dezelfde 27 kinderen met AGS. 
Slechts enkele studies hebben eerder de cardiale functie bij AGS patiënten in kaart 
gebracht. De cardiale functie werd geëvalueerd door een electrocardiogram (ECG), 
conventionele echocardiografie, tissue Doppler imaging en twee-dimensionale (2D) 
myocardiale strain (rate) imaging. De verkregen resultaten werden vergeleken met 27 
op leeftijd en geslacht gematchte gezonde controles. Er werden geen tekenen van 
linker ventrikel hypertrofie of dilatatie waargenomen bij analyse middels ECG en/of 
echocardiografie. De ECG's toonden een hoge prevalentie (25.9%) van een incompleet 
rechter bundeltak blok. Conventionele echocardiografie toonde dat de dikte van de 
achterwand van de linker ventrikel in diastole (LVPWd) significant minder was in AGS 
patiënten vergeleken met controles (5.55 vs 6.53 mm; P=0.009). De LVPWd Z-score 
was ook significant lager in AGS patiënten vergeleken met controles, maar binnen de 
normale range (-1.12 vs -0.35; P=0.002). De isovolumetrische relaxatietijd was 
significant korter bij AGS patiënten (49 vs 62 ms; P=0.003). De globale longitudinale, 
radiale en circumferentiële strain verschilde niet significant tussen AGS patiënten en 
controles. De globale radiale strain rate was significant hoger vergeleken met gezonde 
controles (2.58 vs 2.06 1/s; P=0.046). 
 Concluderend toont de cardiale evaluatie van kinderen met AGS aan dat er geen 
tekenen van linker ventrikelhypertrofie of ventriculaire dilatatie zijn. De LVPWd was 
lager in AGS patiënten dan in controles, maar binnen de normale range. Een kortere 
isovolumetrische relaxatietijd bij AGS patiënten kan een teken zijn van milde 
diastolische dysfunctie van de linker ventrikel. Toekomstige studies zijn wenselijk om 
de cardiale functie bij goed gecontroleerde adolescente en volwassen AGS patiënten 
in kaart te brengen. Vergeleken met de resultaten van andere studies naar de cardiale 
functie bij AGS patiënten lijkt de cardiale functie in onze studie beter. Dit verschil kan 
mogelijk verklaard worden door een langere, chronische blootstelling aan verhoogde 
androgeen waarden in de patiënten in de andere studies aangezien de diagnose bij 
hen later werd gesteld en behandeling daardoor ook later werd opgestart. Wij zijn 
van mening dat vroege diagnose en behandeling van AGS patiënten essentieel is om 
de androgeen concentraties te verlagen, dit zou mogelijk kunnen leiden tot minder 
negatieve effecten op de cardiale functie.
 In hoofdstuk 4 hebben wij het effect van hormoonprecursors, die overmatig 
aanwezig zijn bij 21OHD, op het glucocorticoïde en mineralocorticoïde metabolisme 
in vitro geëvalueerd. Onze hypothese was dat de verhoogde concentraties van deze 
hormoonprecursors een biologisch effect kunnen hebben op de steroïd receptoren 
met klinische consequenties voor de diagnostiek en behandeling van AGS patiënten. 
In hoofdstuk 4.1 beschrijven wij de resultaten van de studie die het effect van 17OHP, 
progesteron, androsteendion en testosteron op de aldosteron gemedieerde translocatie 
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en transactivatie van de humane mineralocorticoïde receptor (hMR) onderzocht. Het 
onderzoek werd uitgevoerd met een transactivatie assay met getransfecteerde COS7 
cellen. De cellen werden geco-transfecteerd met hMR-cDNA, MMTV-luciferase en 
renilla-luciferase expressie vectoren. De getransfecteerde cellen werden geïncubeerd 
met zes verschillende concentraties steroïden in de aanwezigheid van aldosteron 
(10-10M). De luciferase en renilla activiteit werd gemeten om de hMR transactivatie 
te kwantificeren. Een hMR-groen fluorescerend proteïne (GFP) construct werd 
gebruikt voor een intracellulaire lokalisatie assay om de translocatie in kaart te 
brengen. Lineaire regressie analyse toonde een statistisch significante lineaire 
inhibitie van transactivatie van de hMR door 10-10M aldosteron in de aanwezigheid 
van oplopende concentraties 17OHP [F(1,5) = 11.34, P=0.019] en progesteron [F(1,5)= 
11.08, P=0.021]. Daar tegenover stond dat zowel androsteendion als testosteron 
geen effect had op de hMR transactivatie door aldosteron in een concentratie van 
10-10M. Hoofdstuk 4.1 toont aan dat 17OHP en progesteron een anti-mineralocorticoïde 
effect hebben in vitro dat klinisch zou kunnen leiden tot een verhoogde behoefte aan 
mineralocorticoïden bij matig en slecht ingestelde AGS patiënten.
 Hoofdstuk 4.2 richt zich op de effecten van 17OHP, progesteron, 21-deoxycortisol 
(21DF) en androsteendion op de humane glucocorticoïde receptor (hGR). Competitieve 
bindingsassays werden uitgevoerd in HeLa cellen. Nucleaire translocatie van de hGR 
werd bestudeerd middels fluorescentie microscopie na het transfecteren van COS7 
cellen met een hGR-GFP construct. Transactivatie assays werden uitgevoerd in zowel 
COS7 cellen als HEK293 cellen na co-transfectie met hGR en luciferase expressie 
vectoren gebruikmakend van een duaal luciferase assay. Deze studie toonde aan dat 
17OHP, progesteron en 21DF in staat zijn om te binden aan de hGR met een bindings-
affiniteit van 24-43% vergeleken met cortisol. Androsteendion had een lage bindings-
affiniteit. Incubatie met 21DF leidde tot complete translocatie van de hGR naar de 
nucleus, waar incubatie met 17OHP of progesteron resulteerde in gedeeltelijke 
translocatie naar de nucleus. 21DF resulteerde in transactivatie van de hGR met een 
EC50 van ongeveer 6 keer de EC50 van cortisol. 17OHP en progesteron resulteerden 
in transactivatie van de hGR met EC50s van meer dan 100 keer de EC50 van cortisol. 
Incubatie met androsteendion leidde niet tot transactivatie van de hGR. 21DF, 17OHP 
en progesteron zijn dus in staat om te binden aan en te zorgen voor translocatie en 
transactivatie van de hGR in vitro, waardoor zij glucocorticoïde activiteit zouden 
kunnen hebben. 21DF zou een klinisch relevant agonistisch effect op de hGR kunnen 
hebben en mogelijk deels kunnen compenseren voor de cortisol deficiëntie bij AGS 
patiënten.
 Een discussie van de studies in dit proefschrift, de klinische aanbevelingen en 
suggesties voor toekomstig onderzoek kunnen worden gelezen in hoofdstuk 5. Op basis 
van de studies in dit proefschrift en de studies verricht door anderen concluderen 
wij dat verschillende ongunstige veranderingen in het cardiovasculaire risicoprofiel 
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van zowel kinderen als volwassenen met AGS aanwezig kunnen zijn. Ongunstige 
veranderingen in het cardiovasculaire risicoprofiel van AGS patiënten omvatten een 
verhoogd BMI, toegenomen percentage lichaamsvet, verhoogde bloeddruk en insuline-
resistentie. Wij adviseren regelmatige evaluatie van minimaal de bloeddruk en de 
BMI tijdens iedere controle afspraak, aangezien dit kan leiden tot vervroegde detectie 
van veranderingen op het vlak van deze twee belangrijke cardiovasculaire risico-
markers. Obesitas speelt mogelijk een belangrijke rol in het ontwikkelen van verdere 
ongunstige veranderingen in het cardiovasculaire risicoprofiel. Daarom adviseren wij 
om de follow up van AGS patiënten met obesitas per individu vorm te geven 
afhankelijk van het persoonlijke cardiovasculaire risicoprofiel. Verder hebben wij 
aangetoond dat bijnier hormoonprecursors die in verhoogde concentraties aanwezig 
zijn bij 21OHD in vitro zowel een effect kunnen hebben op de glucocorticoïde als de 
mineralocorticoïde receptor. Vooral de glucocorticoïde activiteit van 21DF zou een 
klinisch relevante rol kunnen spelen bij AGS patiënten, waarbij 21DF gedeeltelijk de 
cortisol deficiëntie compenseert. Toekomstig onderzoek zou zich moeten richten op 
het kwantificeren van het mineralocorticoïde en glucocorticoïde effect van hormoon-
precursors in vivo en op het ontwikkelen van een model om de gecombineerde gluco-
corticoïde activiteit te berekenen bij patiënten met een enzymatisch defect in de 
bijnier steroidogenese. 
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Het is zover: mijn promotietraject is afgerond. Bijna 11 jaar na de eerste afspraak met 
Hedi Claahsen en Livia Kapusta om over een gezamenlijk onderzoek te spreken, wat 
gaandeweg is uitgegroeid tot dit promotie onderzoek, is het boekje klaar. It	has	been	
a long journey. Op deze plek zou ik graag stil staan bij de mensen die belangrijk zijn 
geweest tijdens deze reis. Allereerst wil ik graag alle AGS patiënten bedanken die 
vrijwillig hebben deelgenomen aan de onderzoeken beschreven in dit boekje. Zonder 
jullie medewerking zou dit proefschrift er niet zijn geweest.
	 Succes	is	een	combinatie	van	geluk	en	kwaliteiten. Dat is ondertussen mijn levensmotto 
geworden. Daarom wil ik graag een anekdote met jullie delen die illustreert dat je 
soms geluk nodig hebt om te komen waar je nu bent. Tijdens het promotiefeest van 
Hedi Claahsen konden de gasten een persoonlijke wens aan Hedi in een heliumballon 
stoppen. Indien de ballon uiteindelijk gevonden werd, kon de vinder de boodschap 
aan Hedi opsturen. Al twee dagen later ontving Hedi per post uit Noord Duitsland de 
wens die Livia Kapusta in de ballon had opgelaten: samen een artikel schrijven. Omdat 
het niet bij een wens moest blijven werden de plannen concreet gemaakt. Hedi had 
al direct een onderwerp en Livia kende een student die het onderzoek moest gaan 
uitvoeren. En die student, dat was ik. Zo spraken wij eind 2007 met elkaar over het 
uitvoeren van een pilotstudie naar de bloeddruk in het eerste levensjaar bij kinderen 
met AGS. Dat onderzoek, hoofdstuk 3.1 van dit proefschrift, is achteraf gezien het 
begin geweest van mijn promotie onderzoek. En de rest is geschiedenis, en heeft u 
kunnen lezen in de voorgaande hoofdstukken. Maar wat als de wind anders had 
gestaan en die ballon nooit gevonden was, of de vinder de gevonden boodschap niet 
aan Hedi had opgestuurd… Succes	is	een	combinatie	van	geluk	en	kwaliteiten.
 Dr. Hedi Claahsen-van der Grinten, heel veel dank voor jouw inspirerende supervisie 
tijdens het hele promotietraject. Sorry dat het uiteindelijk wat langer heeft geduurd 
om het boekje af te ronden dan we ooit bedacht hadden. Maar ik ben trots op het 
resultaat dat we hebben neergezet. Dank voor de kansen die je me hebt geboden, je 
kritische input tijdens het schrijven van de artikelen, het discussiëren over ons 
onderzoek en je persoonlijke interesse in mij. Ik heb veel van je geleerd. Ook al heb ik 
Nijmegen ondertussen verlaten, we zullen nog genoeg samenwerken binnen de kin-
derendocrinologische zorg in Nederland. Daar kijk ik naar uit.
 Prof. Ad Hermus, na het afronden van de eerder genoemde pilot studie kwam jij 
in beeld. Samen met Hedi vroeg je me of ik verder onderzoek wilde doen naar het 
cardiovasculaire risicoprofiel van AGS patiënten. Je vertelde dat het hele project uit 
kon groeien tot een promotietraject. Ik was direct enthousiast. Dank voor de kans en 
het vertrouwen dat je me hebt geschonken om te participeren in de studies binnen 
de afdeling Endocrinologie. Veel dank ook voor je goede en kritische suggesties die 
het eindresultaat alleen maar beter hebben gemaakt. 
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Prof. Livia Kapusta, waar moet ik beginnen? Jij stond aan het begin van mijn weten-
schappelijke carrière: dankzij jou heb ik onderzoek gedaan op het lab van Henk Blom, 
de mogelijkheid gekregen om onderzoek te doen aan Harvard Medical School, en 
uiteindelijk jouw wens voor Hedi, in de ballon, die het begin heeft gevormd van dit 
promotietraject. Het is geweldig dat je me zo op weg hebt geholpen. Heel veel dank 
daarvoor. En uiteraard ook dank voor jouw werk en begeleiding bij de artikelen die 
we samen hebben geschreven in het kader van dit proefschrift. 
 Prof. Kees Noordam, als promotor werd je pas in een later stadium bij mijn onder - 
zoek betrokken. Dank voor je input tijdens de voortgangsbesprekingen en je tips 
tijdens de afronding van het proefschrift. Samen op de tribune van een hockeystadion 
in New Delhi in 2013, op 12 oktober 2018 tegenover elkaar tijdens de verdediging van 
mijn proefschrift: het is een kleine wereld!
 Dr. Nils Krone, thank you for the opportunity you gave me to work with you in 
the lab in Birmingham. The luciferase assays nearly drove me crazy, but in the end 
I am glad we persisted in continuing the project and delivered several nice papers 
together. It is a great honour that you are part of the opposition during my thesis 
defence. Dr. Silvia Parajes, thank you for your patience in teaching and supervising 
me in the lab. Thanks for all the coffee breaks we had together and your friendship 
during my time in the UK. Prof. Wiebke Arlt, thank you for being part of my German 
supervising team. It was a privilege to work with you. I’m glad that you are in Nijmegen 
for my thesis defence.
 Prof. Cees Tack, Prof. Fred Sweep, Prof. Chris de Korte, Dr. Teun van Herwaarden, 
Dr. Nel Roeleveld, Dr. Gert Weijers, Dr. Barto Otten, Jeanne Margot Kroese, 
Milanthy Pourier, Karijn Pijnenburg-Kleizen, Zina Fejzic, jullie hebben een belangrijke 
bijdrage geleverd aan één of meer artikelen in dit proefschrift. Dank voor jullie input 
en inspiratie. Zonder jullie medewerking was het proefschrift niet zo mooi geworden 
als het nu is.
 Dr. Jos Draaisma, dank voor de ruimte die je me hebt gegeven en de kansen die 
je me hebt geboden om de kinderarts te worden die ik nu ben. Als afsluitend 
co-assistent op de afdeling kindergeneeskunde hoorde ik 1 uur voor mijn eindgesprek, 
door het uitvallen van mijn oorspronkelijke beoordelaar, dat wij dit gesprek samen 
zouden voeren. Ik weet nog dat je me een vraag stelde over het werkingsmechanisme 
van antiretrovirale middelen bij HIV positieve patiënten. Ondanks dat ik die vraag 
toen, en nu nog steeds, niet precies kon beantwoorden was je vanaf het begin positief 
over mijn AGIKO constructie en ondersteunde je de combinatie van mijn opleiding tot 
kinderarts en mijn promotie onderzoek. Ik denk dat je vond dat ik mij vooral moest 
richten op de opleiding en mijn onderzoek, maar ben je dankbaar dat je me toch de 
kans hebt gegeven om me binnen de opleiding ook verder te ontwikkelen binnen het 
profiel Medisch Leiderschap en de daarbij voor mij behorende lokale, regionale en 
landelijke taken. Daarnaast een woord van dank aan Dr. Ben Semmekrot, mijn opleider 
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in het CWZ, voor jouw aandeel in mijn opleiding tot kinderarts. En natuurlijk dank aan 
Sandra Scherpenborg voor haar rol in het soepel laten verlopen van mijn opleiding 
en het plannen van mijn afwisselende opleidings- en onderzoeksmaanden.
 Alle collega arts-assistenten kindergeneeskunde, kinderartsen en verpleeg-
kundigen van het Radboudumc en CWZ: dank voor de fijne samenwerking, de afleiding 
en koffie momenten tijdens mijn onderzoek en de gezelligheid. Het was een feest om 
al die jaren met jullie samen te werken!
 Prof. Paul van Trotsenburg, met veel plezier en enthousiasme werk ik ondertussen 
al weer ruim 2 jaar als fellow kinderendocrinologie in het AMC, en sinds de fusie met 
het VUmc, in het Amsterdam UMC. Dank voor de stimulerende manier waarop je me 
laat werken, het vertrouwen dat je me schenkt en de kansen die je me biedt om 
mezelf verder te ontwikkelen. Ik hoop onze samenwerking nog lang voort te zetten en 
daarbij gezamenlijk onderzoek op te starten de komende tijd. Nitash Zwaveling- 
Soonawala, met elkaar zijn we een sterk en fijn team om in te werken. Binnen één 
maand promoveren we allebei, een mooie mijlpaal! Samen met onze 'nieuwe' collega's 
Joost Rotteveel, Martijn Finken en Marie-Jose Walenkamp en de ondersteuning 
van Brenda Wiedijk kijk ik uit naar de toekomst als Amsterdamse vakgroep kinderen-
docrinologie. Paul en Martijn, dank voor het plaats nemen in de manuscriptcommissie. 
Het symboliseert voor mij de brug tussen mijn periode in Nijmegen en mijn huidige 
werkplek Amsterdam. 
 Cesare Mirabella, molte grazie per essere stato autorizzato a usare il tuo pittura 
sulla copertina di questo libro. Sei un amico della nostra famiglia per sempre!
 Maud, Renate, Marianne en Marloes. Met zijn vijven zijn we familie Mooij, een 
vriendschap voor het leven. Dank voor alle gezellige etentjes, borrels, mini-vakanties 
en ondertussen ook alle uitjes met de kinderen naar pretparken en speeltuinen. 
Ik ben er van overtuigd dat er nog heel veel categorie A, B en C dates zullen volgen. 
Het is heel fijn dat jullie mijn vriendinnen zijn en dat we er altijd voor elkaar zijn. Dank!
 Dorus, Stijn en Nelis.  Wat een avonturen hebben we met elkaar beleefd: Sabbia, 
Istanbul, Wales, de Mont Ventoux en ga zo maar door. Dank voor de goede gesprekken, 
het gezelschap en dat we er voor elkaar zijn als het nodig is. Nelis, we go way back: 
Lent, Boston, co-groep genoten, oud-collega’s. Wat een reis! Trots op waar we staan. 
 Harm. Ondanks dat we elkaar niet meer zo veel zien als tijdens onze studententijd 
blijft onze warme vriendschap vanzelfsprekend. Het is altijd fijn elkaar weer te 
ontmoeten en te spreken. We delen onze gezamenlijke passie voor reizen. Het auto - 
sleutel incident tijdens onze reis door Amerika zal me altijd bijblijven!
 Faas, Karel, Daan, Luuk, Marvin en Lucas. Ook al is de middelbare school al weer 
lang geleden, onze vriendengroep blijft hecht. We zien elkaar niet vaak, maar de 
jaarlijkse tripjes zijn heilig! Dank voor de gezelligheid en avonturen die we met elkaar 
hebben beleefd: of het nu in Cadzand, San Francisco, Tijuana, Rio de Janeiro, Barcelona, 
Amsterdam of Nijmegen is, saai is het nooit!
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Jan and Laura, my housemates in Birmingham. Thanks for being part of my home 
away from home. It was a pleasure sharing a house with the two of you. Great 
memories! Ian, thanks for the friendship and sharing the love for the Villa. 
 Giel, ik koester de band die we al 30 jaar hebben. Mijn liefde voor voetbal en Ajax 
komt zeker voor een groot deel door jou. Vroeger samen op fietsvakantie en later 
onze reizen naar Zuid-Afrika, Oekraïne en Brazilië als trouwe Oranje supporters. Het 
voelt altijd even vertrouwd!
 Casper, mijn roomie in Amsterdam. Samen met Johannes zijn we #np28. Ik geniet 
van jou als huisgenoot. Dank voor de ontspanning als ik thuis kom uit het werk: of het 
nu samen een hapje eten, een potje FIFA of een biertje in het park is.
 Sterre, wees zuinig op mijn broertje! Dank voor alle avonturen die we met elkaar 
meemaken. Je bent een schat.
 Rob, wat een fijne, waardevolle en vanzelfsprekende vriendschap hebben wij door 
de jaren heen opgebouwd. Jarenlang huisgenoten geweest in Lent, en ondertussen 
ben ik kind aan huis bij jou, Evelien, Fedde en Liselot. Het is enorm ontspannen om 
bij jullie te zijn. Ieder weekend samen hardlopen is vaste prik en ook een fijne uitlaat - 
klep na een drukke werkweek. Maar er is weinig dat meer relativerend is dan voetballen 
met Fedde: hij is Nederland en ik moet Groesbeek zijn. We gaan nog heel veel jaren 
vastknopen aan onze vriendschap!
 Marjolijn, Lonneke en Steven, laatst hadden we het erover hoe onze vriendschap 
begonnen is en daar kwamen we niet helemaal uit. Maar dat het een hele fijne 
vriendschap is weet ik zeker. Dank voor de heerlijke tijd samen in Tanzania, jullie 
weten hoe belangrijk dat voor me was. Bedankt voor het lachen! Samen met Ewout 
en Anne zijn we tennisteam de Biscuits. Jullie weten hoe trots ik ben op ons 
kampioenschap afgelopen jaar! Het was een heerlijke manier om met jullie op en 
naast de tennisbaan te ontspannen naast het drukke werk. Quaak, wie had dat 
gedacht, na de lift die ik je gaf na de APLS cursus 6 jaar geleden. Het leven zit vol 
aangename verrassingen! Onze in scene gezette “honeymoon” met champagne en 
munt handdoekjes op Rubondo Island was heerlijk, maar het is zoveel fijner echt 
samen met jou. Je maakt me super gelukkig. Al veel dierbare herinneringen samen 
en ik kijk uit naar alles wat we samen nog gaan beleven. Zo fijn om samen met jou 
het avontuur aan te gaan. Ik hou van je.
 Lara, mijn maatje tijdens de opleiding, goede vriendin en nu mijn paranimf. Het voelt 
zo goed en vertrouwd dat je naast mij staat tijdens mijn promotie. Dank daarvoor. 
Wat hebben we veel gelachen samen. Onze reis naar Boston en New York was 
legendarisch. Maar misschien wel het meest hilarische moment: na een borrel in het 
CWZ bleef ik op de afdeling slapen aangezien ik de dag erna dienst had. Je hebt me 
samen met de verpleegkundigen om half 7 gewekt met beschuit met aardbeien 
(gelukkig hebben we de foto’s nog…). Je bent een topper! 
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Omar, Abdul en Nina, jullie zijn een verrijking van het gezin waarin ik opgroeide. 
We zien elkaar te weinig, maar het voelt altijd vertrouwd!
 Hennie, ruim 14 jaar geleden is het alweer dat je bent overleden. En wat had ik je 
er graag bij gehad tijdens mijn promotie. Ik weet hoe trots je zou zijn geweest. Er is 
nog zoveel wat ik je zou willen vertellen.
 Hans en Anja, mijn lieve ouders, dank voor het creëren van het warme nest 
waarin ik ben opgegroeid. Dank voor alle liefde en onvoorwaardelijke steun. Het is 
een voorrecht het leven samen met jullie te leven. Het is geweldig dat we de mijlpaal 
van het afronden van mijn promotie met elkaar kunnen vieren. En dat is niet vanzelf-
sprekend. Anja, wat was je ziek toen ik in Birmingham woonde en werkte, het was 
niet makkelijk om juist toen zo ver weg te zijn. Het is niet in woorden uit te drukken 
hoe blij ik ben dat je taai genoeg bent om steeds weer terug te knokken. Ik bewonder 
je om hoe je ondanks alle fysieke tegenslagen toen en het afgelopen jaar positief blijft 
en er voor Hans, Johannes en mij bent. Ik koester onze reizen met z'n tweeën naar 
Israël en Marokko. Hans, je staat altijd voor iedereen klaar, van overhoren van Latijn 
of natuurkunde op de middelbare school, tot de oprechte interesse in de medemens. 
Johannes en ik staan altijd op de eerste plaats voor jou. Onze reizen samen naar 
Wimbledon, Lissabon en recent nog naar Argentinië hebben onze vader-zoon band 
alleen maar versterkt. Ooit hoop ik net zo'n vader als jij bent te kunnen zijn voor mijn 
eigen kinderen. Un abbraccio forte! Ik hou van jullie.
 Johannes, mijn broertje, mijn maatje en vanzelfsprekend ook mijn paranimf. 
Wat ben ik trots op jou! Stiekem zou ik mijn hele carrière in de geneeskunde zo om 
willen ruilen voor een topsport carrière.  Dat was en is mijn droom. Maar een gebrek 
aan zowel geluk als sportkwaliteiten maakt dat het altijd een droom zal blijven. 
Gelukkig heb ik kunnen kiezen voor een leven als trouwe supporter. En misschien is 
dat nog wel mooier, ik geniet er enorm van dat jij wel mijn droom verwezenlijkt. 
Hockeyen in de top van Nederland, Europees kampioen met Jong Oranje, international. 
En nu het volgende hoofdstuk: hockeyen bij een Spaanse topclub in Barcelona. 
De #jomofanclub is ontzettend trots. Maar uiteindelijk is topsport natuurlijk niets 
meer dan de belangrijkste bijzaak in het leven. Veel en veel belangrijker is dat je een 
gouden broer bent. Ik heb prachtige herinneringen aan onze reizen samen (Hamburg, 
Londen, Madrid, Indonesië, Namibië). Ik heb er van genoten dat we het afgelopen 
jaar weer samen hebben gewoond in Amsterdam. Dankjewel dat je er altijd voor me 
bent. Weet dat je altijd op mij kan rekenen. Hou van je.
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Christiaan Mooij werd op 14 augustus 1986 geboren in het Radboud ziekenhuis in 
Nijmegen. Samen met zijn jongere broer Johannes groeide hij op in Berg en Dal. In 2002 
behaalde hij zijn diploma aan het Stedelijk Gymnasium in Nijmegen. Aansluitend startte 
hij met zijn studie Geneeskunde aan de Radboud Universiteit. Al tijdens zijn studie 
raakte Christiaan geïnteresseerd in de kindergeneeskunde en begon hij met het doen van 
wetenschappelijk onderzoek binnen de afdeling Kindercardiologie onder supervisie van 
Prof. L. Kapusta. In aansluiting hierop verrichtte hij in het kader van zijn wetenschappelijke 
stage onderzoek op de afdeling Kindercardiologie van het Boston Children's Hospital, 
Harvard Medical School in Boston, USA.
 Tijdens de coschappen maakte Christiaan een eerste start met het onderzoek dat 
uiteindelijk zou uitgroeien tot het promotietraject dat beschreven is in dit proefschrift. 
Na afronding van zijn artsexamen in december 2008 startte hij als arts-onderzoeker 
binnen de afdelingen Kinderendocrinologie en Endocrinologie van het Radboudumc 
met het onderzoek naar het cardiovasculaire risicoprofiel en steroidmetabolisme 
bij AGS patiënten. Dit onder supervisie van Dr. H.L. Claahsen-van der Grinten en 
Prof. A.R.M.M. Hermus. Met de opzet voor het verdere onderzoek wist Christiaan 
een ZonMw AGIKO-beurs binnen te halen. Vanaf dat moment heeft hij zijn promotie 
onderzoek verder gecombineerd met zijn specialisatie tot kinderarts. In de periode 
2010-2011 heeft hij één jaar als research fellow gewerkt aan de University of Birmingham 
in het Verenigd Koninkrijk. 
 In 2011 startte Christiaan officieel met zijn specialisatie tot kinderarts. Zijn opleiding 
vond voor het grootste gedeelte plaats in het Amalia Kinderziekenhuis van het 
Radboudumc (opleider: J.M.T. Draaisma). Tevens werkte hij als kinderarts in opleiding 
in het Canisius-Wilhelmina Ziekenhuis in Nijmegen (opleider: B. Semmekrot) en rondde 
hij met succes het OOR-ON profiel “Medisch Leiderschap” af met verschillende taken 
binnen de (Junior Afdeling van de) Nederlandse Vereniging voor Kindergeneeskunde. 
In april 2017 voltooide hij in het Emma Kinderziekenhuis van het Academisch Medisch 
Centrum in Amsterdam zijn opleiding tot kinderarts (opleider: D.K. Bosman). 
 De laatste fase van zijn opleiding tot kinderarts heeft Christiaan besteed aan de 
 kinderendocrinologie. Vanaf augustus 2016 startte hij al met een vervolgspecialisatie 
tot kinderendocrinoloog in het Emma Kinderziekenhuis (AMC) en het VUmc te Amsterdam 
(opleider: Prof. A.S.P. van Trotsenburg), die hij in februari 2019 verwacht af te ronden.
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